

CITATION REPORT

List of articles citing

The diagnosis of mild cognitive impairment due to Alzheimerts disease: recommendations from the National Institute on Aging-Alzheimerts Association workgroups on diagnostic guidelines for Alzheimerts disease

DOI: 10.1016/j.jalz.2011.03.008

Alzheimerts and Dementia, 2011, 7, 270-9.

Source: <https://exaly.com/paper-pdf/50444262/citation-report.pdf>

Version: 2024-04-11

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2222	PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease. 2011 , 3, 11		32
2221	Defining and describing the pre-dementia stages of familial Alzheimer's disease. 2011 , 3, 29		10
2220	Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications. 2011 , 3, 31		67
2219	Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development. 2011 , 3, 34		36
2218	Patient self-report for evaluating mild cognitive impairment and prodromal Alzheimer's disease. 2011 , 3, 35		33
2217	Use of biomarkers in clinical trials of Alzheimer disease: from concept to application. 2011 , 15, 313-25		15
2216	Distinguishing Alzheimer's disease from other major forms of dementia. 2011 , 11, 1579-91		184
2215	Perspective: in search of biomarkers. 2011 , 475, S8		19
2214	Dose-response relation between physical activity and cognitive function: guangzhou biobank cohort study. 2011 , 21, 857-63		26
2213	Brain aging, Alzheimer's disease, and mitochondria. 2011 , 1812, 1630-9		206
2212	Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. 2011 , 34, 430-42		235
2211	Biomarkers for major depression and its delineation from neurodegenerative disorders. 2011 , 95, 703-17		30
2210	The future of Alzheimer's disease: the next 10 years. 2011 , 95, 718-28		156
2209	Ethical considerations of biomarker use in neurodegenerative diseases--a case study of Alzheimer's disease. 2011 , 95, 517-9		21
2208	[The diagnostic approach to early Alzheimer's disease. What are we talking about? Conceptual considerations]. 2011 , 46 Suppl 1, 33-8		0
2207	Evidence for ordering of Alzheimer disease biomarkers. 2011 , 68, 1526-35		170
2206	Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011 , 7, 280-92	1.2	4210

2205	The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011 , 7, 263-9	1.2	8211
2204	Commentary on "Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease." New criteria for a new era. <i>Alzheimer's and Dementia</i> , 2011 , 7, 328-9	1.2	7
2203	Assessment of cognition in mild cognitive impairment: a comparative study. <i>Alzheimer's and Dementia</i> , 2011 , 7, 338-55	1.2	59
2202	Commentary on "Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease." Addressing the challenge of Alzheimer's disease in the 21st century. <i>Alzheimer's and Dementia</i> , 2011 , 7, 335-7	1.2	22
2201	Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011 , 7, 474-485.e4	1.2	139
2200	Assessment of cognition in early dementia. <i>Alzheimer's and Dementia</i> , 2011 , 7, e60-e76	1.2	59
2199	Imaging the Alzheimer brain. 2011 , 26 Suppl 3, 1-27		30
2198	Diagnosis of Alzheimer's disease in Brazil: Supplementary exams. 2011 , 5, 167-177		14
2197	Criteria for the diagnosis of Alzheimer's disease: Recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. 2011 , 5, 146-152		21
2196	Treatment of Alzheimer's disease in Brazil: I. Cognitive disorders. 2011 , 5, 178-188		4
2195	Treatment of Alzheimer's disease in Brazil: II. Behavioral and psychological symptoms of dementia. 2011 , 5, 189-197		2
2194	Biomarkers in Alzheimer's disease. 2011 , 2, 46		14
2193	Multi-modal MRI analysis with disease-specific spatial filtering: initial testing to predict mild cognitive impairment patients who convert to Alzheimer's disease. 2011 , 2, 54		37
2192	Visualization of Endolymphatic Hydrops in Patients with Ménière Disease by Locally Enhanced Inner Ear MRI: Correlation with Audiovestibular Function. 2011 , 145, P104-P104		
2191	Evolution of the diagnostic criteria for degenerative and cognitive disorders. 2011 , 24, 532-41		32
2190	Age, Alzheimer's disease, and the big picture. 2011 , 23, 1531-4		11
2189	Revised NIA-AA criteria for the diagnosis of Alzheimer's disease: a step forward but not yet ready for widespread clinical use. 2011 , 23, 1191-6		26
2188	[Dementia: progress in diagnosis and treatment: Topics, II. Diagnosis; 2. Neuroimaging diagnosis of dementia (MRI SPECT and PET)]. 2011 , 100, 2116-24		

2187 Treatment of Alzheimer disease: the past, the present, and the future. **2011**, 56, 577-8

2186 Obesity, leptin, and Alzheimer's disease. **2011**, 1243, 15-29

87

2185 Clinical amyloid imaging in Alzheimer's disease. **2011**, 10, 667-70

188

2184 Revised criteria for Alzheimer's disease: what are the lessons for clinicians?. **2011**, 10, 598-601

20

2183 Functional network disruption in the degenerative dementias. **2011**, 10, 829-43

333

2182 Episodic memory on the path to Alzheimer's disease. **2011**, 21, 929-34

82

2181 Brain-derived neurotrophic factor: the link between amyloid- β and memory loss. **2011**, 6, 627-639

36

2180 Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease. **2012**, 10, 187-212

37

2179 Prospective memory impairment in mild cognitive impairment: an analytical review. **2011**, 21, 390-404

49

2178 Simulated brain biopsy for diagnosing neurodegeneration using autopsy-confirmed cases. **2011**, 122, 737-45

13

2177 [The future of biomarkers in dementia diagnostics]. **2011**, 82, 1385-6, 1388, 1390, passim

2

2176 Brain-derived neurotrophic factor and Alzheimer's disease: physiopathology and beyond. **2011**, 13, 217-22

139

2175 Role of cerebrospinal fluid and plasma biomarkers in the diagnosis of neurodegenerative disorders and mild cognitive impairment. **2011**, 11, 455-63

7

2174 Prevalence of cognitive impairment in individuals aged over 65 in an urban area: DERIVA study. **2011**, 11, 147

44

2173 Predicting MCI outcome with clinically available MRI and CSF biomarkers. **2011**, 77, 1619-28

160

2172 New diagnostic criteria for Alzheimer's disease. **2011**, 5, 407-9

4

2171 A perspective on the proposal for neurocognitive disorder criteria in DSM-5 as applied to HIV-associated neurocognitive disorders. **2011**, 1, 431-440

2

2170 Mild cognitive impairment. **2011**, 365, 1357-8; author reply 1358-9

3

2169	Suspected early dementia. 2011 , 343, d5568	2
2168	Mapping the road forward in Alzheimer's disease. 2011 , 3, 114ps48	53
2167	Secretase inhibitors for treating Alzheimer's disease: rationale and clinical data. 2011 , 1, 1175-1194	2
2166	Verbal serial list learning in mild cognitive impairment: a profile analysis of interference, forgetting, and errors. 2011 , 17, 905-14	78
2165	Can the 'head-turning sign' be a clinical marker of Alzheimer's disease?. 2011 , 1, 310-7	29
2164	Protocol for a randomised controlled trial to improve cognitive functioning in older adults: the Iowa Healthy and Active Minds Study. 2011 , 1, e000218	10
2163	Letter by Rodríguez-García and Rodríguez-García [corrected] regarding article, "Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association". 2011 , 42, e584	18
2162	Brain amyloid imaging. 2011 , 52, 1733-40	184
2161	Genome-wide association study identifies multiple novel loci associated with disease progression in subjects with mild cognitive impairment. 2011 , 1, e54	22
2160	Challenges in the development of companion diagnostics for neuropsychiatric disorders. 2011 , 11, 829-37	8
2159	Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease. 2011 , 77, 1487-93	89
2158	A window into the heterogeneity of human cerebrospinal fluid A β peptides. 2011 , 2011, 697036	12
2157	Ethical issues in Alzheimer's disease: an overview. 2012 , 12, 557-67	16
2156	Overview and findings from the rush Memory and Aging Project. 2012 , 9, 646-63	529
2155	Dementia has a categorical, not dimensional, latent structure. 2012 , 27, 791-7; author reply 798-800	6
2154	Short term stability of verbal memory impairment in mild cognitive impairment and Alzheimer's disease measured using the International Shopping List Test. 2012 , 34, 853-63	9
2153	Molecular brain imaging in the multimodality era. 2012 , 32, 1377-92	14
2152	Is the amyloid hypothesis of Alzheimer's disease therapeutically relevant?. 2012 , 446, 165-77	75

2151	Overview and findings from the religious orders study. 2012 , 9, 628-45	412
2150	Early-onset familial Alzheimer's disease (EOFAD). 2012 , 39, 436-45	126
2149	Management of Alzheimer's disease using disease-modifying drugs. 2012 , 2, 375-378	1
2148	The relationship between semantic knowledge and conceptual apraxia in Alzheimer disease. 2012 , 25, 167-74	6
2147	Neuroimaging in dementias. 2012 , 25, 473-9	19
2146	The neurobiology of Alzheimer disease defined by neuroimaging. 2012 , 25, 410-20	28
2145	New criteria for Alzheimer disease and mild cognitive impairment: implications for the practicing clinician. 2012 , 18, 356-63	29
2144	Where, when, and in what form does sporadic Alzheimer's disease begin?. 2012 , 25, 708-14	150
2143	The neuropsychological profile of Alzheimer disease. 2012 , 2, a006171	309
2142	Dual task abilities as a possible preclinical marker of Alzheimer's disease in carriers of the E280A presenilin-1 mutation. 2012 , 18, 234-41	16
2141	Injury markers predict time to dementia in subjects with MCI and amyloid pathology. 2012 , 79, 1809-16	110
2140	Postmortem Pittsburgh Compound B (PiB) binding increases with Alzheimer's disease progression. 2012 , 32, 127-38	14
2139	Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. 2012 , 64, 27-81	66
2138	Amyloid- β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. 2012 , 79, 1636-44	174
2137	Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. 2012 , 2, a006395	48
2136	Clinical measures of prospective memory in amnesic mild cognitive impairment. 2012 , 18, 295-304	29
2135	Activities of daily living: where do they fit in the diagnosis of Alzheimer's disease?. 2012 , 2, 483-491	95
2134	Temporal association tracts and the breakdown of episodic memory in mild cognitive impairment. 2012 , 79, 2233-40	70

2133	Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough. 2012 , 4, 343-357	10
2132	Disclosure of Alzheimer's disease biomarker status in subjects with mild cognitive impairment. 2012 , 6, 365-8	16
2131	Alzheimer's disease in the retina: imaging retinal α plaques for early diagnosis and therapy assessment. 2012 , 10, 285-93	148
2130	Cingulum microstructure predicts cognitive control in older age and mild cognitive impairment. 2012 , 32, 17612-9	116
2129	Immunotherapy for Alzheimer's disease: from anti- β amyloid to tau-based immunization strategies. 2012 , 4, 213-8	106
2128	Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. 2012 , 2, 975-984	144
2127	Names and numberplates: quasi-everyday associative memory tasks for distinguishing amnesic mild cognitive impairment from healthy aging. 2012 , 34, 269-78	12
2126	Dysexecutive functioning in mild cognitive impairment: derailment in temporal gradients. 2012 , 18, 20-8	25
2125	Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison. 2012 , 53, 592-600	73
2124	The technology - activities of daily living questionnaire: a version with a technology-related subscale. 2012 , 33, 361-71	34
2123	P300 and neuropsychological assessment in mild cognitive impairment and Alzheimer dementia. 2012 , 3, 172	47
2122	Fractional anisotropy in three variants of primary progressive aphasia. 2012 , 68, 229-33	6
2121	Cognition in rapid eye movement sleep behavior disorder. 2012 , 3, 82	46
2120	Guidelines for the diagnosis and treatment of Alzheimer's disease. 2012 , 80-86	
2119	Prevalence of Dementia and Mild Cognitive Impairment in the Rural Island Town of Ama-cho, Japan. 2012 , 2, 190-9	32
2118	A random change point model for cognitive decline in Alzheimer's disease and mild cognitive impairment. 2012 , 39, 73-83	37
2117	Shifting our focus to blood-based biomarkers of Alzheimer's disease: the promise of ceramides and sphingomyelins. 2012 , 2, 91-94	
2116	Associative working memory and subsequent episodic memory in Alzheimer's disease. 2012 , 23, 119-23	6

2115	Increased expression of TrkB and Capzb2 accompanies preserved cognitive status in early Alzheimer disease pathology. 2012 , 71, 654-64	19
2114	So wichtig ist frhe Demenzdiagnose. 2012 , 13, 50-57	1
2113	Mild cognitive impairment in moderate to severe COPD: a preliminary study. 2012 , 142, 1516-1523	113
2112	Biomarker reif ff.die Routine?. 2012 , 13, 19-20	
2111	Sleep quality and 1-year incident cognitive impairment in community-dwelling older adults. 2012 , 35, 491-9	174
2110	Selected findings from the Religious Orders Study and Rush Memory and Aging Project. 2013 , 33 Suppl 1, S397-403	40
2109	IQCODE for the diagnosis of Alzheimer's disease dementia and other dementias within a community setting. 2012 ,	8
2108	Managing memory impairment in patients with Alzheimer's disease. 2012 , 2, 459-469	
2107	Will the Revised MCI Criteria Mean Fewer Alzheimer Disease Diagnoses?. 2012 , 12, 1	
2106	Passive immunisation with monoclonal anti-Abeta antibodies for the treatment of Alzheimer's disease. 2012 ,	
2105	Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents. 2012 , 91, 315-20	11
2104	Alzheimer's disease: a clinical practice-oriented review. 2012 , 3, 63	43
2103	Rethinking Alzheimer's disease. 2012 , 3, 45	5
2102	Translational research in neurology: dementia. 2012 , 69, 969-77	10
2101	Comparison of four verbal memory tests for the diagnosis and predictive value of mild cognitive impairment. 2012 , 2, 120-31	43
2100	[Pharmacological treatment strategies targeting cognitive impairment associated with aging]. 2012 , 139, 157-9	1
2099	Molecular approaches to the treatment, prophylaxis, and diagnosis of Alzheimer's disease: clinical molecular and genetic studies on Alzheimer's disease. 2012 , 118, 345-9	9
2098	The role of MRI in the early diagnosis of Alzheimer's disease or other dementias in persons with mild cognitive impairment (MCI). 2012 ,	5

2097	Updated guidelines for the diagnosis of Alzheimer disease: a clinical review. 2012 , 25, 50-5	1
2096	Absence of a relationship between subjective memory complaint and objective memory impairment in mild cognitive impairment (MCI): is it time to abandon subjective memory complaint as an MCI diagnostic criterion?. 2012 , 24, 1505-14	84
2095	Mild cognitive impairment (MCI) twenty years on. 2012 , 24, 1-5	30
2094	The CAMCOG for patients with Alzheimer's disease with low levels of education. 2012 , 24, 1359-60; author reply 1360-1	1
2093	4e Confrence canadienne consensuelle sur le diagnostic et le traitement de la dmnence. 2012 , 39, S1-S8	
2092	4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. 2012 , 39, S1-8	19
2091	Amyloid-related imaging abnormalities associated with immunotherapy in Alzheimer's disease patients. 2012 , 7, 395-401	1
2090	Mild cognitive impairment is associated with selected functional markers: integrating concurrent, longitudinal, and stability effects. 2012 , 26, 209-223	31
2089	Naturalistic assessment of everyday functioning in individuals with mild cognitive impairment: the day-out task. 2012 , 26, 631-41	70
2088	Mapping the long slow progression of neurodegeneration leading to Alzheimer's disease. 2012 , 8, 567-571	
2087	Age and diagnostic performance of Alzheimer disease CSF biomarkers. 2012 , 78, 468-76	133
2086	Huperzine A for mild cognitive impairment. 2012 , 12, CD008827	19
2085	Alzheimer's disease: pathogenesis and prevention. <i>Alzheimer's and Dementia</i> , 2012 , 8, 227-33	1.2 58
2084	Advances in the identification of B-secretase inhibitors for the treatment of Alzheimer's disease. 2012 , 7, 19-37	42
2083	Understanding terminology of delirium and long-term cognitive impairment in critically ill patients. 2012 , 26, 267-76	25
2082	Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. 2012 , 69, 1310-7	142
2081	Alzheimer's disease. 2012 , 65, 329-52	176
2080	The association between late-life depression, mild cognitive impairment and dementia: is inflammation the missing link?. 2012 , 12, 1339-50	57

2079	Mild cognitive impairment associated with underlying Alzheimer's disease versus Lewy body disease. 2012 , 18 Suppl 1, S41-4		45
2078	Imaging cerebral amyloid plaques: clinical perspective. 2012 , 11, 652-3		4
2077	Mild cognitive impairment in older adults. 2012 , 14, 320-7		50
2076	Distinct cerebrospinal fluid amyloid-beta peptide signatures in cognitive decline associated with Alzheimer's disease and schizophrenia. 2012 , 33, 3738-44		25
2075	Prospective memory functioning: a new area of investigation in the clinical neuropsychology and rehabilitation of Parkinson's disease and mild cognitive impairment. Review of evidence. 2012 , 33, 965-72		23
2074	Neuropsychology of Alzheimer's disease. 2012 , 43, 686-93		28
2073	Mild cognitive impairment--the continuing challenge of its "real-world" detection and diagnosis. 2012 , 43, 609-14		21
2072	A community-based approach to trials of aerobic exercise in aging and Alzheimer's disease. 2012 , 33, 1105-16		31
2071	Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimer's and Dementia</i> , 2012 , 8, 65-73	1.2	210
2070	A homopolymer polymorphism in the TOMM40 gene contributes to cognitive performance in aging. <i>Alzheimer's and Dementia</i> , 2012 , 8, 381-8	1.2	41
2069	National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2012 , 8, 1-13	1.2	1396
2068	Comparison of International Working Group criteria and National Institute on Aging-Alzheimer's Association criteria for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2012 , 8, 560-3	1.2	41
2067	2012 Alzheimer's disease facts and figures. <i>Alzheimer's and Dementia</i> , 2012 , 8, 131-68	1.2	700
2066	Worldwide Alzheimer's disease neuroimaging initiative. <i>Alzheimer's and Dementia</i> , 2012 , 8, 337-42	1.2	71
2065	Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot. <i>Alzheimer's and Dementia</i> , 2012 , 8, 312-36	1.2	92
2064	Biomarker development: a population-level perspective. <i>Alzheimer's and Dementia</i> , 2012 , 8, 247-9	1.2	3
2063	Advancing Alzheimer's disease diagnosis, treatment, and care: recommendations from the Ware Invitational Summit. <i>Alzheimer's and Dementia</i> , 2012 , 8, 445-52	1.2	37
2062	Alzheimer's Association Update. 2012 , 8, 458-462		

2061	No se puede tapar el sol con las manos[Nuevos criterios diagn�sticos en la enfermedad de Alzheimer. 2012 , 4, 3-5	
2060	Multiplexing and multivariate analysis in neurodegeneration. 2012 , 56, 464-70	8
2059	Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. 2012 , 50, 2880-2886	318
2058	Mild cognitive impairment: a subset of minor neurocognitive disorder?. 2012 , 20, 821-6	13
2057	[The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinical stages, mild cognitive impairment, and dementia]. 2012 , 168, 471-82	19
2056	Encuesta sobre la enfermedad de Alzheimer en el contexto de los nuevos paradigmas diagn�sticos. 2012 , 4, 118-125	4
2055	[Markers of prodromal Alzheimer's disease]. 2012 , 168, 815-24	
2054	Targeted intervention improves knowledge but not self-care or readmissions in heart failure patients with mild cognitive impairment. 2012 , 14, 1041-9	69
2053	Alzheimer's disease diagnostic criteria: practical applications. 2012 , 4, 35	29
2052	News in aging and dementia at the 13th Pan American Congress of Neurology. 2012 , 12, 777-9	
2051	Use of the CogState Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. 2012 , 34, 345-58	92
2050	Fluid biomarkers in Alzheimer disease. 2012 , 2, a006221	120
2049	Vascular predictors of cognitive decline in patients with mild cognitive impairment. 2012 , 33, 1127.e1-9	60
2048	Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. 2012 , 33, 2272-81	72
2047	Longitudinal imaging pattern analysis (SPARE-CD index) detects early structural and functional changes before cognitive decline in healthy older adults. 2012 , 33, 2733-45	26
2046	Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia. 2012 , 97, 38-51	127
2045	Insights into spared memory capacity in amnesic MCI and Alzheimer's Disease via minimal interference. 2012 , 78, 189-99	36
2044	Increased sensitivity to proactive and retroactive interference in amnesic mild cognitive impairment: new insights. 2012 , 80, 104-10	8

2043	Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease. 2012 , 1822, 631-8	172
2042	The use of PIB-PET as a dual pathological and functional biomarker in AD. 2012 , 1822, 380-5	41
2041	Mouse models of Alzheimer's disease. 2012 , 88, 3-12	191
2040	Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer's disease. 2012 , 16, 1434-55	133
2039	Neurodegenerative dementias: From MR Physics lab to assessment room. 2012 , 127, 1	3
2038	Diagnostic and economic evaluation of new biomarkers for Alzheimer's disease: the research protocol of a prospective cohort study. 2012 , 12, 72	20
2037	Neurological soft signs in persons with amnesic mild cognitive impairment and the relationships to neuropsychological functions. 2012 , 8, 29	12
2036	The profile of executive functioning in amnesic mild cognitive impairment: disproportionate deficits in inhibitory control. 2012 , 18, 541-55	76
2035	Screening and treatment for Alzheimer's disease: predicting population-level outcomes. <i>Alzheimer's and Dementia</i> , 2012 , 8, 31-8	1.2 2
2034	Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community. 2012 , 69, 1621-7	170
2033	CSF biomarkers correlate with cerebral blood flow on SPECT in healthy elderly. 2012 , 33, 156-63	10
2032	Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β . 2012 , 6, 409-17	66
2031	Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers. 2012 , 6, 401-7	20
2030	Prevalence of mild cognitive impairment and its subtypes in the Mexican population. 2012 , 34, 271-81	38
2029	Neuronuclear imaging in the evaluation of dementia and mild decline in cognition. 2012 , 42, 415-22	21
2028	Florbetapir PET analysis of amyloid- β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. 2012 , 11, 1057-65	178
2027	Diagnostic neuroimaging across diseases. 2012 , 61, 457-63	199
2026	Brain imaging in the study of Alzheimer's disease. 2012 , 61, 505-16	83

2025	Multi-region analysis of longitudinal FDG-PET for the classification of Alzheimer's disease. 2012 , 60, 221-9	101
2024	Brain excitability and connectivity of neuronal assemblies in Alzheimer's disease: from animal models to human findings. 2012 , 99, 42-60	98
2023	Early detection of dementia with Lewy bodies in patients with amnesic mild cognitive impairment using 123I-MIBG cardiac scintigraphy. 2012 , 315, 115-9	36
2022	Gray matter atrophy patterns of mild cognitive impairment subtypes. 2012 , 315, 26-32	45
2021	Neurocognitive disorders in DSM 5 project - personal comments. 2012 , 322, 17-9	6
2020	Hippocampal atrophy in Alzheimer's disease. 2012 , 2, 197-209	2
2019	Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer's disease. 2012 , 6, 431-9	37
2018	CSF tau and amyloid β levels in Alzheimer's disease: a meta-analysis. 2012 , 01, 30-44	6
2017	Clinical and research diagnostic criteria for Alzheimer's disease. 2012 , 22, 23-32,viii	39
2016	Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer's disease and other neurodegenerative dementias. 2012 , 262 Suppl 2, S71-7	19
2015	Longitudinal change in neuropsychological performance using latent growth models: a study of mild cognitive impairment. 2012 , 6, 540-50	43
2014	Voxel and surface-based topography of memory and executive deficits in mild cognitive impairment and Alzheimer's disease. 2012 , 6, 551-67	50
2013	Relationship between baseline brain metabolism measured using [18 F]FDG PET and memory and executive function in prodromal and early Alzheimer's disease. 2012 , 6, 568-83	40
2012	Sleep-disordered breathing and cognition in older adults. 2012 , 12, 537-46	49
2011	Évaluation des procédures diagnostiques de la maladie d'Alzheimer : une revue systématique des méta-analyses. 2012 , 4, 330-344	1
2010	Mild cognitive deficits and everyday functioning among older adults in the community: the Monongahela-Youghiogheny Healthy Aging Team study. 2012 , 20, 836-44	34
2009	Clinical research risk assessment among individuals with mild cognitive impairment. 2012 , 20, 878-86	8
2008	Novel risk markers and long-term outcomes of delirium: the successful aging after elective surgery (SAGES) study design and methods. 2012 , 13, 818.e1-10	92

2007	The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease. 2012 , 16, 135-41	20
2006	Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia. 2012 , 69, 700-8	110
2005	Cholinesterase inhibitors for mild cognitive impairment. 2012 , CD009132	76
2004	OPTIMIZING DIAGNOSIS AND MANAGEMENT IN MILD-TO-MODERATE ALZHEIMER'S DISEASE. 2012 , 2, 291-304	9
2003	Development of isotope labeling LC-MS for human salivary metabolomics and application to profiling metabolome changes associated with mild cognitive impairment. 2012 , 84, 10802-11	66
2002	The Veterans Affairs Saint Louis University mental status exam (SLUMS exam) and the Mini-mental status exam as predictors of mortality and institutionalization. 2012 , 16, 636-41	24
2001	Transcranial near-infrared laser therapy applied to promote clinical recovery in acute and chronic neurodegenerative diseases. 2012 , 9, 71-83	43
2000	Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-year follow-up study. 2012 , 7, e38639	56
1999	CSF and brain structural imaging markers of the Alzheimer's pathological cascade. 2012 , 7, e47406	32
1998	Clinical Approach to Diagnosis of Pre-Dementia Alzheimer's Disease (CAD-PAD). 2012 , 2, 332-42	3
1997	Executive Dysfunction in MCI: Subtype or Early Symptom. 2012 , 2012, 936272	32
1996	Mild cognitive impairment: statistical models of transition using longitudinal clinical data. 2012 , 2012, 291920	27
1995	Characterizing cognitive deficits and dementia in an aging urban population in India. 2012 , 2012, 673849	11
1994	Spatial navigation-a unique window into physiological and pathological aging. 2012 , 4, 16	46
1993	Characterizing healthy samples for studies of human cognitive aging. 2012 , 4, 23	7
1992	Clinical, methodological and theoretical issues in the assessment of cognition after anaesthesia and surgery: a review. 2012 , 29, 409-22	28
1991	Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). 2012 , 15, 120-6	98
1990	A two-study comparison of clinical and MRI markers of transition from mild cognitive impairment to Alzheimer's disease. 2012 , 2012, 483469	13

1989	Detection of activities of daily living impairment in Alzheimer's disease and mild cognitive impairment using information and communication technology. 2012 , 7, 539-49	56
1988	Plasma microRNA biomarkers for detection of mild cognitive impairment. 2012 , 4, 590-605	138
1987	A two-year follow-up of cognitive deficits and brain perfusion in mild cognitive impairment and mild Alzheimer's disease. 2012 , 30, 109-20	34
1986	Insulin and sex interactions in older adults with mild cognitive impairment. 2012 , 31, 401-10	6
1985	DAD-6: A 6-Item version of the Disability Assessment for Dementia scale which may differentiate Alzheimer's disease and mild cognitive impairment from controls. 2012 , 33, 210-8	24
1984	Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. 2012 , 263, 344-61	166
1983	Diagnosis. 2012 , 139-191	
1982	Normative performance on the executive clock drawing task in a multi-ethnic bilingual cohort: a project FRONTIER study. 2012 , 27, 959-66	11
1981	Glucose hypometabolism in primary visual cortex is commonly associated with clinical features of dementia with Lewy bodies regardless of cognitive conditions. 2012 , 27, 1138-46	26
1980	CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. 2012 , 124, 23-35	138
1979	New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. 2012 , 73, 504-17	207
1978	Cerebrospinal fluid biomarkers to monitor treatment effects in Alzheimer's disease and related conditions. 2012 , 2, 117-123	
1977	The value of cerebrospinal fluid biomarkers for the differential diagnosis of dementia. 2012 , 2, 211-219	1
1976	Biomarkers of Cognitive Training Effects in Aging. 2012 , 1, 104-110	64
1975	The Analytical Aspects and Regulatory Challenges of Biomarker Discovery: Examples from the Field of Neurodegeneration. 2012 , 1, 94-103	
1974	[Advances in the diagnostics of Alzheimer's disease]. 2012 , 83, 661-73	6
1973	Is there a rationale for including only patients already being treated with acetylcholinesterase inhibitors in a prodromal AD trial?. 2012 , 16, 336-8	1
1972	Are biomarkers harmful to recruitment and retention in Alzheimer's disease clinical trials? An international perspective. 2012 , 16, 346-8	9

1971	Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology. 2012 , 16, 339-45	31
1970	Reduced interhemispheric inhibition in mild cognitive impairment. 2012 , 218, 21-6	20
1969	Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. 2012 , 39, 621-31	163
1968	Assessment of cognition, physical performance, and gait in the context of mild cognitive impairment and dementia. 2012 , 60, 176-7	9
1967	Dementia: new criteria but no new treatments. 2012 , 11, 4-5	19
1966	Predicting Alzheimer's disease: neuropsychological tests, self-reports, and informant reports of cognitive difficulties. 2012 , 60, 1128-34	82
1965	Cognitive intervention in amnesic Mild Cognitive Impairment: a systematic review. 2012 , 36, 1163-78	152
1964	How subjective are subjective language complaints. 2012 , 19, 666-71	20
1963	Mnemonic strategy training partially restores hippocampal activity in patients with mild cognitive impairment. 2012 , 22, 1652-8	112
1962	Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. 2012 , 27, 349-56	1373
1961	Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementia. 2012 , 27, 727-34	39
1960	Neuroimaging results impose new views on Alzheimer's disease--the role of amyloid revised. 2012 , 45, 153-72	38
1959	A brief update on dementia prevention. 2012 , 45, 7-10	2
1958	Mild cognitive impairment: pathology and mechanisms. 2012 , 123, 13-30	150
1957	National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. 2012 , 123, 1-11	1425
1956	Progress in Alzheimer's disease. 2012 , 259, 201-11	71
1955	Unique effects of apathy and depression signs on cognition and function in amnesic mild cognitive impairment. 2013 , 28, 50-6	32
1954	Behavioral symptoms in mild cognitive impairment as compared with Alzheimer's disease and healthy older adults. 2013 , 28, 265-75	38

1953	Cognitive differences among depressed and non-depressed MCI participants: a project FRONTIER study. 2013 , 28, 377-82	24
1952	The UP-TECH project, an intervention to support caregivers of Alzheimer's disease patients in Italy: study protocol for a randomized controlled trial. 2013 , 14, 155	25
1951	(18)F-florbetaben Aβimaging in mild cognitive impairment. 2013 , 5, 4	40
1950	Identifying cognitive impairment in heart failure: a review of screening measures. 2013 , 42, 92-7	53
1949	Efficacy of cognitive rehabilitation therapies for mild cognitive impairment (MCI) in older adults: working toward a theoretical model and evidence-based interventions. 2013 , 23, 63-80	111
1948	Diagnosis and management of the patient with suspected dementia in primary care. 2013 , 30, 667-76	10
1947	Blood and plasma-based proteomic biomarker research in Alzheimer's disease. 2013 , 101-102, 1-17	88
1946	Impact of aerobic exercise on neurobehavioral outcomes. 2013 , 6, 139-153	28
1945	Physical activity and brain function in older adults at increased risk for Alzheimer's disease. 2013 , 3, 54-83	38
1944	Novel disease-modifying therapeutics for the treatment of Alzheimer's disease. 2013 , 6, 423-42	7
1943	Ushering in the study and treatment of preclinical Alzheimer disease. 2013 , 9, 371-81	103
1942	Cognitive decline and cerebrospinal fluid biomarkers: a close relationship. 2013 , 8, 403-406	1
1941	Dementia with Lewy bodies: early diagnostic challenges. 2013 , 13, 128-38	58
1940	The brain-in-motion study: effect of a 6-month aerobic exercise intervention on cerebrovascular regulation and cognitive function in older adults. 2013 , 13, 21	48
1939	Recommendations for ICT use in Alzheimer's disease assessment: Monaco CTAD Expert Meeting. 2013 , 17, 653-60	36
1938	Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement. 2013 , 17, 54-63	24
1937	[Pathogenesis and prevention of Alzheimer's disease: when and in what way does the pathological process begin?]. 2013 , 84, 477-82	4
1936	Early detection of memory impairment in people over 65 years old consulting at Health Examination Centers for the French health insurance: the EVATEM protocol. 2013 , 13, 55	16

1935	Medial temporal lobe function during emotional memory in early Alzheimer's disease, mild cognitive impairment and healthy ageing: an fMRI study. 2013 , 13, 76	28
1934	Is the WMS-IV verbal paired associates as effective as other memory tasks in discriminating amnesic mild cognitive impairment from normal aging?. 2013 , 27, 908-23	9
1933	Linking pesticide exposure and dementia: what is the evidence?. 2013 , 307, 3-11	87
1932	Semiquantitative proteomic analysis of human hippocampal tissues from Alzheimer's disease and age-matched control brains. 2013 , 10, 5	43
1931	Supporting evidence for using biomarkers in the diagnosis of MCI due to AD. 2013 , 260, 640-50	42
1930	Dementia: Mild cognitive impairment--amyloid and beyond. 2013 , 9, 493-5	3
1929	Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer's disease dementia. 2013 , 40, 1394-405	38
1928	Theta responses are abnormal in mild cognitive impairment: evidence from analysis of theta event-related synchronization during a temporal expectancy task. 2013 , 120, 1093-107	12
1927	FDG PET and cognitive symptoms of dementia. 2013 , 1, 247-260	14
1926	FDG PET in dementia multicenter studies and clinical trials. 2013 , 1, 261-270	7
1925	Magnetic resonance spectroscopy in common dementias. 2013 , 23, 393-406	36
1924	Alzheimer's Association Update. 2013 , 9, 615-618	1
1923	Chronic obstructive pulmonary disease and association with mild cognitive impairment: the Mayo Clinic Study of Aging. 2013 , 88, 1222-30	48
1922	Regulatory innovation and drug development for early-stage Alzheimer's disease. 2013 , 368, 1169-71	158
1921	Improving Alzheimer's disease phase II clinical trials. <i>Alzheimer's and Dementia</i> , 2013 , 9, 39-49	1.2 24
1920	Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia. <i>Alzheimer's and Dementia</i> , 2013 , 9, e96-e105	1.2 57
1919	Impact of molecular imaging on the diagnostic process in a memory clinic. <i>Alzheimer's and Dementia</i> , 2013 , 9, 414-21	1.2 137
1918	Classification and epidemiology of MCI. 2013 , 29, 753-72	344

1917	Risk factors for the progression of mild cognitive impairment to dementia. 2013 , 29, 873-93		76
1916	Emerging biomarkers in cognition. 2013 , 29, 809-28		11
1915	Current management decisions in mild cognitive impairment. 2013 , 29, 847-71		7
1914	Cognitive and emotional dysfunction in mild cognitive impairment. 2013 , 29, 773-89		6
1913	Magnetic resonance spectroscopy in mild cognitive impairment: systematic review and meta-analysis. 2013 , 37, 2571-86		63
1912	Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer's disease. 2013 , 4, 1530-6		93
1911	Contemplating Alzheimer's disease and the contribution of white matter hyperintensities. 2013 , 13, 415		75
1910	2013 Alzheimer's disease facts and figures. <i>Alzheimer's and Dementia</i> , 2013 , 9, 208-45	1.2	947
1909	Apathy is associated with increased amyloid burden in mild cognitive impairment. 2013 , 25, 302-7		40
1908	Clinical stages of patients with Alzheimer disease treated in specialist clinics in Spain. The EACE study. 2013 , 28, 477-487		1
1907	An overview of PET neuroimaging. 2013 , 43, 449-61		34
1906	Cued recall measure predicts the progression of gray matter atrophy in patients with amnesic mild cognitive impairment. 2013 , 36, 197-210		7
1905	Cerebral amyloid PET imaging in Alzheimer's disease. 2013 , 126, 643-57		79
1904	Alzheimer's disease biomarkers: walk with deliberate haste, don't run blithely on?. 2013 , 126, 625-9		2
1903	Mild cognitive impairment. 2013 , 13, 1247-61		9
1902	Structural Magnetic Resonance Imaging as a Biomarker for the Diagnosis, Progression, and Treatment of Alzheimer Disease. 2013 , 87-129		1
1901	Epidemiology and Clinical Diagnosis: Alzheimer Disease. 2013 , 8, 391-405		3
1900	Amyloid PET Imaging: MCI and AD. 2013 , 8, 431-45		2

1899	Biomarker modeling of Alzheimer's disease. 2013 , 80, 1347-58	586
1898	Foreign language training as cognitive therapy for age-related cognitive decline: a hypothesis for future research. 2013 , 37, 2689-98	106
1897	Biomarker utility in Alzheimer's disease clinical trials. 2013 , 10, e55-e62	1
1896	After the Diagnosis. 2013 , 97-110	
1895	Molecular neuroimaging in degenerative dementias. 2013 , 32, 301-309	2
1894	Computer-aided diagnostic reporting of FDG PET for the diagnosis of Alzheimer's disease. 2013 , 1, 279-288	2
1893	Clinical utility of the cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer's disease. 2013 , 1, 30	107
1892	Cognitive frailty: rationale and definition from an (I.A.N.A./I.A.G.G.) international consensus group. 2013 , 17, 726-34	442
1891	Do preclinical Alzheimer's disease criteria work?. 2013 , 12, 933-5	6
1890	Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. 2013 , 12, 957-65	389
1889	Using memories to understand others: the role of episodic memory in theory of mind impairment in Alzheimer disease. 2013 , 12, 833-9	23
1888	Alzheimer disease: from biomarkers to diagnosis. 2013 , 169, 744-51	15
1887	Magnetic resonance imaging for diagnosis of early Alzheimer's disease. 2013 , 169, 724-8	1
1886	Alzheimer Disease: Genetic and Environmental Influences. 2013 ,	
1885	Occupational pesticide exposure and screening tests for neurodegenerative disease among an elderly population in Costa Rica. 2013 , 120, 96-101	26
1884	Stratégie diagnostique dans les démences. 2013 , 37, 362-371	
1883	The National Institute on Aging-Alzheimer's Association research criteria for mild cognitive impairment due to Alzheimer's disease: predicting the outcome. 2013 , 263, 325-33	20
1882	Manual segmentation certification platform. 2013 ,	1

1881	Impaired initial vowel versus consonant letter-word fluency in dementia of the Alzheimer type. 2013 , 4, 163-70	2
1880	Statins and cognitive decline in older adults with normal cognition or mild cognitive impairment. 2013 , 61, 1449-55	34
1879	Predicting Alzheimer disease with β -amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. 2013 , 74, 905-13	158
1878	Automated Cognitive Health Assessment Using Smart Home Monitoring of Complex Tasks. 2013 , 43, 1302-1313	115
1877	Modeling the course of Alzheimer's disease to improve clinical trials: symposium report. 2013 , 5, 29	2
1876	Cognitive training and cognitive rehabilitation for persons with mild to moderate dementia of the Alzheimer's or vascular type: a review. 2013 , 5, 35	119
1875	Definitions of dementia and predementia states in Alzheimer's disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia. 2013 , 5, S2	81
1874	Clinical applications of neuroimaging in patients with Alzheimer's disease: a review from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. 2013 , 5, S3	20
1873	Oxidative stress in Alzheimer's disease: Primary villain or physiological by-product?. 2013 , 18, 134-41	49
1872	Effects of multicomponent exercise on spatial-temporal gait parameters among the elderly with amnesic mild cognitive impairment (aMCI): preliminary results from a randomized controlled trial (RCT). 2013 , 56, 104-8	29
1871	Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative. 2013 , 34, 62-72	40
1870	Visual ratings of atrophy in MCI: prediction of conversion and relationship with CSF biomarkers. 2013 , 34, 73-82	38
1869	Apolipoprotein E ϵ 4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. 2013 , 34, 1-12	167
1868	Mild cognitive impairment in Parkinson disease: heterogenous mechanisms. 2013 , 120, 157-67	24
1867	Attitudes of UK psychiatrists to the diagnosis of MCI in clinical practice. 2013 , 25, 286-91	6
1866	Perioperative delirium and its relationship to dementia. 2013 , 43, 108-15	34
1865	Improving dementia care: the role of screening and detection of cognitive impairment. <i>Alzheimer's and Dementia</i> , 2013 , 9, 151-9	1.2 153
1864	Introduction to Cognitive Screening Instruments: Rationale, Desiderata, and Assessment of Utility. 2013 , 1-14	5

1863	Top 20 articles cited from Alzheimer's & Dementia since 2008. <i>Alzheimer's and Dementia</i> , 2013 , 9, 619-211.2		
1862	TOMM40 and APOE: Requirements for replication studies of association with age of disease onset and enrichment of a clinical trial. <i>Alzheimer's and Dementia</i> , 2013 , 9, 132-6	1.2	49
1861	Revisiting the framework of the National Institute on Aging-Alzheimer's Association diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2013 , 9, 594-601	1.2	35
1860	Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. 2013 , 2, 356-65		227
1859	Alzheimer's Association Update for January 2013. 2013 , 9, 98-98		
1858	Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. Amyloid Imaging Task Force of the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging. <i>Alzheimer's and Dementia</i> , 2013 , 9, e106-9	1.2	73
1857	Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. <i>Alzheimer's and Dementia</i> , 2013 , 9, e-1-16	1.2	330
1856	Quantitative EEG and apolipoprotein E-genotype improve classification of patients with suspected Alzheimer's disease. 2013 , 124, 2146-52		17
1855	Using neuroimaging to inform clinical practice for the diagnosis and treatment of mild cognitive impairment. 2013 , 29, 829-45		5
1854	The influence of cerebral small vessel disease on default mode network deactivation in mild cognitive impairment. 2012 , 2, 33-42		27
1853	[Clinical stages of patients with Alzheimer disease treated in specialist clinics in Spain. The EACE study]. 2013 , 28, 477-87		3
1852	Leveraging global resources to end the Alzheimer's pandemic. <i>Alzheimer's and Dementia</i> , 2013 , 9, 363-5	1.2	6
1851	CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimer's and Dementia</i> , 2013 , 9, 251-61	1.2	289
1850	Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future. <i>Alzheimer's and Dementia</i> , 2013 , 9, 602-8	1.2	215
1849	Structural and Functional Magnetic Resonance Imaging: Mild Cognitive Impairment and Alzheimer Disease. 2013 , 8, 407-30		1
1848	Course and etiology of dysexecutive MCI in a community sample. <i>Alzheimer's and Dementia</i> , 2013 , 9, 632-9		25
1847	Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease. 2013 , 2, 497-511		74
1846	Molecular neuroimaging in degenerative dementias. 2013 , 32, 301-9		3

1845	Arterial spin labeled MRI in prodromal Alzheimer's disease: A multi-site study. 2013 , 2, 630-6		65
1844	Amyloid, cognition, and APOE genotype in healthy older adults. <i>Alzheimer's and Dementia</i> , 2013 , 9, 538-45	1.2	45
1843	Imaging markers for Alzheimer disease: which vs how. 2013 , 81, 487-500		173
1842	Common curbsides and conundrums in geriatric medicine. 2013 , 88, 630-5		5
1841	Translational proteomics in Alzheimer's disease and related disorders. 2013 , 46, 480-6		17
1840	Risk factors for mild cognitive impairment among Mexican Americans. <i>Alzheimer's and Dementia</i> , 2013 , 9, 622-631.e1	1.2	54
1839	Identification of promethazine as an amyloid-binding molecule using a fluorescence high-throughput assay and MALDI imaging mass spectrometry. 2013 , 2, 620-9		17
1838	Mild Cognitive Impairment. Preface. 2013 , 29, ix-x		
1837	Cerebrospinal fluid biomarkers in neurological diseases in children. 2013 , 17, 7-13		15
1836	Getting lost in Alzheimer's disease: a break in the mental frame syncing. 2013 , 80, 416-21		44
1835	Familiarity-based memory as an early cognitive marker of preclinical and prodromal AD. 2013 , 51, 1094-102		45
1834	Beta oscillatory responses in healthy subjects and subjects with mild cognitive impairment. 2013 , 3, 39-46		66
1833	The economics of mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2013 , 9, 58-62	1.2	40
1832	Imagerie cérébrale des plaques amyloïdes: le point de vue du clinicien. 2013 , 4, 59-63		
1831	Lateral temporal hyper-activation as a novel biomarker of mild cognitive impairment. 2013 , 51, 2281-93		11
1830	Resting functional connectivity reveals residual functional activity in Alzheimer's disease. 2013 , 74, 375-83		51
1829	Perceptual and response interference in Alzheimer's disease and mild cognitive impairment. 2013 , 124, 2389-96		35
1828	Late life anxiety is associated with decreased memory and executive functioning in community dwelling older adults. 2013 , 27, 567-75		97

1827	Longitudinal, region-specific course of diffusion tensor imaging measures in mild cognitive impairment and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2013 , 9, 519-28	1.2	75
1826	Frailty syndrome and the risk of vascular dementia: the Italian Longitudinal Study on Aging. <i>Alzheimer's and Dementia</i> , 2013 , 9, 113-22	1.2	86
1825	Risk and resilience: A new perspective on Alzheimer's disease. 2013 , 1, 47-55		2
1824	Índice de discriminabilidad en memoria de reconocimiento en deterioro cognitivo leve amnésico y demencia tipo Alzheimer leve. Un estudio preliminar. 2013 , 5, 241-249		
1823	Risk disclosure and preclinical Alzheimer's disease clinical trial enrollment. <i>Alzheimer's and Dementia</i> , 2013 , 9, 356-359.e1	1.2	25
1822	Impaired retention is responsible for temporal order memory deficits in mild cognitive impairment. 2013 , 143, 88-95		15
1821	Hippocampal subfield volumetry in mild cognitive impairment, Alzheimer's disease and semantic dementia. 2013 , 3, 155-62		160
1820	Progression of Alzheimer's disease as measured by Clinical Dementia Rating Sum of Boxes scores. <i>Alzheimer's and Dementia</i> , 2013 , 9, S39-44	1.2	67
1819	Alzheimer's Association Update. 2013 , 9, 360-361		
1818	Reduced frontal activation during a working memory task in mild cognitive impairment: a non-invasive near-infrared spectroscopy study. 2013 , 19, 125-31		42
1817	Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes. 2013 , 75, 146-61		37
1816	Cholinergic enhancement of functional networks in older adults with mild cognitive impairment. 2013 , 73, 762-73		29
1815	Slaying dementia dragons with blood, lungs, and guts. 2013 , 61, 155-7		3
1814	Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. 2013 , 12, 357-67		1336
1813	Positron Emission Tomography in Alzheimer Disease. 2013 , 131-174		2
1812	Effects of acetylcholinesterase inhibitors and memantine on resting-state electroencephalographic rhythms in Alzheimer's disease patients. 2013 , 124, 837-50		60
1811	Does tip-of-the-tongue for proper names discriminate amnesic mild cognitive impairment?. 2013 , 25, 627-34		20
1810	Dementia and Alzheimer Disease: Evidence-Based Neuroimaging. 2013 , 283-298		

1809	Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. <i>Alzheimer's and Dementia</i> , 2013 , 9, 677-86	1.2	43
1808	Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease. 2013 , 12, 469-82		139
1807	Diagnosis and management of Alzheimer's disease: past, present and future ethical issues. 2013 , 110, 102-13		73
1806	Category-specific semantic memory: converging evidence from bold fMRI and Alzheimer's disease. 2013 , 68, 263-74		27
1805	Metabolomics in Alzheimer's disease research. 2013 , 34, n/a-n/a		3
1804	Correlations between serum levels of beta amyloid, cerebrospinal levels of tau and phospho tau, and delayed response tasks in young and aged cynomolgus monkeys (<i>Macaca fascicularis</i>). 2013 , 42, 137-46		13
1803	Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid- β changes occur before increases of tau in cerebrospinal fluid. 2013 , 126, 631-41		103
1802	Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer's disease and vascular dementia. 2013 , CD003260		187
1801	Amyloid imaging with PET in early Alzheimer disease diagnosis. 2013 , 97, 377-98		45
1800	Clinical trials in predementia stages of Alzheimer disease. 2013 , 97, 439-57		37
1799	Emotional and psychological implications of early AD diagnosis. 2013 , 97, 459-75		22
1798	Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease. 2013 , 97, 399-424		108
1797	Lipid raft disarrangement as a result of neuropathological progresses: a novel strategy for early diagnosis?. 2013 , 245, 26-39		37
1796	Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. <i>Alzheimer's and Dementia</i> , 2013 , 9, S72-83	1.2	157
1795	Alzheimer's disease, dementia, mild cognitive impairment and the menopause: a 'window of opportunity'?. 2013 , 9, 279-90		20
1794	Memory training (MT) in mild cognitive impairment (MCI) generates change in cognitive performance. 2013 , 56, 442-7		46
1793	An MRI-based index to measure the severity of Alzheimer's disease-like structural pattern in subjects with mild cognitive impairment. 2013 , 273, 396-409		43
1792	Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection. 2013 , 9, 621-48		84

1791	Videos in clinical medicine. Reduction of paraphimosis in boys. 2013 , 368, e16	6
1790	An observational study with long-term follow-up of canine cognitive dysfunction: clinical characteristics, survival, and risk factors. 2013 , 27, 822-9	53
1789	Synchrotron FTIR reveals lipid around and within amyloid plaques in transgenic mice and Alzheimer's disease brain. 2013 , 138, 3991-7	61
1788	Less depressive symptoms are associated with smaller hippocampus in subjective memory impairment. 2013 , 57, 110-5	19
1787	Mild cognitive impairment due to Alzheimer disease in the community. 2013 , 74, 199-208	175
1786	Random forest-based similarity measures for multi-modal classification of Alzheimer's disease. 2013 , 65, 167-75	286
1785	Prevalence and characteristics of mild cognitive impairment in the general population. Data from an Italian population-based study: The Faenza Project. 2013 , 17, 267-75	22
1784	Health numeracy and cognitive decline in advanced age. 2013 , 20, 639-59	31
1783	Combined prevalence of frailty and mild cognitive impairment in a population of elderly Japanese people. 2013 , 14, 518-24	277
1782	A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease. 2013 , 110, 114-23	19
1781	Tip-of-the-tongue for proper names in non-amnesic mild cognitive impairment. 2013 , 26, 409-420	3
1780	A follow up study of non-demented patients with primary visual cortical hypometabolism: prodromal dementia with Lewy bodies. 2013 , 334, 48-54	40
1779	Developing Targeted PET Tracers in the Era of Personalized Medicine. 2013 , 289-342	
1778	Patterns of functioning in older adults with mild cognitive impairment: a two-year study focusing on everyday technology use. 2013 , 17, 679-88	16
1777	QT dispersion in mild cognitive impairment: a possible tool for predicting the risk of progression to dementia?. 2013 , 28, 632-9	10
1776	Mild Cognitive Impairment and Normal Aging. 2013 , 239-256	6
1775	Can the DSM-5 framework enhance the diagnosis of MCI?. 2013 , 81, 2045-50	18
1774	New diagnostic concepts in Alzheimer's disease. 2013 , 19, 242-249	3

1773	Neuroimaging and the search for a cure for Alzheimer disease. 2013 , 269, 671-91	37
1772	Diagnosing Mild Cognitive Impairment (MCI) in clinical trials: a systematic review. 2013 , 3,	91
1771	The aging brain and cognition: contribution of vascular injury and a to mild cognitive dysfunction. 2013 , 70, 488-95	98
1770	In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. 2013 , 136, 2228-38	232
1769	Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. 2013 , 54, 1011-3	49
1768	An expanded role for neuroimaging in the evaluation of memory impairment. 2013 , 34, 2075-82	20
1767	Effect and mechanism of acupuncture on Alzheimer's disease. 2013 , 111, 181-95	28
1766	Motoric cognitive risk syndrome and the risk of dementia. 2013 , 68, 412-8	265
1765	Analysis of verbal fluency ability in amnesic and non-amnesic mild cognitive impairment. 2013 , 28, 721-31	31
1764	Automated assessment of cognitive health using smart home technologies. 2013 , 21, 323-43	64
1763	The self-fulfilling prophecy of episodic memory impairment in mild cognitive impairment: do episodic memory deficits identified at classification remain evident when later examined with different memory tests?. 2013 , 2013, 437013	1
1762	The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Utility in detection and characterization of mild cognitive impairment due to Alzheimer's disease. 2013 , 28, 837-44	60
1761	Expanding disease definitions in guidelines and expert panel ties to industry: a cross-sectional study of common conditions in the United States. 2013 , 10, e1001500	88
1760	Impaired processing of 3D motion-defined faces in mild cognitive impairment and healthy aging: an fMRI study. 2013 , 23, 2489-99	27
1759	Longitudinal trajectories of everyday function by diagnostic status. 2013 , 28, 1070-5	41
1758	Lexical retrieval in discourse: an early indicator of Alzheimer's dementia. 2013 , 27, 905-21	19
1757	Three-month stability of the CogState brief battery in healthy older adults, mild cognitive impairment, and Alzheimer's disease: results from the Australian Imaging, Biomarkers, and Lifestyle-rate of change substudy (AIBL-ROCS). 2013 , 28, 320-30	70
1756	Semantic memory functional MRI and cognitive function after exercise intervention in mild cognitive impairment. 2013 , 37, 197-215	91

1755	Mild cognitive impairment. 2013 , 19, 411-24	18
1754	Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. 2013 , 72, 1182-92	72
1753	Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. 2013 , 27, 4-15	86
1752	Helping people to live well with dementia. 2013 , 6, 754-762	1
1751	Naturalistic assessment of everyday activities and prompting technologies in mild cognitive impairment. 2013 , 19, 442-52	55
1750	Prevalences of dementia and cognitive impairment among older people in sub-Saharan Africa: a systematic review. 2013 , 91, 773-83	52
1749	Neuroimaging biomarkers of neurodegenerative diseases and dementia. 2013 , 33, 386-416	87
1748	Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. 2013 , 54, 476-90	179
1747	Shared vulnerability of two synaptically-connected medial temporal lobe areas to age and cognitive decline: a seven tesla magnetic resonance imaging study. 2013 , 33, 16666-72	37
1746	Current guidelines for dementia screening: shortcomings and recommended changes. 2013 , 3, 565-573	10
1745	Visual reproduction on the Wechsler Memory Scale-Revised as a predictor of Alzheimer's disease in Japanese patients with mild cognitive impairments. 2013 , 35, 165-76	10
1744	Cerebrospinal fluid biomarkers for pathological processes in Alzheimer's disease. 2013 , 26, 276-82	19
1743	Renovating Alzheimer's: "constructive" reflections on the new clinical and research diagnostic guidelines. 2013 , 53, 378-87	14
1742	The association of Aβ amyloid and composite cognitive measures in healthy older adults and MCI. 2013 , 25, 1667-77	21
1741	Alzheimer's disease clinical and research update for health care practitioners. 2013 , 2013, 207178	33
1740	Profile of cognitive complaints in vascular mild cognitive impairment and mild cognitive impairment. 2013 , 2013, 865827	5
1739	Prevalence and clinical predictors of cognitive impairment in individuals aged 80 years and older in rural China. 2013 , 36, 171-8	14
1738	Decreased white matter integrity in neuropsychologically defined mild cognitive impairment is independent of cortical thinning. 2013 , 19, 925-37	23

1737	Prevalence and characterization of mild cognitive impairment in retired national football league players. 2013 , 19, 873-80	61
1736	In vivo parahippocampal white matter pathology as a biomarker of disease progression to Alzheimer's disease. 2013 , 521, 4300-17	23
1735	Proton MRS in mild cognitive impairment. 2013 , 37, 770-7	46
1734	Positron emission tomography with [18F]flutemetamol and [11C]PiB for in vivo detection of cerebral cortical amyloid in normal pressure hydrocephalus patients. 2013 , 20, 1043-52	33
1733	Dementia and mild cognitive impairment in adults with intellectual disability: issues of diagnosis. 2013 , 18, 31-42	62
1732	The block suppression test uncovers specific inhibitory deficits in mild cognitive impairment. 2013 , 28, 769-70	3
1731	Disrupting Alzheimer's Disease Research. 2013 , 1, 157-160	
1730	Classification and prediction of clinical diagnosis of Alzheimer's disease based on MRI and plasma measures of β -/A β cotrienols and A β copherol. 2013 , 273, 602-21	58
1729	Costs of diagnosing dementia: results from SveDem, the Swedish Dementia Registry. 2013 , 28, 1039-44	26
1728	Prevalence and associated behavioral symptoms of depression in mild cognitive impairment and dementia due to Alzheimer's disease. 2013 , 28, 947-58	41
1727	Everyday technologies across the continuum of dementia care. 2013 , 2013, 7040-3	1
1726	Symptom validity testing in memory clinics: Hippocampal-memory associations and relevance for diagnosing mild cognitive impairment. 2013 , 35, 59-70	23
1725	Biomarker-driven therapeutic management of Alzheimer's disease: establishing the foundations. 2014 , 95, 67-77	17
1724	Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI). 2013 ,	9
1723	Repeated retrieval during working memory is sensitive to amnesic mild cognitive impairment. 2013 , 35, 946-59	8
1722	Naturalistic assessment of executive function and everyday multitasking in healthy older adults. 2013 , 20, 735-56	31
1721	Molecular biomarkers of neurodegeneration. 2013 , 13, 845-61	23
1720	Cerebrospinal A β 1-x and 17-x levels as indicators of mild cognitive impairment and patients' stratification in Alzheimer's disease. 2013 , 3, e281	11

1719	Dementia: Disclosure of results to participants in dementia research. 2013 , 9, 608-9	2
1718	The effect of bilingualism on amnesic mild cognitive impairment. 2013 , 68, 8-12	53
1717	Computerized adaptation of The Placing Test for early detection of both mild cognitive impairment and Alzheimer's disease. 2013 , 35, 846-56	10
1716	Cognitive interventions targeting subjective cognitive complaints. 2013 , 28, 560-7	16
1715	The Challenges of Cognitive Aging: Integrating Approaches from Neuroscience to Intergenerational Relationships. 2013 , 11, 105-117	8
1714	Profiles of cognitive functioning in a population-based sample of centenarians using factor mixture analysis. 2013 , 39, 125-44	12
1713	Sensitivity and specificity of diagnostic accuracy in Alzheimer's disease: a synthesis of existing evidence. 2013 , 28, 337-47	20
1712	Relationship between control beliefs, strategy use, and memory performance in amnesic mild cognitive impairment and healthy aging. 2013 , 68, 862-71	20
1711	Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues. 2013 , 3, 219-229	39
1710	The accuracy of ¹⁸ F-DG-PET in the early diagnosis of Alzheimer's disease dementia and other dementias in people with MCI. 2013 ,	5
1709	Inhaled sevoflurane may promote progression of amnesic mild cognitive impairment: a prospective, randomized parallel-group study. 2013 , 345, 355-60	75
1708	Using genetics to enable studies on the prevention of Alzheimer's disease. 2013 , 93, 177-85	60
1707	The apolipoprotein E genotype predicts longitudinal transitions to mild cognitive impairment but not to Alzheimer's dementia: findings from a nationally representative study. 2013 , 27, 86-94	29
1706	Recognition of famous names predicts cognitive decline in healthy elders. 2013 , 27, 333-42	15
1705	Implicit perceptual-motor skill learning in mild cognitive impairment and Parkinson's disease. 2013 , 27, 314-21	35
1704	Normal Cognitive Aging and Mild Cognitive Impairment: Drawing the Fine Line. 2013 , 23, 1-9	5
1703	Cognitive assessment in Parkinson's disease. 53-64	
1702	Diagnosis and biomarkers: CSF. 97-108	

1701	Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. 2013 , 5, 48	100
1700	Calmodulin levels in blood cells as a potential biomarker of Alzheimer's disease. 2013 , 5, 55	19
1699	Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples. 2013 , 5, 47	31
1698	Is it time to rethink how neuropsychological tests are used to diagnose mild forms of HIV-associated neurocognitive disorders? Impact of false-positive rates on prevalence and power. 2013 , 41, 208-16	46
1697	Pharmacological Treatment of Mild Cognitive Impairment as a Prodromal Syndrome of Alzheimer's Disease. 2013 , 11, 102-8	39
1696	Comparing regional brain atrophy in mild cognitive impairment and Alzheimer's disease. 2013 , 3, 417-426	
1695	Familiarity, knowledge, and preferences of family physicians regarding mild cognitive impairment. 2013 , 25, 805-13	11
1694	CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). 2013 ,	6
1693	Commentary. 2013 , 25, 181-4	1
1692	Self-reported depressive syndromes in mild cognitive impairment and mild Alzheimer's disease. 2013 , 25, 439-44	8
1691	Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with Amyloidosis. 2013 , 70, 1030-8	58
1690	¹¹ C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). 2013 ,	1
1689	Cortical florbetapir-PET amyloid load in prodromal Alzheimer's disease patients. 2013 , 3, 43	29
1688	Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid- β and tau. 2013 , 5, 55	95
1687	IQCODE for the diagnosis of Alzheimer's disease dementia and other dementias within a general practice (primary care) setting. 2013 ,	3
1686	Parkinson's and Alzheimer's diseases in Costa Rica: a feasibility study toward a national screening program. 2013 , 6, 23061	5
1685	Mild cognitive impairment. Part 2: Biological markers for diagnosis and prediction of dementia in Alzheimer's disease. 2013 , 35, 284-94	14
1684	Neurodegenerative disorders. 23-71	

1683	Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly. 2013 , 18, 1150-73	15
1682	Variation in Variables that Predict Progression from MCI to AD Dementia over Duration of Follow-up. 2013 , 2, 12-28	20
1681	The role of the innate immune system in Alzheimer's disease and frontotemporal lobar degeneration: an eye on microglia. 2013 , 2013, 939786	22
1680	Frontal presentation of Alzheimer's disease: a series of patients with biological evidence by CSF biomarkers. 2013 , 7, 66-74	21
1679	Mild cognitive impairment. Part 1: clinical characteristics and predictors of dementia. 2013 , 35, 178-85	34
1678	Non-pharmacological cognitive intervention for aging and dementia: Current perspectives. 2013 , 1, 233-41	22
1677	Predicting AD conversion: comparison between prodromal AD guidelines and computer assisted PredictAD tool. 2013 , 8, e55246	28
1676	Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction. 2013 , 8, e66877	41
1675	Cognitive declines precede and predict functional declines in aging and Alzheimer's disease. 2013 , 8, e73645	47
1674	Epistatic genetic effects among Alzheimer's candidate genes. 2013 , 8, e80839	22
1673	Imaging-based biomarkers of cognitive performance in older adults constructed via high-dimensional pattern regression applied to MRI and PET. 2013 , 8, e85460	10
1672	Cholinergic Enhancement of Brain Activation in Mild Cognitive Impairment during Episodic Memory Encoding. 2013 , 4, 105	22
1671	Behavioral symptoms related to cognitive impairment. 2013 , 9, 1443-55	61
1670	IQCODE for the diagnosis of Alzheimer's disease dementia and other dementias within a secondary care setting. 2013 ,	2
1669	The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). 2013 , 5, 11	110
1668	Refining the diagnosis of Huntington disease: the PREDICT-HD study. 2013 , 5, 12	58
1667	The utility of age-specific cut-offs for visual rating of medial temporal atrophy in classifying Alzheimer's disease, MCI and cognitively normal elderly subjects. 2013 , 5, 47	28
1666	Integrative EEG biomarkers predict progression to Alzheimer's disease at the MCI stage. 2013 , 5, 58	95

1665	EEG upper/low alpha frequency power ratio relates to temporo-parietal brain atrophy and memory performances in mild cognitive impairment. 2013 , 5, 63	31
1664	Mismatch negativity (MMN) amplitude as a biomarker of sensory memory deficit in amnesic mild cognitive impairment. 2013 , 5, 79	38
1663	Increase of theta frequency is associated with reduction in regional cerebral blood flow only in subjects with mild cognitive impairment with higher upper alpha/low alpha EEG frequency power ratio. 2013 , 7, 188	19
1662	The attenuation of retinal nerve fiber layer thickness and cognitive deterioration. 2013 , 7, 142	32
1661	High-throughput neuro-imaging informatics. 2013 , 7, 31	17
1660	Can smartphones enhance telephone-based cognitive assessment (TBCA)?. 2013 , 10, 7110-25	8
1659	Magnetic resonance spectroscopy in Alzheimer's disease. 2013 , 9, 687-96	46
1658	The LIFE Cognition Study: design and baseline characteristics. 2014 , 9, 1425-36	14
1657	Memory concerns, memory performance and risk of dementia in patients with mild cognitive impairment. 2014 , 9, e100812	31
1656	A nationwide survey of mild cognitive impairment and dementia, including very mild dementia, in Taiwan. 2014 , 9, e100303	131
1655	Effect of BDNF Val66Met on memory decline and hippocampal atrophy in prodromal Alzheimer's disease: a preliminary study. 2014 , 9, e86498	57
1654	Autonomic dysfunction in mild cognitive impairment: evidence from power spectral analysis of heart rate variability in a cross-sectional case-control study. 2014 , 9, e96656	37
1653	An efficient approach for differentiating Alzheimer's disease from normal elderly based on multicenter MRI using gray-level invariant features. 2014 , 9, e105563	17
1652	Age-correction of test scores reduces the validity of mild cognitive impairment in predicting progression to dementia. 2014 , 9, e106284	4
1651	A clinical index to predict progression from mild cognitive impairment to dementia due to Alzheimer's disease. 2014 , 9, e113535	26
1650	[Episodic memory in Alzheimer's disease: decline in recollection and familiarity?]. 2014 , 30, 784-9	2
1649	Currently Available Biomarkers and Strategies for the Validation of Novel Candidates for Neurochemical Dementia Diagnostics in Alzheimer's Disease and Mild Cognitive Impairment. 2014 , 2014, 1-15	2
1648	Role of EEG as biomarker in the early detection and classification of dementia. 2014 , 2014, 906038	81

1647	CSF Biomarkers of Alzheimer's Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design. 2014 , 2014, 1-14	11
1646	A quantitative method to monitor reactive oxygen species production by electron paramagnetic resonance in physiological and pathological conditions. 2014 , 2014, 306179	38
1645	Tip-of-the-Tongue in Mild Cognitive Impairment (MCI). 116-143	2
1644	Relative power and coherence of EEG series are related to amnesic mild cognitive impairment in diabetes. 2014 , 6, 11	57
1643	Network-based biomarkers in Alzheimer's disease: review and future directions. 2014 , 6, 12	45
1642	MTA index: a simple 2D-method for assessing atrophy of the medial temporal lobe using clinically available neuroimaging. 2014 , 6, 23	13
1641	Biomarker-based diagnosis of mild cognitive impairment due to Alzheimer's disease: how and what to tell. A kickstart to an ethical discussion. 2014 , 6, 41	13
1640	The many questions on the use of biomarkers for neurodegenerative diseases in clinical practice. 2014 , 6, 45	4
1639	Meta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic Criteria. 2014 , 6, 47	74
1638	Application of a MRI based index to longitudinal atrophy change in Alzheimer disease, mild cognitive impairment and healthy older individuals in the AddNeuroMed cohort. 2014 , 6, 145	23
1637	Intraindividual variability across cognitive tasks as a potential marker for prodromal Alzheimer's disease. 2014 , 6, 147	24
1636	Regional Fluid-Attenuated Inversion Recovery (FLAIR) at 7 Tesla correlates with amyloid beta in hippocampus and brainstem of cognitively normal elderly subjects. 2014 , 6, 240	12
1635	Mild cognitive impairment, poor episodic memory, and late-life depression are associated with cerebral cortical thinning and increased white matter hyperintensities. 2014 , 6, 306	44
1634	Amyloid Beta1-42 and the Phosphorylated Tau Threonine 231 in Brains of Aged Cynomolgus Monkeys (<i>Macaca fascicularis</i>). 2014 , 6, 313	17
1633	Slowing of EEG background activity in Parkinson's and Alzheimer's disease with early cognitive dysfunction. 2014 , 6, 314	35
1632	Frontiers in therapeutic development of allopregnanolone for Alzheimer's disease and other neurological disorders. 2014 , 8, 203	47
1631	Before it is too late: professional responsibilities in late-onset Alzheimer's research and pre-symptomatic prediction. 2014 , 8, 921	19
1630	Help-seeking preferences in the area of mild cognitive impairment: comparing family physicians and the lay public. 2014 , 9, 613-9	5

1629	Cognitive impairment and memory dysfunction after a stroke diagnosis: a post-stroke memory assessment. 2014 , 10, 1677-91	80
1628	Role of cerebrospinal fluid biomarkers in clinical trials for Alzheimer's disease modifying therapies. 2014 , 18, 447-56	11
1627	Biological markers of Alzheimer's disease. 2014 , 72, 227-31	14
1626	Biomarkers for predicting cognitive decline in those with normal cognition. 2014 , 40, 587-94	27
1625	The link between cardiovascular risk, Alzheimer's disease, and mild cognitive impairment: support from recent functional neuroimaging studies. 2014 , 36, 344-57	7
1624	High-Dimensional Medial Lobe Morphometry: An Automated MRI Biomarker for the New AD Diagnostic Criteria. 2014 , 2014, 278096	1
1623	Olfactory dysfunction in dementia. 2014 , 2, 661-7	54
1622	Poder preditivo do MoCa na avaliaç� neuropsicol�gica de pacientes com diagn�stico de dem�ncia. 2014 , 17, 707-719	10
1621	Understanding the complexities of functional ability in Alzheimer's disease: more than just basic and instrumental factors. 2014 , 11, 357-66	12
1620	Plasma and Cerebrospinal fluid (CSF) Abeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting. 2014 ,	6
1619	(11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). 2014 , CD010386	66
1618	Danger and dementia: caregiver experiences and shifting social roles during a highly active hurricane season. 2014 , 57, 825-44	16
1617	Evaluating research for clinical significance: using critically appraised topics to enhance evidence-based neuropsychology. 2014 , 28, 653-68	11
1616	Functional impairment in mild cognitive impairment evidenced using performance-based measurement. 2014 , 27, 253-8	33
1615	Biomarkers of Alzheimer's disease. 2014 , 801-815	
1614	Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a general practice (primary care) setting. 2014 , CD010771	31
1613	Exploring the validity of mild cognitive impairment (MCI) subtypes: multiple-domain amnesic MCI is the only identifiable subtype at longitudinal follow-up. 2014 , 36, 290-301	20
1612	Amyloid imaging in Alzheimer's disease: a literature review. 2014 , 18, 723-40	8

1611	Welche bildgebenden Verfahren sind in der Demenzdiagnostik sinnvoll?. 2014 , 15, 38-49	1
1610	The effect of 18F-florbetapir dose reduction on region-based classification of cortical amyloid deposition. 2014 , 41, 2144-9	10
1609	The Dutch Parelinoer Institute--Neurodegenerative diseases; methods, design and baseline results. 2014 , 14, 254	42
1608	Optimizing the use of expert panel reference diagnoses in diagnostic studies of multidimensional syndromes. 2014 , 14, 190	8
1607	Recognizing mild cognitive impairment based on network connectivity analysis of resting EEG with zero reference. 2014 , 35, 1279-98	27
1606	The diagnosis and management of mild cognitive impairment: a clinical review. 2014 , 312, 2551-61	527
1605	Measuring cognitive change in subjects with prodromal Alzheimer's disease. 2014 , 85, 363-70	39
1604	[Clinically validated molecular biomarkers of neurodegenerative dementia]. 2014 , 85, 1372-81	4
1603	Prognosis of mild cognitive impairment in general practice: results of the German AgeCoDe study. 2014 , 12, 158-65	47
1602	Subjective cognitive complaints contribute to misdiagnosis of mild cognitive impairment. 2014 , 20, 836-47	134
1601	Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease. 2014 , 14, 973-86	33
1600	Body mass index and mild cognitive impairment-to-dementia progression in 24 months: a prospective study. 2014 , 68, 1216-9	33
1599	Differentiating levels of cognitive functioning: a comparison of the Brief Interview for Mental Status (BIMS) and the Brief Cognitive Assessment Tool (BCAT) in a nursing home sample. 2014 , 18, 921-8	34
1598	Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. 2014 , 10, 405-19	70
1597	Advances in MRI biomarkers for the diagnosis of Alzheimer's disease. 2014 , 8, 1151-69	33
1596	Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. 2014 , 19, 1044-51	143
1595	Early Detection of Cognitive-Linguistic Change Associated With Mild Cognitive Impairment. 2014 , 35, 146-157	16
1594	Cognitive dysfunction and age-related macular degeneration. 2014 , 29, 256-62	19

1593	Delay and probability discounting as candidate markers for dementia: an initial investigation. 2014 , 29, 651-62	17
1592	The need for better AD animal models. 2014 , 5, 227	9
1591	Opportunistic sensing and detection of mild cognitive impairment. 2014 ,	1
1590	BACE1 Inhibitors: Attractive Therapeutics for Alzheimer's Disease. 2014 , 518-546	
1589	A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis. 2014 , 2014, 785039	37
1588	Comparison of two analytical platforms for CSF biomarkers of Alzheimer's disease. 2014 , 2014, 765130	7
1587	Alzheimer's disease in African Americans: risk factors and challenges for the future. 2014 , 33, 580-6	154
1586	Consensus statements on driving for persons with dementia. 2014 , 28, 132-9	17
1585	Discounting preferences and response consistency as markers of functional ability in community-dwelling older adults. 2014 , 36, 1112-23	8
1584	Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative. 2014 , 83, 364-73	146
1583	Structural model for estimating the influence of cognitive reserve on cognitive performance in adults with subjective memory complaints. 2014 , 29, 245-55	30
1582	RBANS memory indices are related to medial temporal lobe volumetrics in healthy older adults and those with mild cognitive impairment. 2014 , 29, 322-8	27
1581	Apathy and Leukoaraiosis in Mild Cognitive Impairment and Alzheimer's Disease: Multicenter Diagnostic Criteria according to the Latest Studies. 2014 , 4, 228-35	9
1580	The search for early markers of AD: hippocampal atrophy and memory deficits. 2014 , 26, 1065-6	11
1579	The development and validation of a patient-reported quality of life measure for people with mild cognitive impairment. 2014 , 26, 487-97	10
1578	Working memory span in mild cognitive impairment. Influence of processing speed and cognitive reserve. 2014 , 26, 615-25	8
1577	Hippocampal atrophy in people with memory deficits: results from the population-based IPREA study. 2014 , 26, 1067-81	16
1576	A qualitative review of instrumental activities of daily living in dementia: what's cooking?. 2014 , 4, 393-400	29

1575 New tools for the evaluation of patients with neurodegenerative diseases. **2014**, 4, 403-5

1574 PET approaches for diagnosis of dementia. **2014**, 35, 2030-8

76

1573 Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. **2014**, 6, 445-54

133

1572 Nonamyloid PET biomarkers and Alzheimer's disease: current and future perspectives. **2014**, 9, 597-613

2

1571 Longitudinal alteration of amygdalar functional connectivity in mild cognitive impairment subjects revealed by resting-state FMRI. **2014**, 4, 361-70

21

1570 Influence of age, disease onset and ApoE4 on visual medial temporal lobe atrophy cut-offs. **2014**, 275, 317-30

54

1569 Cognitive correlates of functional abilities in individuals with mild cognitive impairment: comparison of questionnaire, direct observation, and performance-based measures. **2014**, 28, 726-46

28

1568 Bioenergetic medicine. **2014**, 171, 1854-69

30

1567 Subjective and objective cognitive decline at the pre-dementia stage of Alzheimer's disease. **2014**, 264 Suppl 1, S3-7

86

1566 Cerebral small vessel disease affects white matter microstructure in mild cognitive impairment. **2014**, 35, 2836-51

45

1565 Medial temporal lobe atrophy scores translated to clinical practice: editorial comment on 'influence of age, disease onset and ApoE4 on visual medial temporal lobe atrophy cut-offs'. **2014**, 275, 331-3

12

1564 A hierarchy of predictors for dementia-free survival in old-age: results of the AgeCoDe study. **2014**, 129, 63-72

25

1563 Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. **2014**, 275, 251-83

437

1562 Do the Cambridge Neuropsychological Test Automated Battery episodic memory measures discriminate amnesic mild cognitive impairment?. **2014**, 29, 602-9

16

1561 Callosal degeneration topographically correlated with cognitive function in amnesic mild cognitive impairment and Alzheimer's disease dementia. **2014**, 35, 1529-43

22

1560 Lowered performance in working memory and attentional sub-processes are most prominent in multi-domain amnesic mild cognitive impairment subtypes. **2014**, 14, 63-71

11

1559 Neuropathologic assessment of dementia markers in identical and fraternal twins. **2014**, 24, 317-33

9

1558 Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. **2014**, 1, 534-43

78

1557	Imaging discrepancies between magnetic resonance imaging and brain perfusion single-photon emission computed tomography in the diagnosis of Alzheimer's disease, and verification with amyloid positron emission tomography. 2014 , 14, 110-7	5
1556	Socioeconomic and lifestyle factors related to instrumental activity of daily living dynamics: results from the English Longitudinal Study of Ageing. 2014 , 62, 1630-9	46
1555	Neuroanatomical correlates of awareness of illness in patients with amnesic mild cognitive impairment who will or will not convert to Alzheimer's disease. 2014 , 61, 183-95	31
1554	The efficacy of plasma biomarkers in early diagnosis of Alzheimer's disease. 2014 , 29, 713-9	39
1553	Visual memory profiling with CANTAB in mild cognitive impairment (MCI) subtypes. 2014 , 29, 1040-8	7
1552	Oxidative stress-mediated activation of extracellular signal-regulated kinase contributes to mild cognitive impairment-related mitochondrial dysfunction. 2014 , 75, 230-40	47
1551	Subclinical cognitive decline in middle-age is associated with reduced task-induced deactivation of the brain's default mode network. 2014 , 35, 4488-98	40
1550	Early Alzheimer's disease neuropathology detected by proton MR spectroscopy. 2014 , 34, 16247-55	84
1549	Establishing robust cognitive dimensions for characterization and differentiation of patients with Alzheimer's disease, mild cognitive impairment, frontotemporal dementia and depression. 2014 , 29, 624-34	14
1548	Can performance on daily activities discriminate between older adults with normal cognitive function and those with mild cognitive impairment?. 2014 , 62, 1347-52	50
1547	Cognitive impairment in heart failure: towards a consensus on screening. 2014 , 16, 235-7	13
1546	Extracting and summarizing white matter hyperintensities using supervised segmentation methods in Alzheimer's disease risk and aging studies. 2014 , 35, 4219-35	62
1545	Cognitively elite, cognitively normal, and cognitively impaired aging: neurocognitive status and stability moderate memory performance. 2014 , 36, 418-30	9
1544	Recommendations for the use of Serious Games in people with Alzheimer's Disease, related disorders and frailty. 2014 , 6, 54	116
1543	Obstacles and opportunities in Alzheimer's clinical trial recruitment. 2014 , 33, 574-9	85
1542	A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia. 2014 , 12, 575-93	177
1541	Modulation of Amyloid by a single dose of GSK933776 in patients with mild Alzheimer's disease: a phase I study. 2014 , 6, 19	25
1540	The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis. 2014 , 6, 46	135

1539	BrainCheck - a very brief tool to detect incipient cognitive decline: optimized case-finding combining patient- and informant-based data. 2014 , 6, 69	13
1538	Imaging endpoints for clinical trials in Alzheimer's disease. 2014 , 6, 87	40
1537	Advances in imaging-genetic relationships for Alzheimer's disease: clinical implications. 2014 , 4, 73-81	4
1536	Multimodality imaging of Alzheimer disease and other neurodegenerative dementias. 2014 , 55, 2003-11	42
1535	Neuropsychiatric symptoms in the prodromal stages of dementia. 2014 , 27, 230-5	36
1534	Midlife cardiovascular risk impacts executive function: Framingham offspring study. 2014 , 28, 16-22	32
1533	FDG-PET and amyloid-PET imaging: the diverging paths. 2014 , 27, 405-13	48
1532	Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. 2014 , 28, 206-18	373
1531	Communication Difficulty and Relevant Interventions in Mild Cognitive Impairment: Implications for Neuroplasticity. 2014 , 30, 18-34	22
1530	How to Diagnose and Define Alzheimer's. 2014 , 14, 1	
1529	Differences in early and late mild cognitive impairment tractography using a diffusion tensor MRI. 2014 , 25, 1393-8	9
1528	Alpha-band hypersynchronization in progressive mild cognitive impairment: a magnetoencephalography study. 2014 , 34, 14551-9	80
1527	Facilitating Alzheimer disease research recruitment. 2014 , 28, 1-8	63
1526	How well do MCI criteria predict progression to severe cognitive impairment and dementia?. 2014 , 28, 113-21	10
1525	Comparison of 2 informant questionnaire screening tools for dementia and mild cognitive impairment: AD8 and IQCODE. 2014 , 28, 156-61	33
1524	Correlational analysis of 5 commonly used measures of cognitive functioning and mental status: an update. 2014 , 29, 718-22	17
1523	Dynamic working memory performance in individuals with single-domain amnesic mild cognitive impairment. 2014 , 36, 751-60	8
1522	The contribution of acetylcholine and dopamine to subprocesses of visual working memory--what patients with amnesic mild cognitive impairment and Parkinson's disease can tell us. 2014 , 61, 89-95	8

1521	Normative data for the Rappel libre/Rappel indicé 16 items (16-item Free and Cued Recall) in the elderly Quebec-French population. 2015 , 28 Suppl 1, S1-19	26
1520	Biomarkers for Alzheimer's Disease and Frontotemporal Lobar Degeneration: Imaging. 2014 , 159-178	
1519	Functional disorganization of small-world brain networks in mild Alzheimer's Disease and amnesic Mild Cognitive Impairment: an EEG study using Relative Wavelet Entropy (RWE). 2014 , 6, 224	68
1518	Buying time: a rationale for examining the use of circadian rhythm and sleep interventions to delay progression of mild cognitive impairment to Alzheimer's disease. 2014 , 6, 325	59
1517	The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. 2014 , 71, 961-70	372
1516	Brain: positron emission tomography tracers beyond [¹⁸ F]fluorodeoxyglucose. 2014 , 9, 267-76	5
1515	Cognitive rehabilitation multi-family group intervention for individuals with mild cognitive impairment and their care-partners. 2014 , 20, 897-908	44
1514	Cognitive rehabilitation of memory for mild cognitive impairment: a methodological review and model for future research. 2014 , 20, 135-51	38
1513	Alzheimer's Disease. 2014 , 122-127	5
1512	Clinical correlates of awareness for balance, function, and memory: evidence for the modality specificity of awareness. 2014 , 2014, 674716	8
1511	Mild cognitive impairment: a concept and diagnostic entity in need of input from neuropsychology. 2014 , 20, 129-34	57
1510	Public health guidance to facilitate timely diagnosis of dementia: Alzheimer's COoperative Valuation in Europe recommendations. 2014 , 29, 682-93	76
1509	How are we going to live with Alzheimer's disease?. 2014 , 33, 541-6	4
1508	Predicting aggressive decline in mild cognitive impairment: the importance of white matter hyperintensities. 2014 , 71, 872-7	63
1507	Development of the Heart Failure Screening Tool (Heart-FaST) to measure barriers that impede engagement in self-care. 2014 , 13, 408-17	10
1506	Biomarker in der Neurologie (Standardisierung dringend erforderlich). 2014 , 38,	
1505	Prevalence of Dementia, Emotional State and Physical Performance among Older Adults in the Metropolitan Area of Guadalajara, Jalisco, Mexico. 2014 , 2014, 387528	10
1504	Evaluating different aspects of prospective memory in amnesic and nonamnesic mild cognitive impairment. 2014 , 2014, 805929	16

1503	Mild cognitive impairment: clinical and imaging profile in a memory clinic setting in India. 2014 , 37, 113-24		8
1502	Serum 25-hydroxyvitamin D and cognitive decline: a longitudinal study among non-demented older adults. 2014 , 38, 254-63		18
1501	Attempted and successful compensation in preclinical and early manifest neurodegeneration - a review of task FMRI studies. 2014 , 5, 132		43
1500	Three midlife strategies to prevent cognitive impairment due to Alzheimer's disease. 2014 , 17 Suppl 2, 38-46		12
1499	The Lawton Instrumental Activities Daily Living/Activities Daily Living Scales: A Sensitive Test to Alzheimer Disease in Community-Dwelling Elderly People?. 2014 , 27, 85-93		15
1498	Biomarkers for neurological disorders Call for standardization. 2014 , 38,		
1497	After DSM-5: A Critical Mental Health Research Agenda for the 21st Century. 2014 , 24, 5-10		14
1496	Apolipoprotein E alleles in Cuban patients with mild cognitive impairment. 2014 , 29, 236-41		3
1495	Emergence of mild cognitive impairment in late middle-aged adults in the wisconsin registry for Alzheimer's prevention. 2014 , 38, 16-30		59
1494	Cognition, anesthesia, and surgery. 2014 , 52, 42-57		8
1493	Lifestyle engagement affects cognitive status differences and trajectories on executive functions in older adults. 2014 , 29, 16-25		77
1492	Subjective memory complaints, depressive symptoms and cognition in patients attending a memory outpatient clinic. 2014 , 26, 463-73		45
1491	The unbearable lightness of MCI. 2014 , 26, 353-9		6
1490	Contributions of the Computer-Administered Neuropsychological Screen for Mild Cognitive Impairment (CANS-MCI) for the diagnosis of MCI in Brazil. 2014 , 1-9		12
1489	APOE interacts with age to modify rate of decline in cognitive and brain changes in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, 336-48	1.2	27
1488	The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. 2014 , 1842, 1219-31		411
1487	Cortical sources of resting state electroencephalographic alpha rhythms deteriorate across time in subjects with amnesic mild cognitive impairment. 2014 , 35, 130-42		47
1486	Alzheimer's disease in the human eye. Clinical tests that identify ocular and visual information processing deficit as biomarkers. <i>Alzheimer's and Dementia</i> , 2014 , 10, 251-61	1.2	65

1485	Eye Blink Rate as a biological marker of Mild Cognitive Impairment. 2014 , 93, 12-6		32
1484	A point-based tool to predict conversion from mild cognitive impairment to probable Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, 646-55	1.2	34
1483	Dihydrotestosterone treatment delays the conversion from mild cognitive impairment to Alzheimer's disease in SAMP8 mice. 2014 , 65, 505-15		36
1482	Distinct pattern of hypometabolism and atrophy in preclinical and predementia Alzheimer's disease. 2014 , 35, 1973-81		38
1481	Can dementia be diagnosed during hospitalisation?. 2014 , 5, 314-318		1
1480	Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects. 2014 , 4, 45-52		78
1479	The end of Alzheimer's disease--from biochemical pharmacology to ecopsychosociology: a personal perspective. 2014 , 88, 677-81		23
1478	Extension and refinement of the predictive value of different classes of markers in ADNI: four-year follow-up data. <i>Alzheimer's and Dementia</i> , 2014 , 10, 704-12	1.2	49
1477	Biological heterogeneity in ADNI amnesic mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2014 , 10, 511-521.e1	1.2	74
1476	Diagnosticare la malattia di Alzheimer. 2014 , 14, 1-14		
1475	Mild cognitive impairment-a treatable condition. 2014 , 15, 1-5		29
1474	Association of diabetes with amnesic and nonamnesic mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2014 , 10, 18-26	1.2	102
1473	Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia. 2014 , 35, 143-51		85
1472	Full diffusion characterization implicates regionally disparate neuropathology in mild cognitive impairment. 2014 , 219, 367-79		9
1471	Biomarkers in amyloid- β immunotherapy trials in Alzheimer's disease. 2014 , 39, 189-201		54
1470	Impact of cerebro-spinal fluid biomarkers of Alzheimer's disease in clinical practice: a multicentric study. 2014 , 261, 144-51		45
1469	[18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease. 2014 , 41, 290-300		73
1468	Cingulum correlates of cognitive functions in patients with mild cognitive impairment and early Alzheimer's disease: a diffusion spectrum imaging study. 2014 , 27, 393-402		42

1467	Genetic interactions found between calcium channel genes modulate amyloid load measured by positron emission tomography. 2014 , 133, 85-93	25
1466	Apolipoprotein E, gender, and Alzheimer's disease: an overlooked, but potent and promising interaction. 2014 , 8, 262-73	125
1465	Biomarker modelling of early molecular changes in Alzheimer's disease. 2014 , 18, 213-27	4
1464	Sleep-dependent memory consolidation in healthy aging and mild cognitive impairment. 2015 , 25, 307-30	52
1463	Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease. 2014 , 88, 617-30	32
1462	Plasma phospholipids identify antecedent memory impairment in older adults. 2014 , 20, 415-8	706
1461	Magnetic resonance imaging predictors of treatment response in late-life depression. 2014 , 27, 24-32	32
1460	The clinical utility of the auditory P300 latency subcomponent event-related potential in preclinical diagnosis of patients with mild cognitive impairment and Alzheimer's disease. 2014 , 86, 64-74	55
1459	Diagnosis disclosure and advance care planning in Alzheimer disease: opinions of a sample of Italian citizens. 2014 , 26, 427-34	11
1458	MEG spectral analysis in subtypes of mild cognitive impairment. 2014 , 36, 9624	28
1457	A consecutive case series experience with [18 F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition. 2014 , 9, 10	26
1456	The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's disease. 2014 , 41, 1190-8	7
1455	Mild cognitive impairment with associated inflammatory and cortisol alterations as independent risk factor for postoperative delirium. 2014 , 38, 65-78	47
1454	Cognitive complaints correlate with depression rather than concurrent objective cognitive impairment in the successful aging evaluation baseline sample. 2014 , 27, 181-7	82
1453	Alzheimer's and Parkinson's diseases: an environmental proteomic point of view. 2014 , 104, 24-36	7
1452	The Determinants of Dementia After Stroke (DEDEMAS) Study: protocol and pilot data. 2014 , 9, 387-92	27
1451	The tools of the trade: a state of the art "How to Assess Cognition" in the patient with Parkinson's disease. 2014 , 29, 584-96	42
1450	2014 Alzheimer's disease facts and figures. <i>Alzheimer's and Dementia</i> , 2014 , 10, e47-92	1.2 674

1449	The spectrum of cognitive impairment in Lewy body diseases. 2014 , 29, 608-21		89
1448	Apraxia in mild cognitive impairment and Alzheimer's disease: validity and reliability of the Van Heugten test for apraxia. 2014 , 38, 55-64		21
1447	Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset. 2014 , 106, 191-204		172
1446	Mild cognitive impairment: a concept in evolution. 2014 , 275, 214-28		744
1445	MIBG myocardial scintigraphy in pre-motor Parkinson's disease: a review. 2014 , 20, 267-73		70
1444	Plasma tau as a window to the brain-negative associations with brain volume and memory function in mild cognitive impairment and early Alzheimer's disease. 2014 , 35, 3132-42		102
1443	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, 844-52	1.2	1219
1442	Changes in whole-brain functional networks and memory performance in aging. 2014 , 35, 2193-202		88
1441	Early detection of Alzheimer's disease using PiB and FDG PET. 2014 , 72 Pt A, 117-22		131
1440	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. 2014 , 13, 614-29		1985
1439	The learning profile of persistent mild cognitive impairment (MCI): a potential diagnostic marker of persistent amnesic MCI. 2014 , 21, 470-7, e23-4		6
1438	Subregional basal forebrain atrophy in Alzheimer's disease: a multicenter study. 2014 , 40, 687-700		111
1437	Differential Diagnosis: What Is the Lesion? 2014 , 137-269		
1436	Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. 2014 , 137, 221-31		145
1435	Role of depression in predicting time to conversion to mild cognitive impairment. 2014 , 22, 727-34		10
1434	Medication for Alzheimer's disease and associated fall hazard: a retrospective cohort study from the Alzheimer's Disease Neuroimaging Initiative. 2014 , 31, 125-9		23
1433	Early identification and heritability of mild cognitive impairment. 2014 , 43, 600-10		43
1432	CSF A β -42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, 381-92	1.2	53

1431	Advances in the prevention of Alzheimer's disease and dementia. 2014 , 275, 229-50		182
1430	Subjective cognitive concerns, episodic memory, and the APOE ϵ allele. <i>Alzheimer's and Dementia</i> , 2014 , 10, 752-759.e1	1.2	44
1429	Early neuropsychological detection of Alzheimer's disease. 2014 , 68, 1192-9		46
1428	Clinical practice guideline: tinnitus. 2014 , 151, S1-S40		343
1427	Unbiased approaches to biomarker discovery in neurodegenerative diseases. 2014 , 84, 594-607		40
1426	Differences and the relationship in default mode network intrinsic activity and functional connectivity in mild Alzheimer's disease and amnesic mild cognitive impairment. 2014 , 4, 567-74		38
1425	Concordance between (99m)Tc-ECD SPECT and 18F-FDG PET interpretations in patients with cognitive disorders diagnosed according to NIA-AA criteria. 2014 , 29, 1079-86		13
1424	A comparison of neuropsychological performance between US and Russia: preparing for a global clinical trial. <i>Alzheimer's and Dementia</i> , 2014 , 10, 760-768.e1	1.2	12
1423	Editorial. <i>Alzheimer's and Dementia</i> , 2014 , 10, 590-1	1.2	
1422	Short and long telomeres increase risk of amnesic mild cognitive impairment. 2014 , 141-142, 64-9		25
1421	Comparison of dual-biomarker PIB-PET and dual-tracer PET in AD diagnosis. 2014 , 24, 2800-9		20
1420	Prevalence and correlates of mild cognitive impairment in adults aged over 50 years with subjective cognitive complaints in primary care centers. 2014 , 14, 667-73		16
1419	Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs. 2014 , 4, 31-40		59
1418	Minimal functional brain differences between older adults with and without mild cognitive impairment during the stroop. 2014 , 21, 346-69		6
1417	Memory for the 2008 presidential election in healthy ageing and mild cognitive impairment. 2014 , 28, 1407-21		5
1416	An object location memory paradigm for older adults with and without mild cognitive impairment. 2014 , 237, 16-25		11
1415	Intrinsic functional component analysis via sparse representation on Alzheimer's disease neuroimaging initiative database. 2014 , 4, 575-86		14
1414	Harmonized diagnostic criteria for Alzheimer's disease: recommendations. 2014 , 275, 204-13		82

1413	What is the role of neuroimaging in dementia? A review. 2014 , 23, 20120015		
1412	Cluster subtypes of the Spanish version of the California Verbal Learning Test in a sample of adults with subjective memory complaints. 2014 , 36, 317-33		6
1411	Effects of functional tasks exercise on older adults with cognitive impairment at risk of Alzheimer's disease: a randomised controlled trial. 2014 , 43, 813-20		45
1410	Insulin resistance in Alzheimer's disease. 2014 , 72 Pt A, 92-103		78
1409	Pharmacogenomics of Alzheimer's disease: novel therapeutic strategies for drug development. 2014 , 1175, 323-556		50
1408	Mild cognitive impairment: diagnosis, longitudinal course, and emerging treatments. 2014 , 16, 490		82
1407	Mild cognitive impairment and mild dementia: a clinical perspective. 2014 , 89, 1452-9		139
1406	The visual cognitive network, but not the visual sensory network, is affected in amnesic mild cognitive impairment: a study of brain oscillatory responses. 2014 , 1585, 141-9		10
1405	Recommendations of the Alzheimer's disease-related dementias conference. 2014 , 83, 851-60		80
1404	Cognitive deficit reversal as shown by changes in the Veterans Affairs Saint Louis University Mental Status (SLUMS) examination scores 7.5 years later. 2014 , 15, 687.e5-10		27
1403	Alzheimer's disease and vascular dementia: one potentially preventable and modifiable disease. Part I: Pathology, diagnosis and screening. 2014 , 4, 253-9		5
1402	The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimer's and Dementia</i> , 2014 , 10, 808-17	1.2	132
1401	Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, 421-429.e3	1.2	66
1400	Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer's disease. 2014 , 5, 830-6		81
1399	Ecological assessment of mild cognitive impairment and Alzheimer disease using the Rivermead Behavioural Memory Test. 2014 , 29, 339-345		2
1398	Detection of volume loss in hippocampal layers in Alzheimer's disease using 7 T MRI: a feasibility study. 2014 , 5, 341-8		54
1397	Significance of subjective memory complaints in the clinical setting. 2014 , 27, 259-65		27
1396	Classifying neurocognitive disorders: the DSM-5 approach. 2014 , 10, 634-42		337

1395	Recollection and familiarity in aging individuals with mild cognitive impairment and Alzheimer's disease: a literature review. 2014 , 24, 313-31	43
1394	Tracking neuroinflammation in Alzheimer's disease: the role of positron emission tomography imaging. 2014 , 11, 120	66
1393	Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. 2014 , 6, 1	110
1392	Moving beyond the pros and cons of automating cognitive testing in pathological aging and dementia: the case for equal opportunity. 2014 , 6, 58	9
1391	Imago Mundi, Imago AD, Imago ADNI. 2014 , 6, 62	4
1390	Connectome-scale assessments of structural and functional connectivity in MCI. 2014 , 35, 2911-23	52
1389	Fluorodeoxyglucose PET in Neurology and Psychiatry. 2014 , 9, 371-90, v	44
1388	Effect of flavonoids on learning, memory and neurocognitive performance: relevance and potential implications for Alzheimer's disease pathophysiology. 2014 , 94, 1042-56	76
1387	Reducing false positive diagnoses in mild cognitive impairment: the importance of comprehensive neuropsychological assessment. 2014 , 21, 1330-6, e82-3	39
1386	Targeting brain $\alpha 7$ nicotinic acetylcholine receptors in Alzheimer's disease: rationale and current status. 2014 , 28, 975-87	38
1385	Biomarkers in dementia: clinical utility and new directions. 2014 , 85, 1426-34	98
1384	Validation of the 10/66 Dementia Research Group diagnostic assessment for dementia in Arabic: a study in Lebanon. 2014 , 27, 282-90	18
1383	[Neurocognitive disorders in DSM-5: pervasive changes in the diagnostics of dementia]. 2014 , 85, 564-70	19
1382	[Mild neurocognitive disorder - a disease? Against]. 2014 , 85, 632-4	0
1381	Interaction of transactive response DNA binding protein 43 with nuclear factor κB in mild cognitive impairment with episodic memory deficits. 2014 , 2, 37	12
1380	Diagnostic effectiveness of quantitative [^{18}F]flutemetamol PET imaging for detection of fibrillar amyloid β using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus. 2014 , 2, 46	16
1379	Amyloid imaging in Alzheimer's disease: a potential new era of personalized medicine?. 2014 , 5,	1
1378	A comparison of FDG-PET and blood flow SPECT in the diagnosis of neurodegenerative dementias: a systematic review. 2014 , 29, 551-61	51

1377	Health economic evaluation of treatments for Alzheimer's disease: impact of new diagnostic criteria. 2014 , 275, 304-16		43
1376	Association of plasma and cortical amyloid beta is modulated by APOE ϵ status. <i>Alzheimer's and Dementia</i> , 2014 , 10, e9-e18	1.2	35
1375	Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?. 2014 , 14, 1465-76		50
1374	Potential Clinical Applications of PET/MR Imaging in Neurodegenerative Diseases. 2014 , 55, 475-555		46
1373	Synchronization during an internally directed cognitive state in healthy aging and mild cognitive impairment: a MEG study. 2014 , 36, 9643		10
1372	Disrupted structural and functional brain connectomes in mild cognitive impairment and Alzheimer's disease. 2014 , 30, 217-32		95
1371	Grey-matter volume as a potential feature for the classification of Alzheimer's disease and mild cognitive impairment: an exploratory study. 2014 , 30, 477-89		27
1370	Prevention of Late-life Cognitive Disorders: Diet-Related Factors, Dietary Patterns, and Frailty Models. 2014 , 3, 110-129		6
1369	Early intervention in Alzheimer's disease: a health economic study of the effects of diagnostic timing. 2014 , 14, 101		132
1368	Network dysfunction in Alzheimer's disease: refining the disconnection hypothesis. 2014 , 4, 299-311		100
1367	Early miR-155 upregulation contributes to neuroinflammation in Alzheimer's disease triple transgenic mouse model. 2014 , 23, 6286-301		100
1366	Long-term systemic inflammation and cognitive impairment in a population-based cohort. 2014 , 62, 1683-91		55
1365	APOE ϵ worsens hippocampal CA1 apical neuropil atrophy and episodic memory. 2014 , 82, 691-7		59
1364	Personalized Medicine of Alzheimer's Disease. 2014 , 563-615		1
1363	Myeloid microvesicles in cerebrospinal fluid are associated with myelin damage and neuronal loss in mild cognitive impairment and Alzheimer disease. 2014 , 76, 813-25		62
1362	Regional functional connectivity predicts distinct cognitive impairments in Alzheimer's disease spectrum. 2014 , 5, 385-95		43
1361	Use of amyloid PET across the spectrum of Alzheimer's disease: clinical utility and associated ethical issues. 2014 , 21, 143-8		23
1360	Vision function abnormalities in Alzheimer disease. 2014 , 59, 414-33		70

1359	Simulating effects of biomarker enrichment on Alzheimer's disease prevention trials: conceptual framework and example. <i>Alzheimer's and Dementia</i> , 2014 , 10, 152-61	1.2	7
1358	Maximizing ADL performance to facilitate aging in place for people with dementia. 2014 , 49, 157-69		12
1357	The source of cognitive complaints predicts diagnostic conversion differentially among nondemented older adults. <i>Alzheimer's and Dementia</i> , 2014 , 10, 319-27	1.2	92
1356	Automatic temporal lobe atrophy assessment in prodromal AD: Data from the DESCRIPA study. <i>Alzheimer's and Dementia</i> , 2014 , 10, 456-467	1.2	12
1355	Operationalizing hippocampal volume as an enrichment biomarker for amnesic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size. 2014 , 35, 808-18		31
1354	Utilidad de la neuroimagen amiloidea en Neurología asistencial. 2014 , 6, 68-76		
1353	18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. 2014 , 35, 2096-106		85
1352	Structural connectivity of the default mode network and cognition in Alzheimer's disease. 2014 , 223, 15-22		18
1351	The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?. <i>Alzheimer's and Dementia</i> , 2014 , 10, 713-723.e2	1.2	204
1350	Alzheimer's Association Update for January 2014. 2014 , 10, 132-133		1
1349	The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, S12-25	1.2	87
1348	Al and cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, 743-751.e1	1.2	62
1347	Rethinking the Food and Drug Administration's 2013 guidance on developing drugs for early-stage Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, 247-50	1.2	8
1346	Hippocampal subfield volumes at 7T in early Alzheimer's disease and normal aging. 2014 , 35, 2039-45		103
1345	Amyloid burden and neural function in people at risk for Alzheimer's Disease. 2014 , 35, 576-84		117
1344	Ecological assessment of mild cognitive impairment and Alzheimer disease using the Rivermead Behavioural Memory Test. 2014 , 29, 339-45		13
1343	Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers. 2014 , 4, 164-73		88
1342	Connectivity underlying emotion conflict regulation in older adults with 5-HTTLPR short allele: a preliminary investigation. 2014 , 22, 946-50		9

1341	A comparison of three brain atlases for MCI prediction. 2014 , 221, 139-50		36
1340	The role of human cognitive neuroscience in drug discovery for the dementias. 2014 , 14, 62-73		8
1339	Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. 2014 , 88, 426-49		84
1338	Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). 2014 , CD008782		67
1337	Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. 2014 , 42, 275-89		324
1336	Contribution of Alzheimer disease to mortality in the United States. 2014 , 82, 1045-50		219
1335	The critical need for defining preclinical biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, S196-212	1.2	89
1334	Sex and gender differences in the causes of dementia: a narrative review. 2014 , 79, 196-201		103
1333	A Bayesian network decision model for supporting the diagnosis of dementia, Alzheimer's disease and mild cognitive impairment. 2014 , 51, 140-58		108
1332	The role of egocentric and allocentric abilities in Alzheimer's disease: a systematic review. 2014 , 16, 32-44		71
1331	Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, 684-9	1.2	49
1330	CSF contamination contributes to apparent microstructural alterations in mild cognitive impairment. 2014 , 92, 27-35		51
1329	Can a novel computerized cognitive screening test provide additional information for early detection of Alzheimer's disease?. <i>Alzheimer's and Dementia</i> , 2014 , 10, 790-8	1.2	51
1328	Diagnosing Alzheimer's disease: a systematic review of economic evaluations. <i>Alzheimer's and Dementia</i> , 2014 , 10, 225-37	1.2	29
1327	CSF biomarkers for Alzheimer's pathology and the effect size of APOE e4. 2014 , 19, 148-9		26
1326	A blood-based predictor for neocortical A β burden in Alzheimer's disease: results from the AIBL study. 2014 , 19, 519-26		85
1325	Qualification of a surrogate matrix-based absolute quantification method for amyloid- β in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry. 2014 , 41, 441-51		77
1324	Inclusion of an informant yields strong associations between cognitive complaint and longitudinal cognitive outcomes in non-demented elders. 2015 , 43, 121-32		22

1323	Molecular imaging in sporadic Alzheimer's disease populations and those genetically at risk. 2014 , 13, 160-2	5
1322	Cortical Amyloid Beta in Cognitively Normal Elderly Adults is Associated with Decreased Network Efficiency within the Cerebro-Cerebellar System. 2014 , 6, 52	17
1321	APOE and COMT polymorphisms are complementary biomarkers of status, stability, and transitions in normal aging and early mild cognitive impairment. 2014 , 6, 236	28
1320	Improving CSF Biomarkers' Performance for Predicting Progression from Mild Cognitive Impairment to Alzheimer's Disease by Considering Different Confounding Factors: A Meta-Analysis. 2014 , 6, 287	33
1319	3D-CAM: derivation and validation of a 3-minute diagnostic interview for CAM-defined delirium: a cross-sectional diagnostic test study. 2014 , 161, 554-61	187
1318	Electroencephalographic upper/low alpha frequency power ratio relates to cortex thinning in mild cognitive impairment. 2014 , 14, 18-30	14
1317	The Effects of an Uninterrupted Switch from Donepezil to Galantamine without Dose Titration on Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease. 2014 , 4, 131-9	17
1316	Acute stroke syndromes caused by small vessel disease. 217-235	
1315	The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial. 2014 , 6, 47	17
1314	Interaction between cerebral small vessel disease and neurodegenerative changes. 298-310	
1313	Comparison of the diagnostic accuracy of neuropsychological tests in differentiating Alzheimer's disease from mild cognitive impairment: can the montreal cognitive assessment be better than the cambridge cognitive examination?. 2014 , 4, 113-21	16
1312	Novel plasma biomarker surrogating cerebral amyloid deposition. 2014 , 90, 353-64	81
1311	Verbal prompting to improve everyday cognition in MCI and unimpaired older adults. 2014 , 28, 123-34	14
1310	Assessment of functional change and cognitive correlates in the progression from healthy cognitive aging to dementia. 2014 , 28, 881-93	56
1309	Early Intervention in Older Adults [A Focus on Alzheimer's Dementia. 2014 , 103-115	
1308	Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a meta-analysis. [Corrected]. 2014 , 93, e150	48
1307	Brain PET in the diagnosis of Alzheimer's disease. 2014 , 39, e413-22; quiz e423-6	148
1306	Rates of Amyloid accumulation are independent of hippocampal neurodegeneration. 2014 , 82, 1605-12	100

1305	How can we improve transfer of outcomes from randomized clinical trials to clinical practice with disease-modifying drugs in Alzheimer's disease?. 2014 , 13, 197-9	3
1304	Cognitive and functional status predictors of delirium and delirium severity after coronary artery bypass graft surgery: an interim analysis of the Neuropsychiatric Outcomes After Heart Surgery study. 2015 , 27, 1929-38	25
1303	Investigating Associative Learning Effects in Patients with Prodromal Alzheimer's Disease Using the Temporal Context Model. 2015 , 21, 699-708	4
1302	Naturalistic Action Performance Distinguishes Amnesic Mild Cognitive Impairment from Healthy Aging. 2015 , 21, 419-28	7
1301	Improved Cardiorespiratory Fitness Is Associated with Increased Cortical Thickness in Mild Cognitive Impairment. 2015 , 21, 757-67	58
1300	Early Cognitively Based Functional Limitations Predict Loss of Independence in Instrumental Activities of Daily Living in Older Adults. 2015 , 21, 688-98	49
1299	Computer mouse movement patterns: A potential marker of mild cognitive impairment. 2015 , 1, 472-480	45
1298	Memory Complaints in Older Adults: Prognostic Value and Stability in Reporting over Time. 2015 , 3,	11
1297	The economic impact of moderate stage Alzheimer's disease in Italy: evidence from the UP-TECH randomized trial. 2015 , 27, 1563-72	14
1296	Mobility and safety issues in drivers with dementia. 2015 , 27, 1613-22	34
1295	CSF beta-amyloid 1-42 - what are we measuring in Alzheimer's disease?. 2015 , 2, 131-9	25
1294	A practical algorithm for managing Alzheimer's disease: what, when, and why?. 2015 , 2, 307-23	52
1293	Modulation of Renin-Angiotensin System May Slow Conversion from Mild Cognitive Impairment to Alzheimer's Disease. 2015 , 63, 1749-56	50
1292	Clinical impact of (11)C-Pittsburgh compound-B positron emission tomography carried out in addition to magnetic resonance imaging and single-photon emission computed tomography on the diagnosis of Alzheimer's disease in patients with dementia and mild cognitive impairment. 2015 , 63, 744-51	10
1291	Cognitive Function, Progression of Age-related Behavioral Changes, Biomarkers, and Survival in Dogs More Than 8 Years Old. 2015 , 29, 1569-77	34
1290	Cognitive Decline and Hearing Health Care for Older Adults. 2015 , 24, 108-11	15
1289	Differential Expression of microRNA in Cerebrospinal Fluid as a Potential Novel Biomarker for Alzheimer's Disease. 2015 , 47, 243-52	28
1288	Unirhinal Olfactory Testing for the Diagnostic Workup of Mild Cognitive Impairment. 2015 , 47, 253-70	9

1287	Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion. 2016 , 49, 945-959	42
1286	Exercise interventions for preventing dementia or delaying cognitive decline in people with mild cognitive impairment. 2015 ,	10
1285	Aberrant intra- and inter-network connectivity architectures in Alzheimer's disease and mild cognitive impairment. 2015 , 5, 14824	68
1284	BFLCRM: A BAYESIAN FUNCTIONAL LINEAR COX REGRESSION MODEL FOR PREDICTING TIME TO CONVERSION TO ALZHEIMER'S DISEASE. 2015 , 9, 2153-2178	19
1283	Alzheimer's disease. 2015 , 1, 15056	755
1282	Self-referencing and false memory in mild cognitive impairment due to Alzheimer's disease. 2015 , 29, 799-805	19
1281	The β latent dementia phenotype in the uniform data set: Cross-validation and extension. 2015 , 29, 344-52	33
1280	Absence of practice effects in preclinical Alzheimer's disease. 2015 , 29, 940-8	73
1279	Decision Making and Ratio Processing in Patients with Mild Cognitive Impairment. 2015 , 48, 765-79	12
1278	Altered Affective Evaluations of Smells in Alzheimer's Disease. 2016 , 49, 433-41	6
1277	Impaired Parahippocampus Connectivity in 'Mild Cognitive Impairment and 'Alzheimer's Disease. 2016 , 49, 1051-64	31
1276	Prediction of Alzheimer's Disease Dementia: Data from the GuidAge Prevention Trial. 2015 , 48, 793-804	20
1275	The Effects of Bushen Capsule on Episodic Memory in Amnesic Mild Cognitive Impairment Patients: A Pilot Placebo Controlled fMRI Study. 2015 , 46, 665-76	12
1274	Anemia and Mild Cognitive Impairment in the German General Population. 2016 , 49, 1031-42	18
1273	T-Tau is Associated with Objective Memory Decline Over Two Years in Persons Seeking Help for Subjective Cognitive Decline: A Report from the Gothenburg-Oslo MCI Study. 2015 , 47, 619-28	17
1272	Efficacy and Safety of MMFS-01, a Synapse Density Enhancer, for Treating Cognitive Impairment in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial. 2016 , 49, 971-90	26
1271	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. 2015 , 48 Suppl 1, S63-86	253
1270	A Novel Plasma Based Biomarker of Alzheimer's Disease. 2015 , 47, 761-71	5

1269	Distinct Pattern of Gray Matter Atrophy in Mild Alzheimer's Disease Impacts on Cognitive Outcomes of Noninvasive Brain Stimulation. 2015 , 48, 251-60	28
1268	Inflammatory Markers in Mild Cognitive Impairment: A Meta-Analysis. 2015 , 47, 669-79	40
1267	Strategies for improving memory: a randomized trial of memory groups for older people, including those with mild cognitive impairment. 2016 , 49, 31-43	36
1266	Magnetic Resonance Spectroscopy in Alzheimer's Disease: Systematic Review and Meta-Analysis. 2015 , 46, 1049-70	63
1265	Analysis of cerebral lobar microbleeds and a decreased cerebral blood flow in a memory clinic setting. 2015 , 54, 1027-33	10
1264	Validation of the Erlangen Score Algorithm for the Prediction of the Development of Dementia due to Alzheimer's Disease in Pre-Dementia Subjects. 2015 , 48, 433-41	28
1263	Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease. 2016 , 49, 1123-34	24
1262	Diffusion tensor imaging reveals visual pathway damage in patients with mild cognitive impairment and Alzheimer's disease. 2015 , 45, 97-107	17
1261	The Utilization of Retinal Nerve Fiber Layer Thickness to Predict Cognitive Deterioration. 2016 , 49, 399-405	12
1260	Olfactory Dysfunction, Olfactory Bulb Volume and Alzheimer's Disease: Is There a Correlation? A Pilot Study1. 2015 , 48, 395-402	16
1259	Investigation of neurodegenerative diseases from body fluid samples using Fourier transform infrared spectroscopy. 2015 , 4, 341-357	9
1258	Fully Automated Atlas-Based Hippocampus Volumetry for Clinical Routine: Validation in Subjects with Mild Cognitive Impairment from the ADNI Cohort. 2015 , 46, 199-209	21
1257	Coffee Consumption Habits and the Risk of Mild Cognitive Impairment: The Italian Longitudinal Study on Aging. 2015 , 47, 889-99	39
1256	Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias. 2016 , 50, 539-46	28
1255	A correlativity study of plasma APL128 and clusterin levels with MMSE/MoCA/CASI in aMCI patients. 2015 , 5, 15546	7
1254	An integrated microfluidic chip for immunocapture, preconcentration and separation of Amyloid peptides. 2015 , 9, 054117	30
1253	Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. 2015 , 48 Suppl 1, S171-91	29
1252	Sensitivity of Neuropsychological Tests to Identify Cognitive Decline in Highly Educated Elderly Individuals: 12 Months Follow up. 2016 , 49, 607-16	15

1251	Risk Stratification Using Cerebrospinal Fluid Biomarkers in Patients with Mild Cognitive Impairment: An Exploratory Analysis. 2015 , 47, 729-40	6
1250	Resting-State Cardiac Workload is Related to Both Increased Neocortical Aggregation of Amyloid- β and Relative Impairments in Spatial Working Memory in Pre-Clinical Alzheimer's Disease. 2016 , 50, 127-31	3
1249	Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease. 2015 , 47, 231-42	101
1248	The effect of the global positioning system on the driving performance of people with mild Alzheimer's disease. 2015 , 61, 79-88	20
1247	Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study. 2015 , 46, 1079-89	22
1246	Subjective memory complaint only relates to verbal episodic memory performance in mild cognitive impairment. 2015 , 44, 309-18	19
1245	Integrating Biomarkers for Underlying Alzheimer's Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers. 2016 , 50, 261-70	12
1244	Perception of emotions in mild cognitive impairment and Alzheimer's dementia: does intensity matter?. 2015 , 6, 139-149	28
1243	Diffusion Kurtosis Imaging: A Possible MRI Biomarker for AD Diagnosis?. 2015 , 48, 937-48	35
1242	[Value and acceptance of risk assessment for Alzheimer's disease]. 2015 , 86, 1549-54	1
1241	The New Conceptualization of Alzheimer's Disease under the Microscope of Influential Definitions of Disease. 2015 , 48, 359-67	5
1240	Performance of the 16-Item Informant Questionnaire on Cognitive Decline for the Elderly (IQCODE) in an Arabic-Speaking Older Population. 2015 , 40, 276-89	22
1239	DSM-5 and Mental Disorders in Older Individuals: An Overview. 2015 , 23, 320-8	44
1238	Rapid assessment of cognitive function in down syndrome across intellectual level and dementia status. 2015 , 59, 1071-9	20
1237	Interview with Dr Ronald Petersen, 7 February 2013. 2015 , 14, 298-306	
1236	Validation of the Dutch version of the quick mild cognitive impairment screen (Qmci-D). 2015 , 15, 115	20
1235	Assessing clinicopathological correlation in chronic traumatic encephalopathy: rationale and methods for the UNITE study. 2015 , 7, 62	71
1234	Improved predictive ability of the Montreal Cognitive Assessment for diagnosing dementia in a community-based study. 2015 , 7, 69	17

1233	Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease. 2015 , 7, 74	86
1232	Microstate connectivity alterations in patients with early Alzheimer's disease. 2015 , 7, 78	21
1231	Propagation of pathology through brain networks in neurodegenerative diseases: from molecules to clinical phenotypes. 2015 , 21, 754-67	28
1230	Free and Cued Selective Reminding Test is superior to the Wechsler Memory Scale in discriminating mild cognitive impairment from Alzheimer's disease. 2015 , 15, 961-8	7
1229	The Montreal Cognitive Assessment-Basic: A Screening Tool for Mild Cognitive Impairment in Illiterate and Low-Educated Elderly Adults. 2015 , 63, 2550-2554	112
1228	Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting. 2015 , 48, 425-32	14
1227	Timely Diagnosis for Alzheimer's Disease: A Literature Review on Benefits and Challenges. 2016 , 49, 617-31	214
1226	Mild Cognitive Impairment. 2015 , 1-4	
1225	Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease. 2015 , 47, 205-14	39
1224	Practical cut-offs for visual rating scales of medial temporal, frontal and posterior atrophy in Alzheimer's disease and mild cognitive impairment. 2015 , 278, 277-90	72
1223	Identification and assessment of functional performance in mild cognitive impairment: a survey of occupational therapy practices. 2015 , 62, 187-96	13
1222	The utility of the Dementia Severity Rating Scale in differentiating mild cognitive impairment and Alzheimer disease from controls. 2015 , 29, 222-8	5
1221	Brainstem morphological changes in Alzheimer's disease. 2015 , 26, 411-5	40
1220	Advances in the treatment of cognitive impairment in Parkinson's disease. 2015 , 30, 1471-89	50
1219	The Montreal Cognitive Assessment: Creating a Crosswalk with the Mini-Mental State Examination. 2015 , 63, 2370-4	60
1218	A Meta-Analysis of fMRI Activation Differences during Episodic Memory in Alzheimer's Disease and Mild Cognitive Impairment. 2015 , 25, 849-60	23
1217	Relationship of medial temporal lobe atrophy, APOE genotype, and cognitive reserve in preclinical Alzheimer's disease. 2015 , 36, 2826-41	68
1216	Dietary interventions for prevention of dementia in people with mild cognitive impairment. 2015 ,	5

1215	The reliability, validity, sensitivity, specificity and predictive values of the Chinese version of the Rowland Universal Dementia Assessment Scale. 2015 , 24, 3118-28	12
1214	Mild Neurocognitive Disorder: An Old Wine in a New Bottle. 2015 , 23, 368-76	40
1213	Levels of 17 β -Hydroxysteroid Dehydrogenase Type 10 in Cerebrospinal Fluid of People with Mild Cognitive Impairment and Various Types of Dementias. 2015 , 48, 105-14	3
1212	Psychometric characteristics of the full and short versions of the IQCODE-BR among low income elderly persons with a low educational level. 2015 , 18, 715-723	2
1211	Alzheimer's Disease, Neural Basis of. 2015 , 591-596	0
1210	Electroencephalography reveals lower regional blood perfusion and atrophy of the temporoparietal network associated with memory deficits and hippocampal volume reduction in mild cognitive impairment due to Alzheimer's disease. 2015 , 11, 461-70	9
1209	Association of EEG, MRI, and regional blood flow biomarkers is predictive of prodromal Alzheimer's disease. 2015 , 11, 2779-91	9
1208	Visual-spatial perception: a comparison between instruments frequently used in the primary care setting and a computerized cognitive assessment battery. 2015 , 10, 1881-6	1
1207	Assessment of the effects of glutamic acid decarboxylase antibodies and trace elements on cognitive performance in older adults. 2015 , 10, 1901-7	5
1206	The 12 Years Preceding Mild Cognitive Impairment Due to Alzheimer's Disease: The Temporal Emergence of Cognitive Decline. 2015 , 48, 1095-107	59
1205	The Latent Dementia Phenotype \square is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment. 2016 , 49, 547-60	17
1204	Comparison of regional gray matter atrophy, white matter alteration, and glucose metabolism as a predictor of the conversion to Alzheimer's disease in mild cognitive impairment. 2015 , 30, 779-87	10
1203	A consensus in Korea regarding a protocol to reduce preanalytical sources of variability in the measurement of the cerebrospinal fluid biomarkers of Alzheimer's disease. 2015 , 11, 132-41	13
1202	Instrumental activities of daily living performance and role satisfaction in people with and without mild cognitive impairment: a pilot project. 2015 , 69, 6903270020p1-10	11
1201	Metabolic Risk Factors of Sporadic Alzheimer's Disease: Implications in the Pathology, Pathogenesis and Treatment. 2015 , 6, 282-99	75
1200	Nanotechnology-based drug delivery systems for the treatment of Alzheimer's disease. 2015 , 10, 4981-5003	150
1199	Intravenous immunoglobulin for Alzheimer's disease. 2015 ,	
1198	Impaired emotional autobiographical memory associated with right amygdalar-hippocampal atrophy in Alzheimer's disease patients. 2015 , 7, 21	22

1197	Mismatch negativity latency as a biomarker of amnesic mild cognitive impairment in chinese rural elders. 2015 , 7, 22	10
1196	'Kitchen and cooking,' a serious game for mild cognitive impairment and Alzheimer's disease: a pilot study. 2015 , 7, 24	106
1195	Theta and alpha EEG frequency interplay in subjects with mild cognitive impairment: evidence from EEG, MRI, and SPECT brain modifications. 2015 , 7, 31	31
1194	Reliability of a novel serious game using dual-task gait profiles to early characterize aMCI. 2015 , 7, 50	28
1193	Differences in prefrontal cortex activation and deactivation during strategic episodic verbal memory encoding in mild cognitive impairment. 2015 , 7, 147	21
1192	The Vallecas Project: A Cohort to Identify Early Markers and Mechanisms of Alzheimer's Disease. 2015 , 7, 181	17
1191	Mental Rotation as an Indicator of Motor Representation in Patients with Mild Cognitive Impairment. 2015 , 7, 238	7
1190	Common Effects of Amnesic Mild Cognitive Impairment on Resting-State Connectivity Across Four Independent Studies. 2015 , 7, 242	18
1189	Dissecting Alzheimer disease in Down syndrome using mouse models. 2015 , 9, 268	29
1188	Complex network analysis of resting state EEG in amnesic mild cognitive impairment patients with type 2 diabetes. 2015 , 9, 133	29
1187	Mild Cognitive Impairment: Structural, Metabolical, and Neurophysiological Evidence of a Novel EEG Biomarker. 2015 , 6, 152	9
1186	Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics. 2015 , 6, 186	19
1185	Cerebrospinal Fluid A β 0 Improves the Interpretation of A β 2 Concentration for Diagnosing Alzheimer's Disease. 2015 , 6, 247	36
1184	Estimating frontal and parietal involvement in cognitive estimation: a study of focal neurodegenerative diseases. 2015 , 9, 317	13
1183	Magnetic resonance imaging biomarkers for the early diagnosis of Alzheimer's disease: a machine learning approach. 2015 , 9, 307	110
1182	The past and the future of Alzheimer's disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular events. 2015 , 9, 345	58
1181	Evidence for a neuroprotective microRNA pathway in amnesic mild cognitive impairment. 2015 , 9, 430	46
1180	Patterns of Cognitive Decline Prior to Dementia in Persons with Mild Cognitive Impairment. 2015 , 47, 901-13	54

1179	Effect of Tween-20 on Core Biomarkers Measured in Cerebrospinal Fluid from Patients with Alzheimer's Disease, Mild Cognitive Impairment, or Healthy Control Individuals. 2016 , 49, 493-502	11
1178	Alzheimer's Disease FDG PET Imaging Pattern in an Amyloid-Negative Mild Cognitive Impairment Subject. 2015 , 47, 539-43	6
1177	Monitoring the early signs of cognitive decline in elderly by computer games: an MRI study. 2015 , 10, e0117918	29
1176	Interhemispheric Functional and Structural Disconnection in Alzheimer's Disease: A Combined Resting-State fMRI and DTI Study. 2015 , 10, e0126310	55
1175	MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer's Disease. 2015 , 10, e0126423	147
1174	Presenilin-1 Dependent Neurogenesis Regulates Hippocampal Learning and Memory. 2015 , 10, e0131266	26
1173	A Mutual Self- and Informant-Report of Cognitive Complaint Correlates with Neuropathological Outcomes in Mild Cognitive Impairment. 2015 , 10, e0141831	8
1172	The Prevalence of Mild Cognitive Impairment in Diverse Geographical and Ethnocultural Regions: The COSMIC Collaboration. 2015 , 10, e0142388	157
1171	Diagnostic Value of Subjective Memory Complaints Assessed with a Single Item in Dominantly Inherited Alzheimer's Disease: Results of the DIAN Study. 2015 , 2015, 828120	6
1170	Applying Automated MR-Based Diagnostic Methods to the Memory Clinic: A Prospective Study. 2015 , 47, 939-54	43
1169	Neuropsychological Assessment. 2015 , 1-5	
1168	Improved Diagnostic Multimodal Biomarkers for Alzheimer's Disease and Mild Cognitive Impairment. 2015 , 2015, 961314	12
1167	Genetic Interactions Explain Variance in Cingulate Amyloid Burden: An AV-45 PET Genome-Wide Association and Interaction Study in the ADNI Cohort. 2015 , 2015, 647389	17
1166	Working memory and executive function decline across normal aging, mild cognitive impairment, and Alzheimer's disease. 2015 , 2015, 748212	228
1165	Neuroplastic effects of combined computerized physical and cognitive training in elderly individuals at risk for dementia: an eLORETA controlled study on resting states. 2015 , 2015, 172192	48
1164	Mental State Inferences Abilities Contribution to Verbal Irony Comprehension in Older Adults with Mild Cognitive Impairment. 2015 , 2015, 685613	11
1163	Different Temporal Patterns of Specific and General Autobiographical Memories across the Lifespan in Alzheimer's Disease. 2015 , 2015, 963460	6
1162	DSM-5. 2015 , 1-4	

1161	Literacy Independent Cognitive Assessment: Assessing Mild Cognitive Impairment in Older Adults with Low Literacy Skills. 2015 , 12, 341-8		10
1160	Lifelong Reading Disorder and Mild Cognitive Impairment: Implications for Diagnosis. 2016 , 50, 41-5		1
1159	Alternative Splicing in Alzheimer's Disease. 2015 , 2,		19
1158	Prodromal dementia with Lewy bodies. 2015 , 45, 259-68		42
1157	What does it mean to be 'amyloid-positive'?. 2015 , 138, 514-6		8
1156	Research involving subjects with Alzheimer's disease in Italy: the possible role of family members. 2015 , 16, 12		6
1155	Guidelines on Cerebrospinal Fluid Analysis. 2015 , 407-428		
1154	Relationship of cognitive strategy use to prospective memory performance in a diverse sample of nondemented older adults with varying degrees of cognitive complaints and impairment. 2015 , 22, 486-501		16
1153	Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI). 2015 , CD010783		256
1152	Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1191-201	1.2	59
1151	A Simple Tool to Reach Populations at Risk for Developing Dementia and Alzheimer's Disease. 2015 , 46, 151-5		1
1150	Role of cerebrospinal fluid biomarkers to predict conversion to dementia in patients with mild cognitive impairment: a clinical cohort study. 2015 , 53, 453-60		10
1149	Annual Cognitive Assessment for Older Adults: Update for Nurses. 2015 , 32, 187-98		6
1148	Predicting Alzheimer's disease development: a comparison of cognitive criteria and associated neuroimaging biomarkers. 2015 , 7, 68		33
1147	Souvenaid for Alzheimer's disease. 2015 ,		2
1146	Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease. 2015 , 36, 4421-37		142
1145	Understanding early dementia: EEG, MRI, SPECT and memory evaluation. 2015 , 6, 32-46		7
1144	Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease. 2015 , 74, 672-87		25

1143	Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. 2015 , 138, 2020-33	227
1142	Living With Ambiguity: A Metasynthesis of Qualitative Research on Mild Cognitive Impairment. 2015 , 55, 892-912	30
1141	Voices from the field: Expert reflections on mild cognitive impairment. 2015 , 14, 285-97	8
1140	Standardized mini-mental state examination scores and verbal memory performance at a memory center: implications for cognitive screening. 2015 , 30, 145-52	25
1139	The Moderating Effect of Personality Type on the Relationship between Leisure Activity and Executive Control in Older Adults. 2015 , 39, 153-176	1
1138	An adaptive genetic algorithm for selection of blood-based biomarkers for prediction of Alzheimer's disease progression. 2015 , 16 Suppl 18, S1	14
1137	Mild Cognitive Impairment, Slow Gait, and Risk of Disability: A Prospective Study. 2015 , 16, 1082-6	26
1136	Comparing the relationship between subjective memory complaints, objective memory performance, and medial temporal lobe volumes in patients with mild cognitive impairment. 2015 , 1, 242-248	19
1135	The Needs of Older Patients for Peritoneal Dialysis: Training and Support at Home. 2015 , 35, 625-9	10
1134	Correlations between mini-mental state examination score, cerebrospinal fluid biomarkers, and pathology observed in brain biopsies of patients with normal-pressure hydrocephalus. 2015 , 74, 470-9	40
1133	Combination of dynamic (11)C-PIB PET and structural MRI improves diagnosis of Alzheimer's disease. 2015 , 233, 131-40	8
1132	Delays in Manual Reaching Are Associated with Impaired Functional Abilities in Early Dementia Patients. 2015 , 40, 63-71	1
1131	Independent information from cerebrospinal fluid amyloid- β and florbetapir imaging in Alzheimer's disease. 2015 , 138, 772-83	169
1130	Amyloid-beta and depression in healthy older adults: a systematic review. 2015 , 49, 36-46	45
1129	Single time point high-dimensional morphometry in Alzheimer's disease: group statistics on longitudinally acquired data. 2015 , 36 Suppl 1, S11-22	4
1128	Standardized evaluation of algorithms for computer-aided diagnosis of dementia based on structural MRI: the CADDementia challenge. 2015 , 111, 562-79	193
1127	Cognitive function in patients with diabetes mellitus: guidance for daily care. 2015 , 14, 329-40	174
1126	Sugihara causality analysis of scalp EEG for detection of early Alzheimer's disease. 2015 , 7, 258-65	39

1125	Greater cortical thinning in normal older adults predicts later cognitive impairment. 2015 , 36, 903-8	53
1124	Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study. 2015 , 7, 34-42	69
1123	Pilot feasibility and safety study examining the effect of medium chain triglyceride supplementation in subjects with mild cognitive impairment: A randomized controlled trial. 2015 , 3, 123-5	44
1122	The family series workshop: a community-based psychoeducational intervention. 2015 , 30, 573-83	10
1121	Associations between performance of activities of daily living and everyday technology use among older adults with mild stage Alzheimer's disease or mild cognitive impairment. 2015 , 22, 33-42	15
1120	Nicotinic ACh receptors as therapeutic targets in CNS disorders. 2015 , 36, 96-108	299
1119	New DSM-V neurocognitive disorders criteria and their impact on diagnostic classifications of mild cognitive impairment and dementia in a memory clinic setting. 2015 , 23, 768-79	27
1118	Incidence of and risk factors for Alzheimer's disease and mild cognitive impairment in Korean elderly. 2015 , 39, 105-15	60
1117	Life extension factor klotho prevents mortality and enhances cognition in hAPP transgenic mice. 2015 , 35, 2358-71	105
1116	Cognitive Impairment and Dementia. 2015 , 3-11	
1115	Tau Positron Emission Tomography (PET) Imaging: Past, Present, and Future. 2015 , 58, 4365-82	77
1114	Morphometric and histologic substrates of cingulate integrity in elders with exceptional memory capacity. 2015 , 35, 1781-91	71
1113	Occipital sources of resting-state alpha rhythms are related to local gray matter density in subjects with amnesic mild cognitive impairment and Alzheimer's disease. 2015 , 36, 556-70	68
1112	Association of insulin-like growth factor-1 with mild cognitive impairment and slow gait speed. 2015 , 36, 942-7	33
1111	Evaluation and management of the elderly patient presenting with cognitive complaints. 2015 , 99, 311-35	31
1110	Amount and type of everyday technology use over time in older adults with cognitive impairment. 2015 , 22, 196-206	22
1109	White matter disruption at the prodromal stage of Alzheimer's disease: relationships with hippocampal atrophy and episodic memory performance. 2015 , 7, 482-92	52
1108	Relationship between Alzheimer disease-like pattern of 18F-FDG and fasting plasma glucose levels in cognitively normal volunteers. 2015 , 56, 229-33	27

1107	Auditory Verbal Learning Test in a Large Nonclinical Portuguese Population. 2015 , 22, 321-31			62
1106	Explorative and targeted neuroproteomics in Alzheimer's disease. 2015 , 1854, 769-78			36
1105	Disrupted Intrinsic Networks Link Amyloid-Pathology and Impaired Cognition in Prodromal Alzheimer's Disease. 2015 , 25, 4678-88			66
1104	Why do patients with neurodegenerative frontal syndrome fail to answer: 'In what way are an orange and a banana alike?'. 2015 , 138, 456-71			23
1103	18-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). 2015 , 1, CD010632			76
1102	Degree of abnormality is associated with rate of change in measures of beta-amyloid, glucose metabolism and cognition in an autopsy-verified Alzheimer's disease case. 2015 , 21, 738-47			
1101	Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia. 2015 , 7, 187-94			72
1100	Diagnostic differentiation of mild cognitive impairment due to Alzheimer's disease using a hippocampus-dependent test of spatial memory. 2015 , 25, 939-51			42
1099	Do NIA-AA criteria distinguish Alzheimer's disease from frontotemporal dementia?. <i>Alzheimer's and Dementia</i> , 2015 , 11, 207-15	1.2		18
1098	Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic. <i>Alzheimer's and Dementia</i> , 2015 , 11, 523-32	1.2		48
1097	Is there an MCI reversion to cognitively normal? Analysis of Alzheimer's disease biomarkers profiles. 2015 , 27, 429-37			15
1096	Relevance of parahippocampal-locus coeruleus connectivity to memory in early dementia. 2015 , 36, 618-26			41
1095	Fast, but not slow, familiarity is preserved in patients with amnesic mild cognitive impairment. 2015 , 65, 36-49			25
1094	Biomarkers of Alzheimer's disease and mild cognitive impairment: a current perspective. 2015 , 60, 76-82			47
1093	Biomarkers, ketone bodies, and the prevention of Alzheimer's disease. 2015 , 64, S51-7			15
1092	Running exercise delays neurodegeneration in amygdala and hippocampus of Alzheimer's disease (APP/PS1) transgenic mice. 2015 , 118, 189-97			96
1091	Assessing the Neurocognitive Disorders of the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition). 2015 , 50, 1-5			2
1090	The minimizing of fluorescence background in Raman optical activity and Raman spectra of human blood plasma. 2015 , 407, 1335-42			18

1089	The new DSM-5 diagnosis of mild neurocognitive disorder and its relation to research in mild cognitive impairment. 2015 , 19, 2-12	69
1088	Posterior brain white matter abnormalities in older adults with probable mild cognitive impairment. 2015 , 37, 61-9	14
1087	Cholinergic basal forebrain structure influences the reconfiguration of white matter connections to support residual memory in mild cognitive impairment. 2015 , 35, 739-47	32
1086	Clinical utility and applicability of biomarker-based diagnostic criteria for Alzheimer's disease: a BeDeCo survey. 2015 , 115, 547-55	7
1085	Considering the base rates of low performance in cognitively healthy older adults improves the accuracy to identify neurocognitive impairment with the Consortium to Establish a Registry for Alzheimer's Disease-Neuropsychological Assessment Battery (CERAD-NAB). 2015 , 265, 407-17	28
1084	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. 2015 , 138, 1327-38	211
1083	Prodromal dementia with Lewy bodies. 2015 , 15, 817-26	39
1082	Amyloid- β deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. 2015 , 138, 1023-35	143
1081	Enfermedad de Alzheimer. 2015 , 11, 4306-4315	2
1080	Clinical and imaging features of mixed Alzheimer and vascular pathologies. 2015 , 7, 21	69
1079	Mild cognitive impairment definitions: more evolution than revolution. 2015 , 5, 11-7	6
1078	Clinical validation of the WMS-IV-NL brief cognitive status exam (BCSE) in older adults with MCI or dementia. 2014 , 1-9	4
1077	Transient epileptic amnesia: Update on a slowly emerging epileptic syndrome. 2015 , 171, 289-97	16
1076	2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. <i>Alzheimer's and Dementia</i> , 2015 , 11, e1-120	1.2 206
1075	APOE and mild cognitive impairment: the Framingham Heart Study. 2015 , 44, 307-11	15
1074	Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. 2015 , 138, 1370-81	224
1073	The relationship between atrophy and hypometabolism: is it regionally dependent in dementias?. 2015 , 15, 44	6
1072	Cognitive profiles in Mild Cognitive Impairment (MCI) patients associated with Parkinson's disease and cognitive disorders. 2015 , 18, 200-5	4

1071	Usefulness of data from magnetic resonance imaging to improve prediction of dementia: population based cohort study. 2015 , 350, h2863		28
1070	Drug and Exercise Treatment of Alzheimer Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Effects on Cognition in Randomized Controlled Trials. 2015 , 23, 1234-1249		112
1069	Treatment of Mild Cognitive Impairment. 2015 , 17, 372		6
1068	Plasma amyloid <i>Equo vadis?</i> . 2015 , 36, 2671-3		14
1067	Gender differences in the longitudinal associations of depressive symptoms and leisure-time physical activity with cognitive decline in 87-year-old Taiwanese. 2015 , 77, 68-73		8
1066	Are transversal MR images sufficient to distinguish persons with mild cognitive impairment from healthy controls?. 2015 , 22, 1172-80		2
1065	From Evidence to Action: Promoting a Multidimensional Approach to Mild Cognitive Impairment. 2015 , 16, 710-1		15
1064	Le diagnostic précoce de la maladie d'Alzheimer : panacée ou catastrophe ?. 2015 , 1, 151-154		1
1063	The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. <i>Alzheimer's and Dementia</i> , 2015 , 11, 772-91	1.2	53
1062	The effect of white matter hyperintensities on neurodegeneration in mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1510-1519	1.2	62
1061	Sulcal morphology as a new imaging marker for the diagnosis of early onset Alzheimer's disease. 2015 , 36, 2932-2939		30
1060	Emotional processing in patients with mild cognitive impairment: the influence of the valence and intensity of emotional stimuli: the valence and intensity of emotional stimuli influence emotional processing in patients with mild cognitive impairment. 2015 , 357, 222-8		9
1059	A comparison of 2 screening questionnaires for clinical assessment of canine cognitive dysfunction. 2015 , 10, 452-458		9
1058	Resting-state fMRI reveals enhanced functional connectivity in spatial navigation networks after transcranial direct current stimulation. 2015 , 604, 80-5		24
1057	Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. 2015 , 36, 2340-7		40
1056	Better together: Left and right hemisphere engagement to reduce age-related memory loss. 2015 , 293, 125-33		16
1055	Olfactory function and neuropsychological profile to differentiate dementia with Lewy bodies from Alzheimer's disease in patients with mild cognitive impairment: A 5-year follow-up study. 2015 , 355, 174-9		52
1054	Learning temporal statistics for sensory predictions in mild cognitive impairment. 2015 , 75, 368-80		5

1053	Alzheimer's Disease Neuroimaging Initiative: A decade of progress in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015 , 11, 727-9	1.2	7
1052	Regional cerebral blood flow estimated by early PiB uptake is reduced in mild cognitive impairment and associated with age in an amyloid-dependent manner. 2015 , 36, 1619-1628		27
1051	Early stage of behavioral variant frontotemporal dementia: clinical and neuroimaging correlates. 2015 , 36, 3108-3115		26
1050	Relationship of contextual cueing and hippocampal volume in amnesic mild cognitive impairment patients and cognitively normal older adults. 2015 , 21, 285-96		11
1049	Diagnostic transitions in mild cognitive impairment by use of simple Markov models. 2015 , 30, 669-76		23
1048	Harpagosome ameliorates the amyloid-induced cognitive impairment in rats via up-regulating BDNF expression and MAPK/PI3K pathways. 2015 , 303, 103-14		32
1047	Non-rapid eye movement sleep instability in mild cognitive impairment: a pilot study. 2015 , 16, 1139-45		46
1046	Altered whole-brain white matter networks in preclinical Alzheimer's disease. 2015 , 8, 660-6		61
1045	Interaction of Ω 3 fatty acids with B vitamins in slowing the progression of brain atrophy: identifying the elderly at risk. 2015 , 102, 7-8		4
1044	Progression of mild cognitive impairment to dementia due to AD in clinical settings. 2015 , 85, 331-8		50
1043	Amyloid- β as a biomarker for Alzheimer's disease: quantification methods in body fluids. 2015 , 12, 343-54		18
1042	Optimal Target Region for Subject Classification on the Basis of Amyloid PET Images. 2015 , 56, 1351-8		13
1041	The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. 2015 , 138, 2732-49		275
1040	Classification and clinicoradiologic features of primary progressive aphasia (PPA) and apraxia of speech. 2015 , 69, 220-36		99
1039	Neuropsychological tests for predicting cognitive decline in older adults. 2015 , 5, 191-201		10
1038	Visual rating and volumetric measurement of medial temporal atrophy in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort: baseline diagnosis and the prediction of MCI outcome. 2015 , 30, 192-200		25
1037	Cognitive impairment, all-cause and cause-specific mortality among non-demented older adults. 2015 , 44, 445-51		64
1036	Will PET amyloid imaging lead to overdiagnosis of Alzheimer dementia?. 2015 , 22, 988-94		9

1035	Preliminary cognitive scale of basic and instrumental activities of daily living for dementia and mild cognitive impairment. 2015 , 37, 339-53		10
1034	Estrogen-cholinergic interactions: Implications for cognitive aging. 2015 , 74, 173-85		42
1033	Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability. 2015 , 449, 9-15		51
1032	Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1470-1479	1.2	12
1031	[(18)F]Florbetaben: a review in β -Amyloid PET imaging in cognitive impairment. 2015 , 29, 605-13		19
1030	The Worldwide Alzheimer's Disease Neuroimaging Initiative: An update. <i>Alzheimer's and Dementia</i> , 2015 , 11, 850-9	1.2	33
1029	Alzheimer's disease research in the context of the national plan to address Alzheimer's disease. 2015 , 43-44, 16-24		11
1028	A critical review of chronic traumatic encephalopathy. 2015 , 56, 276-93		82
1027	Verbal Fluency and Early Memory Decline: Results from the Wisconsin Registry for Alzheimer's Prevention. 2015 , 30, 448-57		53
1026	Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. <i>Alzheimer's and Dementia</i> , 2015 , 11, 740-56	1.2	101
1025	A Cochrane review on brain [18 F]FDG PET in dementia: limitations and future perspectives. 2015 , 42, 1487-91		44
1024	Altered characteristic of brain networks in mild cognitive impairment during a selective attention task: An EEG study. 2015 , 98, 8-16		10
1023	Network Disruption and Cerebrospinal Fluid Amyloid-Beta and Phospho-Tau Levels in Mild Cognitive Impairment. 2015 , 35, 10325-30		54
1022	IMPROVING THE CLINICAL DETECTION OF LEWY BODY DEMENTIA WITH THE LEWY BODY COMPOSITE RISK SCORE. 2015 , 1, 316-324		33
1021	The impact of the Alzheimer's Disease Neuroimaging Initiative 2: What role do public-private partnerships have in pushing the boundaries of clinical and basic science research on Alzheimer's disease?. <i>Alzheimer's and Dementia</i> , 2015 , 11, 860-4	1.2	12
1020	Longitudinal declines in instrumental activities of daily living in stable and progressive mild cognitive impairment. 2015 , 39, 12-24		10
1019	Converging evidence for the neuroanatomic basis of combinatorial semantics in the angular gyrus. 2015 , 35, 3276-84		150
1018	Amyloid Tracers. 2015 , 633-639		

1017	A review of amnesic MCI screening in east/southeast Asian older adults with low education: implications for early informant-clinician collaboration. 2015 , 30, 144-55		3
1016	Alzheimer's Disease and the Search for Environmental Risk Factors. 2015 , 315-327		
1015	The UP-TECH project, an intervention to support caregivers of Alzheimer's disease patients in Italy: preliminary findings on recruitment and caregiving burden in the baseline population. 2015 , 19, 517-25		17
1014	Diffusion-MRI in neurodegenerative disorders. 2015 , 33, 853-76		60
1013	Associations Between Ankle-Brachial Index and Cognitive Function: Results From the Lifestyle Interventions and Independence for Elders Trial. 2015 , 16, 682-9		7
1012	Harmonized benchmark labels of the hippocampus on magnetic resonance: the EADC-ADNI project. <i>Alzheimer's and Dementia</i> , 2015 , 11, 151-60.e5	1.2	32
1011	Executive function as a strong predictor of recovery from disability in patients with acute stroke: a preliminary study. 2015 , 24, 554-61		25
1010	Cerebral autoregulation, beta amyloid, and white matter hyperintensities are interrelated. 2015 , 592, 54-8		58
1009	Diagnosis of vascular cognitive impairment and its main categories. 2015 , 30, 223-239		1
1008	The role of APOE-e4 and beta amyloid in the differential rate of recovery from ECT: a review. 2015 , 5, e539		7
1007	Manual segmentation qualification platform for the EADC-ADNI harmonized protocol for hippocampal segmentation project. <i>Alzheimer's and Dementia</i> , 2015 , 11, 161-74	1.2	16
1006	Reversing Ribot: does regression hold in language of prodromal Alzheimer's disease?. 2015 , 143, 1-10		5
1005	Hippocampal atrophy varies by neuropsychologically defined MCI among men in their 50s. 2015 , 23, 456-65		14
1004	Quantitative electroencephalogram utility in predicting conversion of mild cognitive impairment to dementia with Lewy bodies. 2015 , 36, 434-45		77
1003	Delphi definition of the EADC-ADNI Harmonized Protocol for hippocampal segmentation on magnetic resonance. <i>Alzheimer's and Dementia</i> , 2015 , 11, 126-38	1.2	96
1002	Improving the predictive value of interventional animal models data. 2015 , 20, 475-82		15
1001	[Novel methods for dementia diagnostics]. 2015 , 86, 452-60		4
1000	Cognitive rehabilitation for mild cognitive impairment: developing and piloting an intervention. 2015 , 22, 280-300		13

999	PET/MR in dementia and other neurodegenerative diseases. 2015 , 45, 224-33	72
998	Neuropsychological Testing Predicts Cerebrospinal Fluid Amyloid- β In Mild Cognitive Impairment. 2015 , 46, 901-12	17
997	A Summary Score for the Framingham Heart Study Neuropsychological Battery. 2015 , 27, 1199-222	7
996	Posteromedial hyperactivation during episodic recognition among people with memory decline: findings from the WRAP study. 2015 , 9, 690-702	2
995	Awareness of Memory Ability and Change: (In)Accuracy of Memory Self-Assessments in Relation to Performance. 2015 , 8, 71-99	19
994	Systematic review of strengths and limitations of randomized controlled trials for non-pharmacological interventions in mild cognitive impairment: focus on Alzheimer's disease. 2015 , 19, 141-53	33
993	Visuo-constructional functions in patients with mild cognitive impairment, Alzheimer's disease, and Parkinson's disease. 2015 , 29, 112-9	5
992	The use of amyloid imaging in clinical praxis: a critical review. 2015 , 3, 7-11	4
991	Beta-amyloid imaging with florbetaben. 2015 , 3, 13-26	93
990	Insights into cognitive aging and Alzheimer's disease using amyloid PET and structural MRI scans. 2015 , 3, 65-74	6
989	Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's disease. 2015 , 36, 2018-23	64
988	New criteria for Alzheimer's disease: which, when and why?. 2015 , 138, 1134-7	9
987	Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review. 2015 , 7, 17	282
986	Early neurone loss in Alzheimer's disease: cortical or subcortical?. 2015 , 3, 10	101
985	Biochemical and neuroimaging studies in subjective cognitive decline: progress and perspectives. 2015 , 21, 768-75	36
984	Amyloid- β and α -synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease. 2015 , 21, 758-64	41
983	Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. 2015 , 72, 316-24	112
982	Functional and physical abilities in the early continuum of cognitive decline. 2015 , 39, 41-51	7

981	Imaging Correlates of Memory and Concussion History in Retired National Football League Athletes. 2015 , 72, 773-80		74
980	Transcranial direct current stimulation in mild cognitive impairment: Behavioral effects and neural mechanisms. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1032-40	1.2	115
979	Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a secondary care setting. 2015 , CD010772		54
978	Commonalities and challenges in the development of clinical trial measures in neurology. 2015 , 12, 151-69		5
977	Verbal memory and brain aging: an exploratory analysis of the role of error responses in the Framingham Study. 2015 , 30, 622-8		4
976	Plasma amyloid- β and risk of Alzheimer's disease in the Framingham Heart Study. <i>Alzheimer's and Dementia</i> , 2015 , 11, 249-57.e1	1.2	66
975	2015 Alzheimer's disease facts and figures. <i>Alzheimer's and Dementia</i> , 2015 , 11, 332-84	1.2	1212
974	Effects of game-based virtual reality on health-related quality of life in chronic stroke patients: A randomized, controlled study. 2015 , 63, 92-8		68
973	Mild cognitive impairment: a history and the state of current diagnostic criteria. 2014 , 1-13		9
972	Cognitive Frailty: A Systematic Review of Epidemiological and Neurobiological Evidence of an Age-Related Clinical Condition. 2015 , 18, 389-412		83
971	Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease. 2015 , 72, 699-706		54
970	Precision medicine: Clarity for the clinical and biological complexity of Alzheimer's and Parkinson's diseases. 2015 , 212, 601-5		28
969	Early detection of dementia in multilingual populations: Visual Cognitive Assessment Test (VCAT). 2016 , 87, 156-60		9
968	Mild cognitive impairment due to alzheimer disease is less likely under the age of 65. 2015 , 29, 26-31		6
967	Recommendations from the Italian Interdisciplinary Working Group (AIMN, AIP, SINDEM) for the utilization of amyloid imaging in clinical practice. 2015 , 36, 1075-81		29
966	Predictors of heart failure self-care in patients who screened positive for mild cognitive impairment. 2015 , 30, 152-60		39
965	The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer disease. 2015 , 72, 520-9		83
964	Cognitive impairment in Parkinson's disease. 2015 , 91, 212-20		36

963	The level of Alzheimer-associated neuronal thread protein in urine may be an important biomarker of mild cognitive impairment. 2015 , 22, 649-52		32
962	Specific food preferences of older adults with a poor appetite. A forced-choice test conducted in various care settings. 2015 , 90, 168-75		25
961	Immediate story recall in elderly individuals with memory complaints: how much does it contribute to memory assessment?. 2015 , 27, 1679-86		10
960	Differentiated clinical presentation of early and late-onset Alzheimer's disease: is 65 years of age providing a reliable threshold?. 2015 , 262, 1238-46		27
959	Cerebellum Can Serve As a Pseudo-Reference Region in Alzheimer Disease to Detect Neuroinflammation Measured with PET Radioligand Binding to Translocator Protein. 2015 , 56, 701-6		146
958	The Potential Utility of Eye Movements in the Detection and Characterization of Everyday Functional Difficulties in Mild Cognitive Impairment. 2015 , 25, 199-215		23
957	Amyloid biomarkers in Alzheimer's disease. 2015 , 36, 297-309		320
956	Hearing, Cognition, and Healthy Aging: Social and Public Health Implications of the Links between Age-Related Declines in Hearing and Cognition. 2015 , 36, 122-39		57
955	Cognitive Function: Is There More to Anticoagulation in Atrial Fibrillation Than Stroke?. 2015 , 4, e001573		17
954	Imaging-based enrichment criteria using deep learning algorithms for efficient clinical trials in mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1489-1499	1.2	42
953	Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. 2015 , 7, 59		80
952	Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease. 2015 , 5, 425-43		19
951	Relationship between cerebrospinal fluid biomarkers of Alzheimer's disease and cognition in cognitively normal older adults. 2015 , 78, 63-72		28
950	Benefits and risks of add-on therapies for Alzheimer's disease. 2015 , 5, 445-62		3
949	Development of a subjective cognitive decline questionnaire using item response theory: a pilot study. 2015 , 1, 429-439		37
948	A History of Mild and Major Neurocognitive Disorders. 2015 , 29, 570-572		
947	Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. 2015 , 138, 3747-59		128
946	THE QUICK DEMENTIA RATING SYSTEM (QDRS): A RAPID DEMENTIA STAGING TOOL. 2015 , 1, 249-259		59

945	Observations on DSM-5 Mild Neurocognitive Disorder vs. its predecessor, Mild Cognitive Impairment. 2015 , 131, 15-7		8
944	Low Levels of a Urinary Biomarker of Dietary Polyphenol Are Associated with Substantial Cognitive Decline over a 3-Year Period in Older Adults: The Invecchiare in Chianti Study. 2015 , 63, 938-46		45
943	A multicenter study of the early detection of synaptic dysfunction in Mild Cognitive Impairment using Magnetoencephalography-derived functional connectivity. 2015 , 9, 103-9		55
942	Relative 11C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session 15O-Water and 11C-PiB PET. 2015 , 56, 1199-205		48
941	The Rapid Cognitive Screen (RCS): A Point-of-Care Screening for Dementia and Mild Cognitive Impairment. 2015 , 19, 741-4		79
940	Development of a straightforward and sensitive scale for MCI and early AD clinical trials. <i>Alzheimer's and Dementia</i> , 2015 , 11, 404-14	1.2	14
939	A novel method for early diagnosis of Alzheimer's disease based on pseudo Zernike moment from structural MRI. 2015 , 305, 361-71		39
938	Modifications of the endosomal compartment in peripheral blood mononuclear cells and fibroblasts from Alzheimer's disease patients. 2015 , 5, e595		12
937	Predicting the conversion of mild cognitive impairment to Alzheimer's disease based on the volumetric measurements of the selected brain structures in magnetic resonance imaging. 2015 , 49, 349-53		11
936	Role of β Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. 2015 , 72, 1475-83		19
935	Neuropathological comparisons of amnesic and nonamnesic mild cognitive impairment. 2015 , 15, 146		28
934	Neuropsychological test selection for cognitive impairment classification: A machine learning approach. 2015 , 37, 899-916		25
933	Spectrum of cognition short of dementia: Framingham Heart Study and Mayo Clinic Study of Aging. 2015 , 85, 1712-21		52
932	Learning to predict is spared in mild cognitive impairment due to Alzheimer's disease. 2015 , 233, 2859-67		6
931	Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: consensus proposal from the SEMNIM and SEN. 2015 , 34, 303-313		2
930	14th Annual Meeting of the Society of Toxicology: Threading through peripheral and central nervous system presentations. 2015 , 75, 143-57		2
929	Structural imaging of hippocampal subfields in healthy aging and Alzheimer's disease. 2015 , 309, 29-50		174
928	How many biomarkers to discriminate neurodegenerative dementia?. 2015 , 52, 314-26		14

927	Effect of a 24-Month Physical Activity Intervention vs Health Education on Cognitive Outcomes in Sedentary Older Adults: The LIFE Randomized Trial. 2015 , 314, 781-90		224
926	Multimodal imaging in Alzheimer's disease: validity and usefulness for early detection. 2015 , 14, 1037-53		172
925	Regional mosaic genomic heterogeneity in the elderly and in Alzheimer's disease as a correlate of neuronal vulnerability. 2015 , 130, 501-10		31
924	The preclinical phase of the pathological process underlying sporadic Alzheimer's disease. 2015 , 138, 2814-33		260
923	Asymmetries of amyloid- β burden and neuronal dysfunction are positively correlated in Alzheimer's disease. 2015 , 138, 3089-99		39
922	Metabolic and Non-Cognitive Manifestations of Alzheimer's Disease: The Hypothalamus as Both Culprit and Target of Pathology. 2015 , 22, 761-76		109
921	C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1461-1469	1.2	95
920	Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. 2015 , 85, 1240-9		192
919	Individually modifiable risk factors to ameliorate cognitive aging: a systematic review and meta-analysis. 2015 , 18, 678-89		62
918	Current and Future Treatments for Alzheimer Disease. 2015 , 23, 1101-5		6
917	Benefits of mindfulness training for patients with progressive cognitive decline and their caregivers. 2015 , 30, 257-67		72
916	Global Trends in Alzheimer Disease Clinical Development: Increasing the Probability of Success. 2015 , 37, 1632-42		29
915	Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations. 2015 , 1, 358-67		30
914	Cognitive Function in Individuals With Physical Frailty but Without Dementia or Cognitive Complaints: Results From the I-Lan Longitudinal Aging Study. 2015 , 16, 899.e9-16		55
913	Awareness of cognitive deficits in older adults with epilepsy and mild cognitive impairment. 2015 , 37, 785-93		6
912	Burden of Care and Patient's Neuropsychiatric Symptoms Influence Carer's Evaluation of Cognitive Impairment. 2015 , 40, 256-67		14
911	FDG-PET Contributions to the Pathophysiology of Memory Impairment. 2015 , 25, 326-55		17
910	Effects of imaging modalities, brain atlases and feature selection on prediction of Alzheimer's disease. 2015 , 256, 168-83		42

909	Whole-genome sequencing suggests a chemokine gene cluster that modifies age at onset in familial Alzheimer's disease. 2015 , 20, 1294-300		36
908	Cognitive screening in persons with chronic diseases in primary care: challenges and recommendations for practice. 2015 , 30, 547-58		11
907	Conventional and robust norming in identifying preclinical dementia. 2015 , 37, 1098-106		8
906	DNA repair factor BRCA1 depletion occurs in Alzheimer brains and impairs cognitive function in mice. 2015 , 6, 8897		104
905	Early cost-utility analysis of general and cerebrospinal fluid-specific Alzheimer's disease biomarkers for hypothetical disease-modifying treatment decision in mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2015 , 11, 896-905	1.2	16
904	A multi-contrast MRI study of microstructural brain damage in patients with mild cognitive impairment. 2015 , 8, 631-9		17
903	Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus. 2015 , 34, 303-13		11
902	Effects of pioglitazone or exercise in older adults with mild cognitive impairment and insulin resistance: a pilot study. 2015 , 5, 51-63		24
901	Is the Electroencephalogram Power Spectrum Valuable for Diagnosis of the Elderly with Cognitive Impairment?. 2015 , 9, 196-200		7
900	Isobaric Quantification of Cerebrospinal Fluid Amyloid- β Peptides in Alzheimer's Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration. 2015 , 14, 4834-43		6
899	Piramal Imaging. 2015 , 5, 283-8		1
898	Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. 2015 , 15, 83-105		53
897	Imaging biomarkers associated with cognitive decline: a review. 2015 , 77, 685-92		39
896	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. 2015 , 11, 41-55		116
895	Roles of resveratrol and other grape-derived polyphenols in Alzheimer's disease prevention and treatment. 2015 , 1852, 1202-8		151
894	Adverse vascular risk is related to cognitive decline in older adults. 2015 , 44, 1361-73		44
893	Mild cognitive impairment etiologic subtyping using pragmatic and conventional criteria: preliminary experience in the Florence VAS-COG clinic. 2015 , 27, 345-50		0
892	Posterior cingulate β -aminobutyric acid and glutamate/glutamine are reduced in amnesic mild cognitive impairment and are unrelated to amyloid deposition and apolipoprotein E genotype. 2015 , 36, 53-9		46

891	Hippocampal volume, early cognitive decline and gait variability: which association?. 2015 , 61, 98-104		46
890	Apathy as a feature of prodromal Alzheimer's disease: an FDG-PET ADNI study. 2015 , 30, 470-7		37
889	The influence of age and mild cognitive impairment on associative memory performance and underlying brain networks. 2015 , 9, 776-89		17
888	The neuropsychological profile of vascular cognitive impairment not demented: a meta-analysis. 2015 , 9, 109-36		86
887	Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015 , 11, 455-61	1.2	7
886	Gray & white matter tissue contrast differentiates Mild Cognitive Impairment converters from non-converters. 2015 , 9, 141-8		17
885	Operationalizing protocol differences for EADC-ADNI manual hippocampal segmentation. <i>Alzheimer's and Dementia</i> , 2015 , 11, 184-94	1.2	40
884	Diagnosis of vascular cognitive impairment and its main categories. 2015 , 30, 223-39		19
883	Epigenomics of Alzheimer's disease. 2015 , 165, 200-20		79
882	Potential benefits of mindfulness-based interventions in mild cognitive impairment and Alzheimer's disease: an interdisciplinary perspective. 2015 , 276, 199-212		51
881	Anxiety symptoms in amnesic mild cognitive impairment are associated with medial temporal atrophy and predict conversion to Alzheimer disease. 2015 , 23, 466-76		84
880	DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequencesPart 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders, personality disorders, and substance-related and addictive disorders. 2015 , 215, 87-107		19
879	Al imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study. 2015 , 86, 431-6		63
878	World Federation of Societies of Biological Psychiatry guidelines for the pharmacological treatment of dementias in primary care. 2015 , 19, 2-7		16
877	Using visual evoked potentials for the early detection of amnesic mild cognitive impairment: a pilot investigation. 2015 , 30, 72-9		20
876	MRS in mild cognitive impairment: early differentiation of dementia with Lewy bodies and Alzheimer's disease. 2015 , 25, 269-274		12
875	At the interface of sensory and motor dysfunctions and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015 , 11, 70-98	1.2	271
874	Widespread white matter degeneration preceding the onset of dementia. <i>Alzheimer's and Dementia</i> , 2015 , 11, 485-493.e2	1.2	49

873	The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey. <i>Alzheimer's and Dementia</i> , 2015 , 11, 195-206.e1	1.2	45
872	The free and cued selective reminding test: Validation for mild cognitive impairment and Alzheimer's disease. 2015 , 9, 242-57		31
871	Clinical characterization of mild cognitive impairment as a prodrome to dementia with Lewy bodies. 2015 , 30, 173-7		11
870	Toward an integrated pipeline for protein biomarker development. 2015 , 1854, 677-86		41
869	Bioactive Nutrients for Brain Health. 2015 , 49-56		
868	Patients with mild cognitive impairment have an abnormal upper-alpha event-related desynchronization/synchronization (ERD/ERS) during a task of temporal attention. 2015 , 122, 441-53		14
867	Measuring hope among families impacted by cognitive impairment. 2016 , 15, 596-608		12
866	Cortical Amyloid Burden Differences Across Empirically-Derived Mild Cognitive Impairment Subtypes and Interaction with APOE e4 Genotype. 2016 , 52, 849-61		43
865	[Not Available]. 2016 , 19, 74-82		2
864	Impairment of fine motor dexterity in mild cognitive impairment and Alzheimer's disease dementia: association with activities of daily living. 2016 , 38, 235-8		36
863	El bilingüismo como protección ante la demencia: Inconsistencias empíricas y nuevas propuestas metodológicas. 2016 , 68, 3-44		
862	The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease. 2016 , 53, 1523-38		40
861	Development of TUA-WELLNESS screening tool for screening risk of mild cognitive impairment among community-dwelling older adults. 2016 , 11, 579-87		3
860	Electroencephalography-driven approach to prodromal Alzheimer's disease diagnosis: from biomarker integration to network-level comprehension. 2016 , 11, 897-912		8
859	Imaging Alzheimer's disease pathophysiology with PET. 2016 , 10, 79-90		21
858	Contribution of the Cholinergic System to Verbal Memory Performance in Mild Cognitive Impairment. 2016 , 53, 991-1001		18
857	Performance of low-educated elders with depression on Addenbrooke's Cognitive Examination-Revised (ace-r) test. 2016 , 10, 19-25		2
856	Abnormal organization of white matter networks in patients with subjective cognitive decline and mild cognitive impairment. 2016 , 7, 48953-48962		26

855	The New Criteria for Alzheimer's Disease - Implications for Geriatricians. 2016 , 19, 66-73	10
854	Cognitive Training in Later Adulthood. 2016 , 219-243	6
853	Plasma Brain-Derived Neurotrophic Factor as a Biomarker for the Main Types of Mild Neurocognitive Disorders and Treatment Efficacy: A Preliminary Study. 2016 , 2016, 4095723	17
852	Clinical practice guidelines for dementia in Australia. 2016 , 204, 191-3	64
851	Awareness of memory deficits is useful to distinguish between depression and mild cognitive impairment in the elderly. 2016 , 38, 231-4	6
850	Connected Language in Late Middle-Aged Adults at Risk for Alzheimer's Disease. 2016 , 54, 1539-1550	33
849	FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging. 2016 , 53, 1609-16	25
848	The Five Systems of Dysphagia: MCI to the AD Spectrum of Disorders. 2016 , 1, 37-52	3
847	Feasibility of a Memory Clinic-Based Physical Activity Prescription Program. 2016 , 53, 161-70	15
846	Personality-Related Determinants of Subtle Cognitive Decline in Old Age: A Population-Based Study. 2016 , 6, 120-132	2
845	Bilingualism and Cognitive Reserve: A Critical Overview and a Plea for Methodological Innovations. 2015 , 7, 249	52
844	Cerebrospinal Fluid Levels of Amyloid Beta 1-43 in Patients with Amnesic Mild Cognitive Impairment or Early Alzheimer's Disease: A 2-Year Follow-Up Study. 2016 , 8, 30	10
843	Electrophysiological Advances on Multiple Object Processing in Aging. 2016 , 8, 46	4
842	The Differentiation of Amnesic Type MCI from the Non-Amnesic Types by Structural MRI. 2016 , 8, 52	68
841	Altered Frontal Lateralization Underlies the Category Fluency Deficits in Older Adults with Mild Cognitive Impairment: A Near-Infrared Spectroscopy Study. 2016 , 8, 59	36
840	Abnormal Changes of Brain Cortical Anatomy and the Association with Plasma MicroRNA107 Level in Amnesic Mild Cognitive Impairment. 2016 , 8, 112	10
839	Magnetic Resonance Imaging to Detect Early Molecular and Cellular Changes in Alzheimer's Disease. 2016 , 8, 139	23
838	The Effects of Mindfulness on Persons with Mild Cognitive Impairment: Protocol for a Mixed-Methods Longitudinal Study. 2016 , 8, 156	7

837	The Early Indicators of Functional Decrease in Mild Cognitive Impairment. 2016 , 8, 193	13
836	Clinical Relevance of Specific Cognitive Complaints in Determining Mild Cognitive Impairment from Cognitively Normal States in a Study of Healthy Elderly Controls. 2016 , 8, 233	7
835	The Primacy Effect in Amnesic Mild Cognitive Impairment: Associations with Hippocampal Functional Connectivity. 2016 , 8, 244	12
834	Impaired White Matter Connections of the Limbic System Networks Associated with Impaired Emotional Memory in Alzheimer's Disease. 2016 , 8, 250	22
833	Mobility and Upright Posture Are Associated with Different Aspects of Cognition in Older Adults. 2016 , 8, 257	14
832	Global Efficiency of Structural Networks Mediates Cognitive Control in Mild Cognitive Impairment. 2016 , 8, 292	30
831	Classifying Cognitive Profiles Using Machine Learning with Privileged Information in Mild Cognitive Impairment. 2016 , 10, 117	7
830	Visual and Ocular Manifestations of Alzheimer's Disease and Their Use as Biomarkers for Diagnosis and Progression. 2016 , 7, 55	90
829	Progressively Disrupted Intrinsic Functional Connectivity of Basolateral Amygdala in Very Early Alzheimer's Disease. 2016 , 7, 132	10
828	Allocentric Spatial Memory Testing Predicts Conversion from Mild Cognitive Impairment to Dementia: An Initial Proof-of-Concept Study. 2016 , 7, 215	20
827	Older Adults with Mild Cognitive Impairments Show Less Driving Errors after a Multiple Sessions Simulator Training Program but Do Not Exhibit Long Term Retention. 2016 , 10, 653	9
826	Interference Impacts Working Memory in Mild Cognitive Impairment. 2016 , 10, 443	10
825	Early Dementia Screening. 2016 , 6,	41
824	Weighted-Permutation Entropy Analysis of Resting State EEG from Diabetics with Amnesic Mild Cognitive Impairment. 2016 , 18, 307	7
823	Prognosis of Early-Onset Late-Onset Mild Cognitive Impairment: Comparison of Conversion Rates and Its Predictors. 2016 , 1,	11
822	Jointly using computationally selected and clinically suggested cortical volumes for automated identification of mild cognitive impairment. 2016 ,	
821	Regional Cerebral Blood Flow in [123]I-IMP Single-photon Emission Computed Tomography and the Wechsler Memory Scale-revised in Nondemented Elderly Subjects with Subjective Cognitive Impairment. 2016 , 55, 3571-3578	4
820	Biomarker für die Alzheimer-Erkrankung in der klinischen Praxis. 2016 , 27, 46-52	

819	Application and Revision of Montreal Cognitive Assessment in China's Military Retirees with Mild Cognitive Impairment. 2016 , 11, e0145547	4
818	Predicting Progression from Mild Cognitive Impairment to Alzheimer's Dementia Using Clinical, MRI, and Plasma Biomarkers via Probabilistic Pattern Classification. 2016 , 11, e0138866	121
817	I'd Do Anything for Research, But I Won't Do That: Interest in Pharmacological Interventions in Older Adults Enrolled in a Longitudinal Aging Study. 2016 , 11, e0159664	11
816	Structural MR Imaging in the Diagnosis of Alzheimer's Disease and Other Neurodegenerative Dementia: Current Imaging Approach and Future Perspectives. 2016 , 17, 827-845	38
815	Neuropsychological Profiles in Mild Cognitive Impairment due to Alzheimer's and Parkinson's Diseases. 2016 , 6, 413-21	9
814	What can imaging tell us about cognitive impairment and dementia?. 2016 , 8, 240-54	26
813	Assessment of impairment in activities of daily living in mild cognitive impairment using an individualized scale. 2016 , 74, 549-54	7
812	Altered Topology in Information Processing of a Narrated Story in Older Adults with Mild Cognitive Impairment. 2016 , 53, 517-33	4
811	Optimizing the Coassessment of Gait and Cognitive Functioning. 2016 , 32, 127-133	
810	Determinants of Activity Levels in African Americans With Mild Cognitive Impairment. 2016 , 30, 41-6	7
809	NSAID Use and Incident Cognitive Impairment in a Population-based Cohort. 2016 , 30, 105-12	13
808	Embedded Online Questionnaire Measures Are Sensitive to Identifying Mild Cognitive Impairment. 2016 , 30, 152-9	20
807	Both Financial and Cognitive Decline Predict Clinical Progression in MCI. 2016 , 30, 27-34	13
806	Diagnosing Mild Cognitive Impairment as a Precursor to Dementia: Fact or Fallacy?. 2016 , 51, 366-373	6
805	Cognitive and Neural Effects of Vision-Based Speed-of-Processing Training in Older Adults with Amnesic Mild Cognitive Impairment: A Pilot Study. 2016 , 64, 1293-8	58
804	Supporting Safety in the Older Adult Driver: A Public Health Nursing Opportunity. 2016 , 33, 460-71	2
803	Diabetes and brain health: implications for practice. 2016 , 33, 179-191	
802	Physiological, pathological, and engineered cell identity reprogramming in the central nervous system. 2016 , 5, 499-517	5

801	Diagnostic Accuracy of Cognitive Screening Instruments in Heart Failure: A Systematic Review. 2016 , 31, 412-24	8
800	Medicare Expenditures of Individuals with Alzheimer's Disease and Related Dementias or Mild Cognitive Impairment Before and After Diagnosis. 2016 , 64, 1549-57	54
799	Peripheral Inflammation and Alzheimer's Disease: Periodontal Disease. 2016 , 93-106	
798	Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada. 2016 , 43, 503-12	22
797	Development of a Novel Urine Alzheimer-Associated Neuronal Thread Protein ELISA Kit and Its Potential Use in the Diagnosis of Alzheimer's Disease. 2016 , 30, 308-14	16
796	Default Mode Network Functional Connectivity in Early and Late Mild Cognitive Impairment: Results From the Alzheimer's Disease Neuroimaging Initiative. 2016 , 30, 289-296	52
795	Wayfinding in ageing and Alzheimer's disease within a virtual senior residence: study protocol. 2016 , 72, 1677-88	20
794	Applicability of digital analysis and imaging technology in neuropathology assessment. 2016 , 36, 270-82	9
793	Amyloid Imaging With 11C-PIB in Patients With Cognitive Impairment in a Clinical Setting: A Visual and Semiquantitative Analysis. 2016 , 41, e18-23	14
792	Mild cognitive impairment in a Spanish representative sample: prevalence and associated factors. 2016 , 31, 858-67	44
791	A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. 2016 , 87, 539-47	710
790	Effects of change in FreeSurfer version on classification accuracy of patients with Alzheimer's disease and mild cognitive impairment. 2016 , 37, 1831-41	18
789	Telomere longitudinal shortening as a biomarker for dementia status of adults with Down syndrome. 2016 , 171B, 169-74	12
788	Education modifies the type of subjective memory complaints in older people. 2016 , 31, 153-60	16
787	Association of Plasma DPP4 Activity With Mild Cognitive Impairment in Elderly Patients With Type 2 Diabetes: Results From the GDMD Study in China. 2016 , 39, 1594-601	41
786	Functional Disability in Mild Cognitive Impairment: A Systematic Review and Meta-Analysis. 2016 , 26, 129-59	85
785	Impact of the combination of cognitive and balance training on gait, fear and risk of falling and quality of life in seniors with mild cognitive impairment. 2016 , 16, 1043-50	37
784	Impact of Personality on Cognitive Aging: A Prospective Cohort Study. 2016 , 22, 765-76	32

783	Reversion From Mild Cognitive Impairment to Normal Cognition: A Meta-Analysis. 2016 , 30, 324-330	92
782	Phthalimide-Derived N-Benzylpyridinium Halides Targeting Cholinesterases: Synthesis and Bioactivity of New Potential Anti-Alzheimer's Disease Agents. 2016 , 349, 293-301	17
781	Depressive symptoms increase the risk of progression to dementia in subjects with mild cognitive impairment: systematic review and meta-analysis. 2016 , 31, 905-11	117
780	Early symptoms of Alzheimer's disease in Japan and Taiwan. 2016 , 16, 797-803	7
779	The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer's Disease: Shortcomings in Prodromal Diagnosis. 2016 , 53, 373-92	6
778	Insula and Inferior Frontal Gyrus' Activities Protect Memory Performance Against Alzheimer's Disease Pathology in Old Age. 2017 , 55, 669-678	42
777	Analysis of the MIRIAD Data Shows Sex Differences in Hippocampal Atrophy Progression. 2016 , 50, 847-57	73
776	Optimal Cutoff Scores for Alzheimer's Disease Using the Chinese Version of Mini-Mental State Examination Among Chinese Population Living in Rural Areas. 2016 , 31, 650-657	9
775	Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer's Disease. 2016 , 54, 1395-1408	29
774	Combining the Rowland Universal Dementia Assessment Scale and the Informant Questionnaire on Cognitive Decline in the Elderly to Improve Detection of Dementia in an Arabic-Speaking Population. 2016 , 41, 46-54	15
773	Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. 2016 , 8, 1184-1196	152
772	Using the Disease State Fingerprint Tool for Differential Diagnosis of Frontotemporal Dementia and Alzheimer's Disease. 2016 , 6, 313-329	9
771	Memory for Public Events in Mild Cognitive Impairment and Alzheimer's Disease: The Importance of Rehearsal. 2016 , 50, 1023-33	9
770	Searching for Primary Predictors of Conversion from Mild Cognitive Impairment to Alzheimer's Disease: A Multivariate Follow-Up Study. 2016 , 52, 133-43	37
769	Patients with Amyloid-Negative Mild Cognitive Impairment have Cortical Hypometabolism but the Hippocampus is Preserved. 2016 , 53, 651-60	9
768	Relational memory and self-efficacy measures reveal distinct profiles of subjective memory concerns in older adults. 2016 , 30, 568-578	11
767	Occupational Attainment as Risk Factor for Progression from Mild Cognitive Impairment to Alzheimer's Disease: A CREDOS Study. 2017 , 55, 283-292	16
766	A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium. 2016 , 54, 383-95	31

765	Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. 2017 , 55, 159-170	19
764	CALHM1 deficiency impairs cerebral neuron activity and memory flexibility in mice. 2016 , 6, 24250	19
763	Technology-enhanced multi-domain at home continuum of care program with respect to usual care for people with cognitive impairment: the Ability-TelerehABILITation study protocol for a randomized controlled trial. 2016 , 16, 425	44
762	Homotaurine Effects on Hippocampal Volume Loss and Episodic Memory in Amnesic Mild Cognitive Impairment. 2016 , 50, 807-16	11
761	Alcohol Consumption and Incident Dementia: Evidence from the Sydney Memory and Ageing Study. 2016 , 52, 529-38	16
760	Clinical and neuroimaging differences between posterior cortical atrophy and typical amnesic Alzheimer's disease patients at an early disease stage. 2016 , 6, 29372	15
759	Relationship between oxysterols and mild cognitive impairment in the elderly: a case-control study. 2016 , 15, 177	27
758	Prevention Trials in Alzheimer's Disease: Current Status and Future Perspectives. 2016 , 50, 927-45	19
757	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team. 2017 , 55, 19-35	29
756	Identifying biomarkers of dementia prevalent among amnesic mild cognitively impaired ethnic female patients. 2016 , 8, 43	9
755	HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer's disease. 2016 , 13, 194	114
754	Subjective Memory Impairment and 'Gait' Variability in Cognitively Healthy Individuals: Results from a Cross-Sectional Pilot Study. 2017 , 55, 965-971	10
753	Subtypes of mild cognitive impairment in patients with Parkinson's disease: evidence from the LANDSCAPE study. 2016 , 87, 1099-105	56
752	Metabolic Syndrome and Mild Cognitive Impairment: A Case-Control Study among Elderly in a Shanghai Suburb. 2016 , 51, 1175-82	9
751	18F PET ligands for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). 2016 ,	5
750	Computerised cognition-based interventions for preventing dementia in people with mild cognitive impairment. 2016 ,	1
749	Brain imaging in dementia. 2016 , 92, 333-40	17
748	Altered DNA base excision repair profile in brain tissue and blood in Alzheimer's disease. 2016 , 9, 61	25

747	stREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. 2016 , 8, 466-76	256
746	Low episodic memory performance in cognitively normal elderly subjects is associated with increased posterior cingulate gray matter N-acetylaspartate: a H MRSI study at 7 Tesla. 2016 , 48, 195-203	15
745	Classification of Alzheimer's disease and mild cognitive impairment: Machine learning applied to rs-fMRI brain graphs. 2016 ,	2
744	Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study. 2016 , 52, 1321-33	34
743	Epileptic Prodromal Alzheimer's Disease, a Retrospective Study of 13 New Cases: Expanding the Spectrum of Alzheimer's Disease to an Epileptic Variant?. 2016 , 52, 1125-33	61
742	ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials. 2016 , 87, 993-9	82
741	Topographical Information-Based High-Order Functional Connectivity and Its Application in Abnormality Detection for Mild Cognitive Impairment. 2016 , 54, 1095-1112	70
740	Cerebral Glucose Metabolism is Associated with Verbal but not Visual Memory Performance in Community-Dwelling Older Adults. 2016 , 52, 661-72	19
739	Motoric Cognitive Risk Syndrome and Falls Risk: A Multi-Center Study. 2016 , 53, 1043-52	48
738	Looking for Measures of Disease Severity in the Frontotemporal Dementia Continuum. 2016 , 52, 1227-35	12
737	Subtle changes in daily functioning predict conversion from normal to mild cognitive impairment or dementia: an analysis of the NACC database. 2016 , 28, 2009-2018	21
736	Added Prognostic Value of Cerebrospinal Fluid Biomarkers in Predicting Decline in Memory Clinic Patients in a Prospective Cohort. 2016 , 52, 875-85	7
735	The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease. 2016 , 8, 41	78
734	A Six-Month Cognitive-Motor and Aerobic Exercise Program Improves Executive Function in Persons with an Objective Cognitive Impairment: A Pilot Investigation Using the Antisaccade Task. 2016 , 54, 923-931	15
733	Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia. 2016 , 54, 1495-1508	17
732	Effect of Normal Aging and of Mild Cognitive Impairment on Event-Related Potentials to a Stroop Color-Word Task. 2016 , 52, 1487-501	18
731	Autobiographical Memory Performance in Alzheimer's Disease Depends on Retrieval Frequency. 2016 , 52, 1215-25	9
730	Visual Rating of Posterior Atrophy as a Marker of Progression to Dementia in Mild Cognitive Impairment Patients. 2017 , 55, 137-146	4

729	Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment. 2016 , 18, e13	26
728	Altered Brain Activities Associated with Neural Repetition Effects in Mild Cognitive Impairment Patients. 2016 , 53, 693-704	10
727	A Systematic Review of the Definitions of Vascular Cognitive Impairment, No Dementia in Cohort Studies. 2016 , 42, 69-79	15
726	Application of the IWG-2 Diagnostic Criteria for Alzheimer's Disease to the ADNI. 2016 , 51, 227-36	10
725	Intraindividual Cognitive Variability in Middle Age Predicts Cognitive Impairment 8-10 Years Later: Results from the Wisconsin Registry for Alzheimer's Prevention. 2016 , 22, 1016-1025	24
724	Redox Based-Peripheral Biomarkers in Alzheimer's Disease: Challenges, Limits and Prospects. 2016 , 377-397	1
723	Prediction of Free and Cued Selective Reminding Test Performance Using Volumetric and Amyloid-Based Biomarkers of Alzheimer's Disease. 2016 , 22, 991-1004	9
722	Night-to-night variation in sleep associates with day-to-day variation in vigilance, cognition, memory, and behavioral problems in Alzheimer's disease. 2022 , 14,	
721	Exploring the brain metabolic correlates of process-specific CSF biomarkers in patients with MCI due to Alzheimer's disease: preliminary data. 2022 , 117, 212-212	0
720	Influence of Previous General Anesthesia on Cognitive Impairment: An Observational Study Among 151 Patients. 2022 , 16,	0
719	Treatment effects on event-related EEG potentials and oscillations in Alzheimer's disease.. 2022 ,	0
718	The Current Landscape of Prevention Trials in Dementia.. 2022 ,	0
717	Serum GFAP differentiates Alzheimer's disease from frontotemporal dementia and predicts MCI-to-dementia conversion.. 2022 ,	4
716	Brain Metabolism and Amyloid Load in Individuals With Subjective Cognitive Decline or Pre-Mild Cognitive Impairment.. 2022 ,	0
715	Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology.. 2022 ,	1
714	An Activation Likelihood Estimation Meta-Analysis of Specific Functional Alterations in Dorsal Attention Network in Mild Cognitive Impairment.. 2022 , 16, 876568	1
713	Prodromal Dementias with Lewy Bodies: A Paradigm for Identifying People at Ultra-High Risk. 2022 , 325-333	
712	Medication Rules in Herbal Medicine for Mild Cognitive Impairment: A Network Pharmacology and Data Mining Study. 2022 , 2022, 1-15	0

- 711 Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort study. **2022**, 14, 1
- 710 Brain-Derived Neurotrophic Factor: A Connecting Link Between Nutrition, Lifestyle, and Alzheimer's Disease. **2022**, 16, 2
- 709 Altered TIMP-3 Levels in the Cerebrospinal Fluid and Plasma of Patients with Alzheimer's Disease. **2022**, 12, 827 1
- 708 Shared pathophysiology: Understanding stroke and Alzheimer's disease. **2022**, 218, 107306 2
- 707 Factors Associated with Behavioral and Psychological Symptoms of Dementia During Covid-19 factors Associated with Behavioral and Psychological Symptoms of Dementia During COVID-19.
- 706 Association between Cerebral Small Vessel and Alzheimer's Disease. **2022**, 83, 486
- 705 Single-Cell Analysis of the Peripheral Immune Landscape in Alzheimer's Disease Reveals a Distinct Adaptive Immune Signature.
- 704 A Functional Assessment Tool to Distinguish Controls From Alzheimer's Disease in Lima, Peru. **2022**, 37, 153331752211043
- 703 Differential diagnosis of vascular cognitive impairment. **2022**, 24, 85-89
- 702 Pre-Trained CNN Models in Early Alzheimer's Prediction Using Post-Processed MRI. **2022**, 47-95
- 701 Single-Channel EEG Features Reveal an Association With Cognitive Decline in Seniors Performing Auditory Cognitive Assessment. 14,
- 700 Distinct Patterns Link the BDNF Val66Met Polymorphism to Alzheimer's Disease Pathology. **2022**, 1-7
- 699 Regional spectral ratios as potential neural markers to identify mild cognitive impairment related to Alzheimer's disease. 1-15
- 698 A multi-site, multi-participant magnetoencephalography resting-state dataset to study dementia: The BioFIND dataset. **2022**, 119344 0
- 697 BDNF Val66Met Moderates the Effects of Hypertension on Executive Functioning in Older Adults Diagnosed with aMCI. **2022**,
- 696 Survey Results of Speech-Language Pathologists Working With Cognitive-Communication Disorders: Improving Practices for Mild Cognitive Impairment and Early-Stage Dementia From Alzheimer's Disease. 1-19 1
- 695 Can early phase cardiac [123I]mIBG images be used to diagnose Lewy body disease?. **20**, Publish Ahead of Print,
- 694 A History of Senile Plaques: From Alzheimer to Amyloid Imaging. **2022**, 81, 387-413 0

693	Altered excitatory and inhibitory neuronal subpopulation parameters are distinctly associated with tau and amyloid in Alzheimer's disease. 11,	0
692	Peripheral Inflammatory Biomarkers of Alzheimer's Disease. 2022 , 1-10	1
691	Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging. 10.1212/WNL.0000000000200735	1
690	Increasing the Cognitive Screening Efficiency of Global Phase III Trials in Early Alzheimer Disease. 10 , Publish Ahead of Print,	0
689	Segmental Bioimpedance Variables in Association With Mild Cognitive Impairment. 2022 , 9,	0
688	The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review. 2022 , 63, 13S-19S	4
687	Structural and functional connectivity abnormalities of the default mode network in patients with Alzheimer's disease and mild cognitive impairment within two independent datasets. 2022 ,	2
686	Plasma repressor element 1-silencing transcription factor levels are decreased in patients with Alzheimer's disease. 2022 , 22,	
685	Changes in Adiposity and Cerebrospinal Fluid Biomarkers Following a Modified Mediterranean Ketogenic Diet in Older Adults at Risk for Alzheimer's Disease. 2022 , 16,	1
684	Volumetric Assessment of Hippocampus and Subcortical Gray Matter Regions in Alzheimer Disease and Amnesic Mild Cognitive Impairment. 2022 , 35, 95-103	
683	Different Profiles of Spatial Navigation Deficits In Alzheimer's Disease Biomarker-Positive Versus Biomarker-Negative Older Adults With Amnesic Mild Cognitive Impairment. 14,	2
682	Histoire naturelle et diagnostic de la maladie d'Alzheimer. 2022 , 143-161	
681	Cortical Gray to White Matter Signal Intensity Ratio as an Early Sign of Cognitive Decline in Alzheimer's Dementia and Mild Cognitive Impairment.	
680	Neurocognitive Disorders. 2022 ,	
679	Dissociative Disorders. 2022 ,	
678	Clinical applicability of quantitative atrophy measures on MRI in patients suspected of Alzheimer's disease.	2
677	Specific Cerebrospinal Fluid SerpinA1 Isoform Pattern in Alzheimer's Disease. 2022 , 23, 6922	1
676	Age-Dependent Association Between Cognitive Reserve Proxy and Longitudinal White Matter Microstructure in Older Adults. 13,	0

- 675 Deficits in spontaneous and stimulus-dependent retrieval as an early sign of abnormal aging. **2022**, 12,
- 674 Effects of multi-component non-pharmacological interventions on cognition in participants with mild cognitive impairment: a systematic review and meta-analysis. **2022**, 104751 1
- 673 The Value of Neuroimaging in Dementia Diagnosis. **2022**, 28, 800-821 0
- 672 Procedural learning, declarative learning, and working memory as predictors of learning the use of a memory compensation tool in persons with amnesic mild cognitive impairment. 1-26
- 671 Associations of vascular risk and amyloid burden with subsequent dementia. 2
- 670 Acetylcholine bidirectionally regulates learning and memory. **2022**, 100002 0
- 669 Clinical Features and Potential Mechanisms Relating Neuropathological Biomarkers and Blood-Brain Barrier in Patients With Alzheimer's Disease and Hearing Loss. 14,
- 668 Abnormal Functional Hierarchies of EEG Networks in Familial and Sporadic Prodromal Alzheimer's Disease During Visual Short-Term Memory Binding. 1,
- 667 Differential Patterns of Domain-Specific Cognitive Complaints and Awareness Across the Alzheimer's Disease Spectrum. 14, 0
- 666 Prevalence of Depressive Symptoms in a Memory Clinic Cohort: A Retrospective Study. **2022**, 1-9 1
- 665 Feasibility of Cognitive Training in Combination With Transcranial Direct Current Stimulation in a Home-Based Context (TrainStim-Home): study protocol for a randomised controlled trial. **2022**, 12, e059943 0
- 664 Alzheimer's Disease with Epileptiform EEG Activity: Abnormal Cortical Sources of Resting State Delta Rhythms in Patients with Amnesic Mild Cognitive Impairment. **2022**, 1-29 0
- 663 Automated Early Detection of Alzheimer's Disease by Capturing Impairments in Multiple Cognitive Domains with Multiple Drawing Tasks. **2022**, 1-15 1
- 662 Associations of Bilateral Vestibulopathy With Cognition in Older Adults Matched With Healthy Controls for Hearing Status. 0
- 661 Fully automated and highly specific plasma β -amyloid immunoassays predict β -amyloid status defined by amyloid positron emission tomography with high accuracy. **2022**, 14, 1
- 660 Atypical Alzheimer Disease Variants. **2022**, 28, 676-701 0
- 659 Description of a European memory clinic cohort undergoing amyloid-PET: The AMYPAD Diagnostic and Patient Management Study. *Alzheimer's and Dementia*, 1.2 1
- 658 Phosphorylated Tau 181 Serum Levels Predict Alzheimer's Disease in the Preclinical Stage. 14, 1

- 657 CT-Detected MTA Score Related to Disability and Behavior in Older People with Cognitive Impairment. **2022**, 10, 1381
- 656 Protocol for Rhapsody: a longitudinal observational study examining the feasibility of speech phenotyping for remote assessment of neurodegenerative and psychiatric disorders. **2022**, 12, e061193 0
- 655 Inflammation, tau pathology, and synaptic integrity associated with sleep spindles and memory prior to Amyloid positivity. 0
- 654 Implementation of a Hybrid Teleneuropsychology Method to Assess Middle Aged and Older Adults During the COVID-19 Pandemic. 1
- 653 Efficient self-attention mechanism and structural distilling model for Alzheimer's disease diagnosis. **2022**, 105737 1
- 652 The Influence of 24-h Ambulatory Blood Pressure on Cognitive Function and Neuropathological Biomarker in Patients With Alzheimer's Disease. 14,
- 651 Enhancing neurocognitive health, abilities, networks, & community engagement for older adults with cognitive impairments through technology: a scoping review introducing the ENHANCE Center. 1-11
- 650 Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease. 5
- 649 Staging of Alzheimer's disease: past, present, and future perspectives. **2022**, 1
- 648 Cost-effectiveness of Alzheimer's disease CSF biomarkers and amyloid-PET in early-onset cognitive impairment diagnosis.
- 647 Anticipated reactions to learning Alzheimer's disease biomarker results. **2022**, 14, 0
- 646 Neuropsychiatric disorders correction in Alzheimer's disease. **2022**, 14, 54-61
- 645 Combined therapy for Alzheimer's disease. **2022**, 14, 74-80
- 644 Plasma biomarkers for prognosis of cognitive decline in patients with mild cognitive impairment. 0
- 643 Alteration of Visuospatial System as an Early Marker of Cognitive Decline: A Double-Center Neuroimaging Study. 14,
- 642 Positron Emission Tomography-Based Assessment of Cognitive Impairment and Dementias, Critical Role of Fluorodeoxyglucose in such Settings. **2022**, 17, 479-494 0
- 641 Clinical and biological subtypes of late-life depression. **2022**, 312, 46-53 1
- 640 Central Nervous System. **2022**, 445-524

- 639 Vascular and microstructural markers of cognitive pathology. **2022**, 14, 0
- 638 A Metallomic Approach to Assess Associations of Plasma Metal Levels with Amnestic Mild Cognitive Impairment and Alzheimer's Disease: An Exploratory Study. **2022**, 11, 3655
- 637 Clinical Progression of Baseline Risk States for Mild Cognitive Impairment. **2022**, 1-8
- 636 Relations of impaired blood flow and cerebrospinal fluid flow with damage of strategic for cognitive impairment brain regions in cerebral small vessel disease. **2022**, 16, 25-35 0
- 635 Validation of a Multivariate Prediction Model of the Clinical Progression of Alzheimer's Disease in a Community-Dwelling Multiethnic Cohort.
- 634 Verbal Encoding Deficits Impact Recognition Memory in Atypical Non-Amnestic Alzheimer's Disease. **2022**, 12, 843 1
- 633 Mediation of the APOE Associations With Cognition Through Cerebral Blood Flow: The CIBL Study. 14,
- 632 Item-Level Story Recall Predictors of Amyloid-Beta in Late Middle-Aged Adults at Increased Risk for Alzheimer's Disease. 13, 0
- 631 EEG Resting-State Functional Networks in Amnestic Mild Cognitive Impairment. 15500594221100 0
- 630 Re-examining popular screening measures in neuro-oncology: MMSE and RBANS.
- 629 Study protocol for the Alzheimer and music therapy study: An RCT to compare the efficacy of music therapy and physical activity on brain plasticity, depressive symptoms, and cognitive decline, in a population with and at risk for Alzheimer's disease. **2022**, 17, e0270682 0
- 628 Network-based meta-analysis and the candidate gene association studies reveal novel ethnicity-specific variants in MFSD3 and MRPL43 associated with dementia with Lewy bodies.
- 627 Recent advances in Lewy body dementia: A comprehensive review. **2022**, 101441 0
- 626 Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease. 0
- 625 Cerebrospinal Fluid Cortisol and Dehydroepiandrosterone Sulfate, Alzheimer's Disease Pathology, and Cognitive Decline. 14, 2
- 624 Correlation Between Plasma Oligomeric Amyloid- β and Performance on the Language Neutral Visual Cognitive Assessment Test in a Southeast Asian Population. **2022**, 1-5
- 623 Structural and Functional Brain Connectivity Uniquely Contribute to Episodic Memory Performance in Older Adults. 14,
- 622 Differential spatial distribution of white matter lesions in Parkinson's and Alzheimer's diseases and cognitive sequelae. 0

621	Robust Assessment of EEG Connectivity Patterns in Mild Cognitive Impairment and Alzheimer's Disease. 1,	
620	Evaluating measurement properties of subjective cognitive decline self-reported outcome measures: a systematic review. 2022 , 11,	0
619	Introducing a gatekeeping system for amyloid status assessment in mild cognitive impairment.	
618	Inconsistencies between Subjective Reports of Cognitive Difficulties and Performance on Cognitive Tests are Associated with Elevated Internalising and Externalising Symptoms in Children with Learning-related Problems.	1
617	GA-MADRID: design and validation of a machine learning tool for the diagnosis of Alzheimer's disease and frontotemporal dementia using genetic algorithms.	1
616	Biological Correlates of Elevated Soluble TREM2 in 2 Cerebrospinal Fluid. 2022 ,	0
615	Upregulated Blood miR-150-5p in Alzheimer's Disease Dementia Is Associated with Cognition, Cerebrospinal Fluid Amyloid- β and Cerebral Atrophy. 2022 , 1-18	
614	fMRI complexity correlates with tau-PET in Late-Onset and Autosomal Dominant Alzheimer's Disease.	
613	Identification of Alzheimer's Disease Progression Stages Using Topological Measures of Resting-State Functional Connectivity Networks: A Comparative Study. 2022 , 2022, 1-13	
612	Patients With Severe Alcohol-Related Cognitive Impairment Improve in Flexibility When Abstinence Is Maintained: A Comparative Study With Alzheimer's Disease. 13,	
611	Validation of At-Home Application of a Digital Cognitive Screener for Older Adults. 14,	
610	Clinical Staging of Alzheimer's Disease: Concordance of Subjective and Objective Assessments in the Veteran's Affairs Healthcare System.	0
609	Effects of combined cognitive and physical intervention on enhancing cognition in older adults with and without mild cognitive impairment: A systematic review and meta-analysis. 14,	0
608	Longitudinal association between nutritional status and behavioral and psychological symptoms of dementia in older women with mild cognitive impairment and early-stage Alzheimer's disease. 2022 ,	0
607	Distinguishing Between Genuine and Feigned Dementia Using Event-related Potentials. Publish Ahead of Print,	0
606	A Comparison of Operational Definitions for Mild Cognitive Impairment. 2022 , 1-16	0
605	Latest Trends in Outcome Measures in Dementia and Mild Cognitive Impairment Trials. 2022 , 12, 922	
604	Blood-based A β 2 increases in the earliest pre-pathological stage before decreasing with progressive amyloid pathology in preclinical models and human subjects: opening new avenues for prevention.	1

- 603 P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles. **2022**, 14, 0
- 602 Identification and validation of a gray matter volume network in Alzheimer's disease. **2022**, 120344
- 601 From Subjective Cognitive Decline to Mild Cognitive Impairment to Dementia: Clinical and Capacity Assessment Considerations.
- 600 The Influence of Cerebrovascular Pathology on Cluster Analysis of Neuropsychological Scores in Patients With Mild Cognitive Impairment.
- 599 Spatial decrease of synaptic density in amnesic mild cognitive impairment follows the tau build-up pattern. 1
- 598 Cerebral Small Vessel Disease is Associated with Mild Cognitive Impairment in Type 2 Diabetes Mellitus. Volume 15, 1985-1994 0
- 597 A Deep Spatiotemporal Attention Network for Mild Cognitive Impairment Identification. 14,
- 596 Sleep Quality and Aging: A Systematic Review on Healthy Older People, Mild Cognitive Impairment and Alzheimer's Disease. **2022**, 19, 8457 3
- 595 Identification of Leukocyte Surface P2X7 as a Biomarker Associated with Alzheimer's Disease. **2022**, 23, 7867 0
- 594 Long-term exposure to outdoor light at night and mild cognitive impairment: A nationwide study in Chinese veterans. **2022**, 157441 0
- 593 Exercise Training for Mild Cognitive Impairment Adults Older Than 60: A Systematic Review and Meta-Analysis. **2022**, 1-16 1
- 592 Organized Registration for the Assessment of Dementia by the Nationwide General Consortium Toward Effective Treatment (ORANGE) Registry: Current Status and Perspectives of Mild Cognitive Impairment. **2022**, 1-11
- 591 Early Electrophysiological Aberrations in the Hippocampus of the TgF344-AD Rat Model as a Potential Biomarker for Alzheimer's Disease Prognosis.
- 590 Impaired type I interferon signaling activity implicated in the peripheral blood transcriptome of preclinical Alzheimer's disease. **2022**, 82, 104175 1
- 589 Effects of cognitive interventions on quality of life among adults with mild cognitive impairment: A systematic review and meta-analysis of randomised controlled trials. **2022**, 47, 23-34
- 588 Copolymer-1 as a potential therapy for mild cognitive impairment. **2022**, 162, 105892
- 587 Home-based electronic cognitive therapy in patients with Alzheimer's disease dementia: A Feasibility Study (Preprint).
- 586 In Individuals With Subjective Cognitive Decline, Age, Memory and Speed Scores at Baseline Predict Progression to Cognitive Impairment. Publish Ahead of Print,

- 585 Arterial hypertension and Aβ amyloid accumulation have spatially overlapping effects on posterior white matter hyperintensity presence and volume.
- 584 Early-phase 18F-Florbetapir and 18F-Flutemetamol images as proxies of brain metabolism in a memory clinic setting. *Jnumed*.122.264256 ○
- 583 Is Greenness Associated with Dementia? A Systematic Review and Dose-Response Meta-analysis. ○
- 582 Relations of neuropsychiatric symptoms with disease stage, sex, and daily function in mild cognitive impairment and dementia due to Alzheimer's disease: A cross-sectional study. **2022**, 110994 ○
- 581 Potential Diagnostic Applications of Multi-Delay Arterial Spin Labeling in Early Alzheimer's Disease: The Chinese Imaging, Biomarkers, and Lifestyle Study. 16, ○
- 580 The unique effect of TDP-43 on hippocampal subfield morphometry and cognition. **2022**, 103125
- 579 The age differences and effect of mild cognitive impairment on perceptual-motor and executive functions. 13,
- 578 Prospective Biomarkers of Alzheimer's Disease: A Systematic Review and Meta-analysis. **2022**, 101699 ○
- 577 The Effects on Gait of 4-Wheeled Walker Use in People with Alzheimer's Disease Dementia and Gait Impairment: A Pilot Study. **2022**, 1-6
- 576 Non-Invasive Nasal Discharge Fluid and Other Body Fluid Biomarkers in Alzheimer's Disease. **2022**, 14, 1532 ○
- 575 Kosten der Diagnostik kognitiver Störungen in deutschen Gedächtnisambulanzen. **2022**, 90, 361-367
- 574 Factors Associated with Fear of Falling in Individuals with Different Types of Mild Cognitive Impairment. **2022**, 12, 990
- 573 Digital Cognitive Biomarker for Mild Cognitive Impairments and Dementia: A Systematic Review. **2022**, 11, 4191 ○
- 572 Posterior pole analysis and ganglion cell layer measurements in Alzheimer's disease.
- 571 Epigenetic Peripheral Biomarkers for Early Diagnosis of Alzheimer's Disease. **2022**, 13, 1308 2
- 570 Cognitive Disorders: Outcomes After Intensive Care. **2022**, 395-402
- 569 From clinical phenotype to proteinopathy: molecular neuroimaging in neurodegenerative dementias. **2022**, 80, 24-35
- 568 Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment. ○

- 567 Automated Analysis of Drawing Process for Detecting Prodromal and Clinical Dementia. **2022**,
- 566 The Effectiveness of Community Aging Care Centers on Global Function for People Living with Dementia. **2022**, 1-10
- 565 Episodic Memory, Hippocampal Volume, and Function for Classification of Mild Cognitive Impairment Patients Regarding Amyloid Pathology. **2022**, 1-12
- 564 The Clinical Use of Alzheimer's Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer's Disease Consortium Survey. **2022**, 1-17 1
- 563 Subjective Cognitive Decline Associated with Discrimination in Medical Settings among Transgender and Nonbinary Older Adults. **2022**, 19, 9168 0
- 562 Long-term test-retest of cerebral [18F]MK-6240 binding and longitudinal evaluation of extracerebral tracer uptake in healthy controls and amnesic MCI patients.
- 561 Chinese version of the auditory verbal learning test: normative study and clinical applications in Chinese-speaking population in Shijiazhuang city.
- 560 The Role of Blood-Brain Barrier Dysfunction in Mild Cognitive Impairment: a Scientometric and Visualization Analysis from 2000 to 2021. **2022**, 72, 1977-1989
- 559 Complement 3 Is a Potential Biomarker for Cerebral Amyloid Angiopathy. **2022**, 1-7
- 558 Estimating high-order brain functional networks by correlation-preserving embedding. 0
- 557 Multivariate Base Rates of Low Neuropsychological Test Scores in Cognitively Intact Older Adults with Subjective Cognitive Decline from a Specialist Memory Clinic.
- 556 The New Zealand Genetic Frontotemporal Dementia Study (FTDGeNZ): a longitudinal study of pre-symptomatic biomarkers. 1-21
- 555 Multiple step saccades in simply reactive saccades could serve as a complementary biomarker for the early diagnosis of Parkinson's disease. 14, 0
- 554 Adenosine receptor signalling in Alzheimer's disease. **2022**, 18, 359-381 0
- 553 Altered visual entrainment in patients with Alzheimer's disease: magnetoencephalography evidence. **2022**, 4, 0
- 552 Leichte kognitive Beeinträchtigung (MCI) in der altersmedizinischen Praxis: Patientenorientierung, Diagnostik, Behandlung und Ethik.
- 551 Cortical neuroanatomical changes related to specific language impairments in primary progressive aphasia. 14,
- 550 Early diagnosis of Alzheimer's disease using machine learning: a multi-diagnostic, generalizable approach. **2022**, 14, 1

- 549 Biomarkers for the Diagnosis of Alzheimer's Disease in Clinical Practice: The Role of CSF Biomarkers during the Evolution of Diagnostic Criteria. **2022**, 23, 8598 o
- 548 Proteomic Discovery and Validation of Novel Fluid Biomarkers for Improved Patient Selection and Prediction of Clinical Outcomes in Alzheimer's Disease Patient Cohorts. **2022**, 10, 26 o
- 547 A Mini-Mental State Examination Formula May Help to Distinguish Alzheimer's Disease from Dementia with Lewy Bodies. **2022**, 1-11
- 546 Structural Correlates of Overt Sentence Reading in Mild Cognitive Impairment and Mild-to-Moderate Alzheimer's Disease. **2022**, 19,
- 545 Striatal tau burden is increased in APOE-e4+ mild cognitive impairment.
- 544 A + T τ status across MCI and dementia due to AD: a clinic-based, retrospective study. o
- 543 Effects of a cognitive rehabilitation program based on mnemonic skills and memory compensatory strategies for older adults: A pilot study. **2022**, 101, e29581
- 542 Factors Associated with Behavioral and Psychological Symptoms of Dementia during COVID-19. **2022**, 19, 10094
- 541 Prevalence of cognitive impairment in Brazilian indigenous community from Amazonas.
- 540 Development of multivariable prediction models for institutionalization and mortality in the full spectrum of Alzheimer's disease. **2022**, 14, o
- 539 Real-world applicability of glial fibrillary acidic protein and neurofilament light chain in Alzheimer's disease. 14,
- 538 Evaluating the performance of Bayesian and frequentist approaches for longitudinal modeling: application to Alzheimer's disease. **2022**, 12,
- 537 Sex differences in early-onset Alzheimer's disease. o
- 536 A Novel Deep Learning Radiomics Model to Discriminate AD, MCI and NC: An Exploratory Study Based on Tau PET Scans from ADNI. **2022**, 12, 1067 1
- 535 MoCA 7.1: Multicenter Validation of the First Italian Version of Montreal Cognitive Assessment. **2022**, 6, 509-520 1
- 534 Exploring cognitive and brain oxygenation changes over a 1-year period in physically active individuals with mild cognitive impairment: a longitudinal fNIRS pilot study. **2022**, 22, o
- 533 Comparison of brain microstructure alterations on diffusion kurtosis imaging among Alzheimer's disease, mild cognitive impairment, and cognitively normal individuals. 14,
- 532 Cerebrospinal fluid β -synuclein as a synaptic biomarker for preclinical Alzheimer's disease. jnp-2022-329124 o

- 531 Nationally Informed Recommendations on Approaching the Detection, Assessment, and Management of Mild Cognitive Impairment. **2022**, 1-7
- 530 Effect of cognitive reserve on amnesic mild cognitive impairment due to Alzheimer's disease defined by fluorodeoxyglucose-positron emission tomography. 14,
- 529 Association between cooking fuels and mild cognitive impairment among older adults from six low- and middle-income countries. **2022**, 12,
- 528 Resting state electroencephalographic rhythms are affected by immediately preceding memory demands in cognitively unimpaired elderly and patients with mild cognitive impairment. 14,
- 527 Non-linear association between serum spermidine and mild cognitive impairment: Results from a cross-sectional and longitudinal study. 14, 0
- 526 The genetic and environmental etiology of blood-based biomarkers related to risk of Alzheimer's Disease in a population-based sample of early old-age men.
- 525 Sex specific EEG signatures associated with cerebrospinal fluid biomarkers in mild cognitive impairment. **2022**, 0
- 524 Association Plasma A β 2 Levels with Alzheimer's Disease and Its Influencing Factors in Chinese Elderly Population. Volume 18, 1831-1841
- 523 Biological determinants of blood-based cytokines in the Alzheimer's disease clinical continuum. 0
- 522 Develop a diagnostic tool for dementia using machine learning and non-imaging features. 14,
- 521 Improving Our Understanding of Driving Changes in Preclinical and Early Symptomatic Alzheimer's Disease: The Role of Naturalistic Driving Studies. **2022**, 6, 521-528
- 520 Cognitive Reserve Modulates Brain Structure and Cortical Architecture in the Alzheimer's Disease. **2022**, 1-14 1
- 519 Designing the next-generation clinical care pathway for Alzheimer's disease. **2022**, 2, 692-703 3
- 518 The CORCOBIA study: Cut-off points of Alzheimer's disease CSF biomarkers in a clinical cohort. **2022**, 1
- 517 Regression-based normative data for the Rey Auditory Verbal Learning Test in Norwegian and Swedish adults aged 49-79 and comparison with published norms. 1-25 0
- 516 APOE ϵ and Alzheimer's disease diagnosis associated differences in L-carnitine, GBB, TMAO and acylcarnitines in blood and brain.. **2022**, 103362 0
- 515 Specific Challenges in Geriatric Cirrhosis and Hepatic Encephalopathy. **2022**, 20, S20-S29 0
- 514 Network synchronization deficits caused by dementia and Alzheimer's disease serve as topographical biomarkers: a pilot study. 0

- 513 Impact of constipation on progression of Alzheimer's disease: A retrospective study. o
- 512 Biomarker and therapeutic potential of peripheral extracellular vesicles in Alzheimer's disease. **2022**, 114486 o
- 511 Predicting progression to dementia with a comprehensive visual rating scale and machine learning algorithms. 13,
- 510 Associations Between Intrathecal Levels of Vitamin D, Cytokines, and Core Biomarkers of Alzheimer's Disease: A Cross-Sectional Study. **2022**, 1-10 o
- 509 Are the inhibitory and facilitatory effects during retrieval of semantically related items present in amnesic mild cognitive impairment?.
- 508 Dementia Prevention Research Clinic: a longitudinal study investigating factors influencing the development of Alzheimer's disease in Aotearoa, New Zealand. 1-22
- 507 Prediction of conversion to dementia using interpretable machine learning in patients with amnesic mild cognitive impairment. 14, 1
- 506 Sex differences in patterns of associative memory-related activation in individuals at risk of Alzheimer's disease. **2022**, 119, 89-101 o
- 505 Proteomics of serum exosomes identified fibulin-1 as a novel biomarker for mild cognitive impairment. **2023**, 18, 587 o
- 504 Longitudinal change in ATN biomarkers in cognitively normal individuals. **2022**, 14, o
- 503 Gait in Cerebral Amyloid Angiopathy. o
- 502 Social participation and mild cognitive impairment in low- and middle-income countries. **2022**, 164, 107230 o
- 501 Tract-specific differences in white matter microstructure between young adult APOE ϵ carriers and non-carriers: A replication and extension study. **2022**, 2, 100126 o
- 500 Altered retinal cerebral vessel oscillation frequencies in Alzheimer's disease compatible with impaired amyloid clearance. **2022**, 120, 117-127 o
- 499 Diminishing accelerated long-term forgetting in mild cognitive impairment: Study protocol for a prospective, double-blind, placebo-controlled, randomized controlled trial. **2022**, 30, 100989 o
- 498 Are Wearable Sensors Useful to Assess the Psychophysical Fatigue Due to Physical Activity in Elderly People with Mild Cognitive Impairment? A Preliminary Study. **2022**, 346-354 o
- 497 A Pilot Study of Whole-Brain Low-Intensity Pulsed Ultrasound Therapy for Early Stage of Alzheimer's Disease (LIPUS-AD): A Randomized, Double-Blind, Placebo-Controlled Trial. **2022**, 1
- 496 Associations of the Lifestyle for Brain Health index with longitudinal cognition and brain amyloid beta in clinically unimpaired older adults: Findings from the Wisconsin Registry for Alzheimer's Prevention. **2022**, 14, o

- 495 The temporal lobe in typical and atypical Alzheimer disease. **2022**, 449-466 o
- 494 Olfactory Function Reflects Episodic Memory Performance and Atrophy in the Medial Temporal Lobe in Individuals at Risk for Alzheimer's Disease. o
- 493 High-performance medicine in cognitive impairment: Brain-computer interfacing for prodromal Alzheimer's disease. **2022**, 105-121 o
- 492 Home EEG sleep assessment shows reduced slow-wave sleep in mild-to-moderate Alzheimer's disease. **2022**, 8, o
- 491 Phenotype-informed polygenic risk scores are associated with worse outcome in individuals at risk of Alzheimer's disease. **2022**, 14, o
- 490 Brain atrophy pattern in patients with mild cognitive impairment: MRI study. **2022**, 13, 335-348 o
- 489 Development of Virtual Reality Neurocognitive Test for Mild Cognitive Impairment: Preliminary Study. **2022**, 61, 186 o
- 488 White matter hyperintensity distribution differences in aging and neurodegenerative disease cohorts. **2022**, 36, 103204 o
- 487 Combined treatment with Ginkgo biloba extract EGb 761 plus acetylcholinesterase inhibitors improved cognitive function and neuropsychiatric symptoms in patients with mild cognitive impairment. **2022**, 8, o
- 486 Development of the Colorado posterior cortical questionnaire within an Alzheimer's disease study cohort. **2022**, 44, 226-236 o
- 485 Toward Sensor-Based Early Diagnosis of Cognitive Impairment using Poisson Process Models. **2022**, o
- 484 Screening for Cognitive Impairment with the Quick Memory Check: Validation of a Caregiver Administered Cognitive Screen. **2022**, 1-11 1
- 483 Alzheimer's Disease Severity Is Associated with an Imbalance in Serum Levels of Enzymes Regulating Plasmin Synthesis. **2022**, 15, 1074 1
- 482 Screening for preclinical Alzheimer's disease: Deriving optimal policies using a partially observable Markov model. o
- 481 Frailty as a Predictor of Hospitalization and Low Quality of Life in Geriatric Patients at an Internal Medicine Outpatient Clinic: A Cross-Sectional Study. **2022**, 7, 89 1
- 480 Erfassung von Sprache und Kommunikation bei Personen mit MCI. o
- 479 Enlarged perivascular spaces are associated with decreased brain tau deposition. o
- 478 Cognitive reserve and mental health in cognitive frailty phenotypes: Insights from a study with a Portuguese sample. 13, o

477	Membrane transporters control cerebrospinal fluid formation independently of conventional osmosis to modulate intracranial pressure. 2022 , 19,	o
476	High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects. 2022 ,	1
475	Plasma glycocholic acid and linoleic acid identified as potential mediators of mitochondrial bioenergetics in Alzheimer's dementia. 14,	o
474	Quantitative gait analysis in mild cognitive impairment, dementia, and cognitively intact individuals: a cross-sectional case-control study. 2022 , 22,	o
473	Default-mode network connectivity changes during the progression towards Alzheimer's dementia: A longitudinal functional MRI study.	o
472	Level of Amyloid- β Binding Leading to Differential Effects on Resting State Functional Connectivity in Major Brain Networks. 2022 , 10, 2321	o
471	Alzheimer's Disease Diagnosis Based on the Amyloid, Tau, and Neurodegeneration Scheme (ATN) in a Real-Life Multicenter Cohort of General Neurological Centers. 2022 , 1-14	o
470	Estudio CORCOBIA: determinaci3n de puntos de corte de biomarcadores de enfermedad de Alzheimer en LCR en una cohorte cl3nica. 2022 ,	o
469	Effectiveness of an integrative medicine approach to improve cognitive dysfunction and dementia: An observational study. 2022 , 101, e30301	o
468	Layer-specific microstructural patterns of anterior hippocampus in Alzheimer's disease with ex vivo diffusion MRI at 14.1 T.	o
467	A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias. 2022 , 1-18	o
466	Episodic memory dysfunction and hypersynchrony in brain functional networks in cognitively intact subjects and MCI: a study of 379 individuals.	o
465	Autonomic function predicts cognitive decline in mild cognitive impairment: Evidence from power spectral analysis of heart rate variability in a longitudinal study. 14,	o
464	Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease.	o
463	Prediction of Alzheimer's Disease Using Patterns of Methylation Levels in Key Immunologic-Related Genes. 2022 , 1-12	o
462	Validation of a Remote and Fully Automated Story Recall Task to Assess for Early Cognitive Impairment in Older Adults: Longitudinal Case-Control Observational Study. 2022 , 5, e37090	2
461	Vascular-water-exchange MRI (VEXI) enables the detection of subtle BBB breakdown in Alzheimer's disease without MRI contrast agent.	o
460	Dynamic network model reveals distinct tau spreading patterns in early- and late-onset Alzheimer disease. 2022 , 14,	o

- 459 Altered local gyrification and functional connectivity in type 2 diabetes mellitus patients with mild cognitive impairment: A pilot cross-sectional small-scale single center study. 14, ○
- 458 mRNA isoform balance in neuronal development and disease. ○
- 457 Mild cognitive impairment is associated with low copy number of ribosomal genes in the genomes of elderly people. 13, ○
- 456 Inflammation-Related microRNAs-146a and -155 Are Upregulated in Mild Cognitive Impairment Subjects Among Older Age Population in Montenegro. **2022**, 1-14 1
- 455 Stable CSF neurogranin and BACE1 levels differentiate predementia Alzheimer's disease patients. ○
- 454 Cognitive Improvement Following Physical Exercise and Cognitive Training Intervention for Older Adults with MCI. ○
- 453 Tooth loss, periodontal disease, and mild cognitive impairment among Hispanic/Latino immigrants: The moderating effects of age at immigration. ○
- 452 It's all about cognitive trajectory: accuracy of the cognitive charts MoCA in normal aging, MCI , and dementia. ○
- 451 White Matter Hyperintensities and Cortical Atrophy are associated with Neuropsychiatric Symptoms in Neurodegenerative and Cerebrovascular Diseases. ○
- 450 A longitudinal study on quality of life along the spectrum of Alzheimer's disease. **2022**, 14, ○
- 449 Plasma Myeloperoxidase as a Potential Biomarker of Patient Response to Anti-Dementia Treatment in Alzheimer's Disease. **2022**, 1-10 ○
- 448 Memory markers in the continuum of the Alzheimer's clinical syndrome. **2022**, 14, ○
- 447 Clinical efficacy of acupuncture combined with Western medicine in the treatment of mild to moderate Alzheimer disease: A protocol of a randomized controlled trial. **2022**, 101, e30705 ○
- 446 Progressive attenuation of visual global precedence across healthy aging and Alzheimer's disease. 14, ○
- 445 Plasma microRNAs as potential biomarkers in early Alzheimer disease expression. **2022**, 12, ○
- 444 Capturing Cognitive Aging in Vivo: Application of a Neuropsychological Framework for Emerging Digital Tools. **2022**, 5, e38130 1
- 443 Sum of boxes of the clinical dementia rating scale highly predicts conversion or reversion in predementia stages. 14, 1
- 442 Cohort profile: the Norwegian Registry of Persons Assessed for Cognitive Symptoms (NorCog) a national research and quality registry with a biomaterial collection. **2022**, 12, e058810 1

441	Reshaping the path of mild cognitive impairment by refining exercise prescription: a study protocol of a randomized controlled trial to understand the What, For whom, And How of exercise to promote cognitive function. 2022 , 23,	0
440	Diagnostic accuracy of multi-component spatial-temporal gait parameters in older adults with amnesic mild cognitive impairment. 16,	0
439	Synthesizing Images of Tau Pathology from Cross-modal Neuroimaging using Deep Learning.	0
438	Amyloid-Tau-Neurodegeneration Profiles and Longitudinal Cognition in Sporadic Young-Onset Dementia. 2022 , 1-9	1
437	Evaluation of the Efficacy and Feasibility of a Telerehabilitation Program Using Language and Cognitive Exercises in Multi-Domain Amnesic Mild Cognitive Impairment.	1
436	Gut inflammation associated with age and Alzheimer's disease pathology.	0
435	Positive Effect of Cognitive Training in Older Adults with Different APOE Genotypes and COVID-19 History: A 1-Year Follow-Up Cohort Study. 2022 , 12, 2312	1
434	Integrity of neuronal size in the entorhinal cortex is a biologic substrate of exceptional cognitive aging. JN-RM-0679-22	0
433	Neural correlates of delusion in Alzheimer's disease and Mild Cognitive Impairment.	1
432	Patients carrying the mutation p.R406W in MAPT present with non-conforming phenotypic spectrum.	0
431	Markers of Systemic Inflammation in Assessing the Effectiveness of Neurocognitive Rehabilitation in Aged Patients with Mild Cognitive Impairment. 2022 , 20, 47-56	1
430	BACE1 Aptamer-Modified Tetrahedral Framework Nucleic Acid to Treat Alzheimer's Disease in an APP-PS1 Animal Model. 2022 , 14, 44228-44238	1
429	AI Protein Detector Based on AAO Confined Self-assembly System.	0
428	The complex burden of determining prevalence rates of mild cognitive impairment: A systematic review. 13,	2
427	Evaluating The Accuracy Of Medicare Risk Adjustment For Alzheimer's Disease And Related Dementias. 2022 , 41, 1324-1332	0
426	Impact of Amyloid and Tau PET on Changes in Diagnosis and Patient Management. 10.1212/WNL.0000000000001389	0
425	Cognitive and Brain Metabolism Profiles of Mild Cognitive Impairment in Prodromal Alpha-Synucleinopathy. 2022 , 1-12	0
424	The impact of conventional versus robust norming on cognitive characterization and clinical classification of MCI and dementia.	0

423	Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease.	5
422	High Cerebrospinal Fluid CX3CL1 Levels in Alzheimer's Disease Patients but Not in Non-Alzheimer's Disease Dementia. 2022 , 11, 5498	1
421	Associations of depressive symptoms with white matter abnormalities and regional cerebral blood flow in patients with amnesic mild cognitive impairment. 2022 , 22, 846-850	0
420	Characteristics of Drawing Process Differentiate Alzheimer's Disease and Dementia with Lewy Bodies. 2022 , 1-12	0
419	Aberrant pattern of regional cerebral blood flow in mild cognitive impairment: A meta-analysis of arterial spin labeling magnetic resonance imaging. 14,	0
418	Roles of traditional chinese medicine regulating neuroendocrinology on AD treatment. 13,	0
417	Mental health care for older adults: recent advances and new directions in clinical practice and research. 2022 , 21, 336-363	1
416	Biomarkers Related to Synaptic Dysfunction to Discriminate Alzheimer's Disease from Other Neurological Disorders. 2022 , 23, 10831	1
415	Serum Homocysteine, Vitamin B12, Folate, and Their Association with Mild Cognitive Impairment and Subtypes of Dementia. 2022 , 1-11	1
414	Integrating Mild Cognitive Impairment Screening Tools in Audiologic Care: A Review. 1-17	0
413	Predicting Cognitive Decline in Primary Progressive Aphasia: Can Brain Networks Be Crystal Balls?. 10.1212/WNL.0000000000000000	0
412	Altered CD8+ T cell associated aging gene signature in the peripheral blood of patients with Alzheimer's disease	0
411	Preliminary Validation Study of the French-Quebec Version of the Mild Behavioral Impairment Checklist. Publish Ahead of Print,	0
410	Peer-supported exercise intervention for persons with mild cognitive impairment: a waitlist randomised controlled trial (the BRAin Vitality Enhancement trial). 2022 , 51,	0
409	Decreased locus coeruleus signal associated with Alzheimer's disease based on neuromelanin-sensitive magnetic resonance imaging technique. 16,	0
408	Magnetic resonance imaging Locus Coeruleus abnormality in amnesic Mild Cognitive Impairment is associated with future progression to dementia.	1
407	Speech and language characteristics differentiate Alzheimer's disease and dementia with Lewy bodies. 2022 , 14,	0
406	Correlation of Global and Regional Amyloid Burden by 18F-Florbetaben PET/CT With Cognitive Impairment Profile and Severity. 2022 , 47, 923-930	0

405	Leveraging speech and artificial intelligence to screen for early Alzheimer's disease and amyloid beta positivity. 2022 , 4,	0
404	Gait variability during abrupt slow and fast speed transitions in older adults with mild cognitive impairment. 2022 , 17, e0276658	0
403	Associations of Naturally Occurring Antibodies to Presenilin-1 with Brain Amyloid-Load and Cognitive Impairment in Alzheimer's Disease. 2022 , 1-8	0
402	Improved Alzheimer's Disease versus Frontotemporal Lobar Degeneration Differential Diagnosis Combining EEG and Neurochemical Biomarkers: A Pilot Study. 2022 , 1-9	0
401	Cholinergic white matter pathways along the Alzheimer's disease continuum.	0
400	Evidence-Based Evaluation and Management of Cognitive Impairment in Dementia With Lewy Bodies. 2022 , 52, 404-409	0
399	Pharmacological Investigations of Selected Multitarget-Direct Ligands for the Treatment of Alzheimer's Disease. 2022 , 7,	0
398	Retinal Examinations Provides Early Warning of Alzheimer's Disease. 2022 , 1-17	0
397	Altered metamemory precedes cognitive impairment in subjective cognitive decline with positive amyloid-beta. 14,	0
396	Reliability, Validity, and User-Experience of Remote Unsupervised Computerized Neuropsychological Assessments in Community-Living 55 to 75-Year-Olds. 2022 , 1-17	0
395	Naturally occurring Alzheimer's disease in rhesus monkeys.	0
394	Hypothesis review: Alzheimer's overture guidelines.	1
393	Developing a Danish version of the LASSI-L test reliability and predictive value in patients with mild cognitive impairment, mild dementia due to AD and subjective cognitive decline. 1-13	0
392	Physical Functional Impairment and the Risk of Incident Mild Cognitive Impairment in an Observational Study of World Trade Center Responders. 10.1212/CPJ.0000000000200089	1
391	Comparative analysis of sensitivity and specificity of computer-aided cognitive test in screening mild cognitive impairment patients and test of reliability and validity. 1-7	0
390	Deep learning-based diagnosis of Alzheimer's disease using brain magnetic resonance images: an empirical study. 2022 , 12,	1
389	Neuropathology-basedAPOEgenetic risk score better quantifies Alzheimer's risk.	0
388	CSF Alzheimer Disease Biomarkers. 2022 , 99, e1640-e1650	2

- 387 Touchscreen Cognitive Tools for Mild Cognitive Impairment and Dementia Used in Primary Care Across Diverse Cultural and Literacy Populations: A Systematic Review. **2022**, 1-22 o
- 386 A head-to-head comparison between plasma pTau181 and tau-PET along the Alzheimer's disease continuum. *J. Neurosci.* 122.264279 o
- 385 Multi-Omics, an Integrated Approach to Identify Novel Blood Biomarkers of Alzheimer's Disease. **2022**, 12, 949 o
- 384 Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the US. 4
- 383 Cerebrospinal Fluid Biomarker Profile in TDP-43-Related Genetic Frontotemporal Dementia. **2022**, 12, 1747 o
- 382 Nonenzymatic function of DPP4 promotes diabetes-associated cognitive dysfunction through IGF-2R/PKA/SP1/ERp29/IP3R2 pathway-mediated impairment of Treg function and M1 microglia polarization. **2022**, 155340 o
- 381 Theory of mind in patients with mild cognitive impairment: A systematic review. 13, o
- 380 Homocysteine, Cognitive Functions, and Degenerative Dementias: State of the Art. **2022**, 10, 2741 o
- 379 Forgetting rate for the familiarity and recollection components of recognition in amnesic mild cognitive impairment: A longitudinal study. 1-13 o
- 378 Brain signal complexity in adults with Down syndrome: Potential application in the detection of mild cognitive impairment. 14, 1
- 377 Longitudinal tau PET using ¹⁸F-florbetapir: the Effect of relative Cerebral Blood Flow on (semi)quantitative parameters. *J. Neurosci.* 122.263926 o
- 376 Association Between Dietary Habits in Midlife With Dementia Incidence Over a 20-Year Period. 10.1212/WNL.0000000000000000 o
- 375 The use of subjective cognitive complaints for detecting mild cognitive impairment in older adults across cultural and linguistic groups: A comparison of the Cognitive Function Instrument to the Montreal Cognitive Assessment. o
- 374 Montreal cognitive assessment as a screening instrument for cognitive impairment in systemic lupus erythematosus patients without overt neuropsychiatric manifestations. 096120332211322 o
- 373 Integrated analyses of brain and platelet omics reveal their common altered and driven molecules in Alzheimer's disease. **2022**, 3, o
- 372 Emerging Role of miR-21-5p in Neuron-Glia Dysregulation and Exosome Transfer Using Multiple Models of Alzheimer's Disease. **2022**, 11, 3377 o
- 371 Is Mitochondria DNA Variation a Biomarker for AD?. **2022**, 13, 1789 o
- 370 Investigating Tissue-Specific Abnormalities in Alzheimer's Disease with Multi-Shell Diffusion MRI. **2022**, 1-21 o

369	Multimomics and artificial intelligence enabled peripheral blood-based prediction of amnesic mild cognitive impairment. 2022 , 103367	0
368	Do informant-reported subjective cognitive complaints predict progression to mild cognitive impairment and dementia better than self-reported complaints in old adults? A meta-analytical study. 2022 , 101772	1
367	Hypertensive Aspects of Cardiometabolic Disorders Are Associated with Lower Brain Microstructure, Perfusion, and Cognition. 2022 , 1-11	0
366	Frequency and Underlying Pathology of Pure Vascular Cognitive Impairment.	1
365	Evaluation of the Predictive Ability and User Acceptance of Panoramix 2.0, an AI-Based E-Health Tool for the Detection of Cognitive Impairment. 2022 , 11, 3424	0
364	Brain PET and Cerebrovascular Disease. 2022 ,	0
363	Patterns of the physical, cognitive, and mental health status of older individuals in a real-life primary care setting and differences in coping styles. 9,	0
362	Emotion recognition and processing in patients with mild cognitive impairment: A systematic review. 13,	0
361	Cognitive Impairment in Older Adults. 2022 ,	0
360	Arterial hypertension and Amyloid accumulation have spatially overlapping effects on posterior white matter hyperintensity volume: A cross-sectional study.	0
359	The Brain Health Platform: Combining Resilience, Vulnerability, and Performance to Assess Brain Health and Risk of Alzheimer's Disease and Related Disorders. 2022 , 1-13	0
358	Characterizing mild cognitive impairment to predict incident dementia in adults with bipolar disorder: What should the benchmark be?. 1-24	0
357	Dementia risk prediction in individuals with mild cognitive impairment: a comparison of Cox regression and machine learning models. 2022 , 22,	0
356	Can hippocampal subfield measures supply information that could be used to improve the diagnosis of Alzheimer's disease?. 2022 , 17, e0275233	0
355	The impact of mild cognitive impairment on decision-making under explicit risk conditions: Evidence from the Personality and Total Health (PATH) Through Life longitudinal study. 1-11	0
354	Plasma amyloid-beta oligomer is related to subjective cognitive decline and brain amyloid status. 2022 , 14,	0
353	Impaired Visual Inhibition in Amnesic Mild Cognitive Impairment. 155005942211368	0
352	Effects of long-term Wuqinxi exercise on working memory in older adults with mild cognitive impairment.	1

- 351 Transgenic animal models to explore and modulate the blood brain and blood retinal barriers of the CNS. **2022**, 19, 1
- 350 Cholesterol dysregulation in peripheral blood mononuclear cells of Alzheimer's disease. **2022**, 373, 577996 o
- 349 Sözel Akçelik Testleri, Alzheimer Hastalığı klinik değerlendirme için evrensel demans ve HKB ayrımlarında yarar sağlayabilir. 1403-1411 1
- 348 The Preventing Alzheimer's with Cognitive Training (PACT) randomized clinical trial. **2022**, 123, 106978 o
- 347 A randomized controlled trial to test the efficacy of a diabetes behavioral intervention to prevent memory decline in older blacks/African Americans with diabetes and mild cognitive impairment. **2022**, 123, 106977 o
- 346 Need for an Update for the Guideline for the Management of Mild Cognitive Impairment. **2022**, 21, 107 o
- 345 A remote speech-based AI system to screen for early Alzheimer's disease via smartphones. **2022**, 14, o
- 344 Cognitive dysfunction and the 25-item National Eye Institute Visual Function Questionnaire. **2022**, 14, o
- 343 Alterations in metamemory capacity and neural correlates in a subtype of subjective cognitive decline. **2022**, 36, 103255 o
- 342 Emotional characteristics of socially isolated older adults with MCI using tablet administered NIH toolbox: I-CONNECT study. **2022**, 14, o
- 341 AChE as a spark in the Alzheimer's blaze: Antagonizing effect of a cyclized variant. **2023**, 83, 101787 1
- 340 Longitudinal neighbourhood determinants with cognitive health and dementia disparities: protocol of the Multi-Ethnic Study of Atherosclerosis Neighborhoods and Aging prospective cohort study. **2022**, 12, e066971 o
- 339 Salivary inflammatory biomarkers are predictive of mild cognitive impairment and Alzheimer's disease in a feasibility study. 14, o
- 338 A two-year longitudinal study of retinal vascular impairment in patients with amnesic mild cognitive impairment. 14, o
- 337 Advance directives among cognitively impaired persons who had an amyloid PET scan and their care partners: a mixed-methods study. **2022**, 21, o
- 336 Pre-existing mental health disorders and fear of COVID-19 pandemic: Data from a phone survey in community-dwelling older adults recruited in the NutBrain study. 13, o
- 335 Alzheimer's Disease: Treatment Strategies and Their Limitations. **2022**, 23, 13954 o
- 334 Perivascular space burden associations with arterial stiffness and cognition. **2022**, o

333	Excessive Dietary Salt Intake Exacerbates Cognitive Impairment Progression and Increases Dementia Risk in Older Adults. 2022 ,	0
332	Cognitive Performance following Single- or Multi-Session Exercise Intervention in Middle Age: A Systematic Review. 1-37	0
331	Brain metabolic correlates of Locus Coeruleus degeneration in Alzheimer's Disease: A multimodal neuroimaging study. 2022 ,	0
330	Examining real-world Alzheimer's disease heterogeneity using neuroanatomical normative modelling.	0
329	CSF proteome profiling across the Alzheimer's disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels.	0
328	Neuroimaging and machine learning for studying the pathways from mild cognitive impairment to Alzheimer's disease: A systematic review.	0
327	Machine Learning-Based Classification of Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Dementia Using Neuroimage and Plasma Biomarkers.	1
326	PET molecular imaging for pathophysiological visualization in Alzheimer's disease.	1
325	Implication of EEG theta/alpha and theta/beta ratio in Alzheimer's and Lewy body disease. 2022 , 12,	2
324	Frontal and temporal lobe correlates of verbal learning and memory in aMCI and suspected Alzheimer's disease dementia. 1-17	0
323	Topological changes of fast large-scale brain dynamics in Mild Cognitive Impairment predict the decay of the hippocampal memory.	0
322	LC-MS/MS Isomeric Profiling of N-Glycans Derived from Low-Abundant Serum Glycoproteins in Mild Cognitive Impairment Patients. 2022 , 12, 1657	0
321	Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer's disease. 2022 , 14,	0
320	Influence of a 12-Month Structured Exercise Program on the Micronutrient-Cognitive Fitness-Physical Association Profiles in Mild Cognitive Impairment. 1-12	0
319	Hippocampal neuronal integrity and functional connectivity within the default mode network in mild cognitive impairment: a multimodal investigation.	0
318	Identification of potential blood biomarkers for early diagnosis of Alzheimer's disease through immune landscape analysis. 2022 , 8,	0
317	Hearing impairment is associated with cognitive decline, brain atrophy and tau pathology. 2022 , 86, 104336	2
316	Abnormal cerebral micro-structures in end-stage renal disease patients related to mild cognitive impairment. 2022 , 157, 110597	0

- 315 C9orf72 repeat length might influence clinical sub-phenotypes in dementia patients. **2022**, 175, 105927 1
- 314 Affective Theory of Mind as a residual ability to preserve mentalizing in amnesic Mild Cognitive Impairment: A 12-months longitudinal study. 13, 0
- 313 Triglyceride Glucose Index is Related with the Risk of Mild Cognitive Impairment in Type 2 Diabetes. Volume 15, 3577-3587 0
- 312 Herpes simplex virus alters Alzheimer's disease biomarkers - A hypothesis paper. 0
- 311 Baseline characterization of the ARMADA (Assessing Reliable Measurement in Alzheimer's Disease) study cohorts. 0
- 310 Early-onset Alzheimer's disease shows a distinct neuropsychological profile and more aggressive trajectories of cognitive decline than late-onset. 0
- 309 Graphene as the basis of biological sensors for the diagnosis of neurodegenerative dementia. **2022**, 41, 421-428 0
- 308 Eye-Gaze and Mouse-Movements on Web Search as Indicators of Cognitive Impairment. **2022**, 187-200 0
- 307 Life satisfaction across the entire trajectory of Alzheimer's disease: A mediation analysis. **2022**, 14, 0
- 306 Targeting G-quadruplex in an ageing epigenetic regulator promoter for rescuing mitochondrial dysfunction in Alzheimer's disease. 0
- 305 The impact of sleep components, quality and patterns on glymphatic system functioning in healthy adults: A systematic review. **2023**, 101, 322-349 0
- 304 Classification of mild cognitive impairment based on handwriting dynamics and qEEG. **2023**, 152, 106418 0
- 303 Genetic associations between sleep traits and cognitive ageing outcomes in the Hispanic Community Health Study/Study of Latinos. **2023**, 87, 104393 0
- 302 Investigating changes in cognition associated with the use of CPAP in cognitive impairment and dementia: A retrospective study. **2023**, 101, 437-444 0
- 301 Evolution of the diagnostic frontiers of Alzheimer's disease and new therapeutic possibilities. **2022**, 122, 38 0
- 300 Memory-driven eye movements prospectively predict dementia in people at risk of Alzheimer's disease. **2022**, 14, 0
- 299 Controlled arterial hypertension and blood-brain barrier damage in patients with age-related cerebral small vessel disease and cognitive impairments. **2022**, 122, 74 0
- 298 Longitudinal CSF Alzheimer's disease biomarker changes from middle age to late adulthood. **2022**, 14, 0

297	Stakeholders' Perspectives on Preclinical Testing for Alzheimer's Disease. 2015 , 26, 297-306	3
296	Subjective cognitive decline, mild cognitive impairment, and dementia - syndromic approach: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. 2022 , 16, 1-24	2
295	Declínio cognitivo subjetivo, comprometimento cognitivo leve e demência - diagnóstico síndrômico: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia. 2022 , 16, 1-24	0
294	Toward the optimized assessment of clinical outcomes in studies of novel treatments for Alzheimer's disease. 2022 , 22, 863-873	0
293	Usability of an embodied CAVE system for spatial navigation rehabilitation in mild cognitive impairment. 2022 ,	0
292	The role of tonifying kidney decoction and acupuncture in the treatment of Alzheimer's disease: A network meta-analysis. 2022 , 101, e31243	0
291	A Phenome-Wide Association Study (Phewas) Of Late Onset Alzheimer Disease Genetic Risk in Children of European Ancestry at Middle Childhood: Results From the ABCD Study.	0
290	Association of Subjective Cognitive Decline With Progression to Dementia in a Cognitively Unimpaired Multiracial Community Sample. 10.1212/WNL.0000000000201658	1
289	A Review of the Recent Advances in Alzheimer's Disease Research and the Utilization of Network Biology Approaches for Prioritizing Diagnostics and Therapeutics. 2022 , 12, 2975	1
288	An AS-qPCR-based method for the detection of Alzheimer's disease-related SNPs.	0
287	Diencephalic versus Hippocampal Amnesia in Alzheimer's Disease: The Possible Confabulation-Misidentification Phenotype. 2022 , 1-26	0
286	The Impact of a Yoga-Based Mindfulness Intervention versus Psycho-Educational Session for Older Adults with Mild Cognitive Impairment: The Protocol of a Randomized Controlled Trial. 2022 , 19, 15374	1
285	Brain Microstructural Changes in Patients with Amnesic mild Cognitive Impairment.	0
284	The Utility of Arterial Spin Labeling MRI in Medial Temporal Lobe as a Vascular Biomarker in Alzheimer's Disease Spectrum: A Systematic Review and Meta-Analysis. 2022 , 12, 2967	0
283	Kinetic evaluation and assessment of longitudinal changes in reference region and extracerebral [18F]MK-6240 PET uptake. 0271678X2211421	1
282	Association of Klotho Protein Levels and KL-VS Heterozygosity With Alzheimer Disease and Amyloid and Tau Burden. 2022 , 5, e2243232	0
281	The Frontal Assessment Battery (FAB) effectively discriminates between MCI and dementia within the clinical spectrum of neurochemically confirmed Alzheimer's disease. 13,	0
280	Effects of preventive interventions on neuroimaging biomarkers in subjects at-risk to develop Alzheimer's disease: A systematic review. 14,	0

- 279 Head-to-head comparison between plasma p-tau217 and Flortaucipir-PET in amyloid-positive patients with cognitive impairment. ○
- 278 Discovering new peripheral plasma biomarkers to identify cognitive decline in type 2 diabetes. 10, ○
- 277 Cell type-specific changes identified by single-cell transcriptomics in Alzheimer's disease. **2022**, 14, ○
- 276 A more precise diagnosis by means of amyloid PET contributes to delayed institutionalization, lower mortality, and reduced care costs in a tertiary memory clinic setting. 1
- 275 Which motor-cognitive abilities underlie the digital Trail-Making Test? Decomposing various test scores to detect cognitive impairment in Parkinson's diseasePilot study. 1-15 ○
- 274 Self Assessment Memory Scale (SAMS), a new simple method for evaluating memory function. 14, ○
- 273 What a Single Electroencephalographic (EEG) Channel Can Tell us About Alzheimer's Disease Patients With Mild Cognitive Impairment. **2023**, 54, 21-35 ○
- 272 Alzheimer's Disease: A Systems View Provides a Unifying Explanation of Its Development. **2022**, 1-28 ○
- 271 MRI-based machine learning model: A potential modality for predicting cognitive dysfunction in patients with type 2 diabetes mellitus. 10, ○
- 270 Impact of Amyloid Pathology in Mild Cognitive Impairment Subjects: The Longitudinal Cognition and Surface Morphometry Data. **2022**, 23, 14635 ○
- 269 Preliminary report of Iranian Registry of Alzheimer's disease in Tehran province: A cross-sectional study in Iran. **2022**, 5, ○
- 268 Actigraphic and melatonin alignment in older adults with varying dementia risk. 1-12 1
- 267 Lecanemab in Early Alzheimer's Disease. 44
- 266 Sex-Specific Multiparameter Blood Test for the Early Diagnosis of Alzheimer's Disease. **2022**, 23, 15670 ○
- 265 Effects of Remote Expressive Arts Program in Older Adults with Mild Cognitive Impairment: A Randomized Controlled Trial. **2022**, 1-17 ○
- 264 Neuroinflammation is independently associated with brain network dysfunction in Alzheimer's disease. ○
- 263 A 19-Year-Old Adolescent with Probable Alzheimer's Disease. **2022**, 1-8 2
- 262 The effects of herbal medicine (Jujadokseo-hwan) on quality of life in patients with mild cognitive impairment: Cost-effectiveness analysis alongside randomized controlled trial. **2022**, 100914 ○

- 261 Amyloid-IPET in Alzheimer's disease: A systematic review and Bayesian meta-analysis. o
- 260 Persisting neuropsychiatric symptoms, Alzheimer's disease, and cerebrospinal fluid cortisol and dehydroepiandrosterone sulfate. **2022**, 14, o
- 259 Enlarged perivascular spaces are associated with decreased brain tau deposition. o
- 258 The Use of Executive Fluency Tasks to Detect Cognitive Impairment in Individuals with Subjective Cognitive Decline. **2022**, 12, 491 1
- 257 Effects of APOE ϵ allele on basal forebrain functional connectivity in mild cognitive impairment. o
- 256 Clinical and Economic Assessment in Early-Stage Dementia by Severity and Amyloid- β Status: A 5-Year Retrospective Claims Study of GERAS-US Patients. **2022**, 1-13 o
- 255 Arrhythmia and other modifiable risk factors in incident dementia and MCI among elderly individuals with low educational levels in Taiwan. 14, o
- 254 The use of an individual-based FDG-PET volume of interest approach in mild cognitive impairment: a multi-modality longitudinal follow-up study. o
- 253 The Utility of High Intensity Interval Training to Improve Cognitive Aging in Heart Disease Patients. **2022**, 19, 16926 o
- 252 Combining Aperiodic 1/f Slopes and Brain Simulation: An EEG/MEG Proxy Marker of Excitation/Inhibition Imbalance in Alzheimer's Disease. o
- 251 Update Amyloid-Bildgebung in der Diagnostik der Neurodegeneration. **2022**, 45, 256-265 o
- 250 Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer's disease. o
- 249 The Functional External Memory Aid Tool Version 2.0: A How-To Clinical Guide. 1-11 o
- 248 Cognitive Function Trajectories and Factors among Chinese Older Adults with Subjective Memory Decline: CHARLS Longitudinal Study Results (2011-2018). **2022**, 19, 16707 o
- 247 Comparative efficacy and acceptability of treatments for depressive symptoms in cognitive impairment: A systematic review and Bayesian network meta-analysis. 14, o
- 246 Association of Self-Reported Psychological Stress with Cognitive Decline: A Systematic Review. o
- 245 E/I unbalance and aberrant oscillation dynamics predict preclinical Alzheimer's disease. o
- 244 Serotonin Receptor Gene Polymorphisms Are Associated with Cerebrospinal Fluid, Genetic, and Neuropsychological Biomarkers of Alzheimer's Disease. **2022**, 10, 3118 o

- 243 Recognizing Atypical Presentations of Alzheimer's Disease: The Importance of CSF Biomarkers in Clinical Practice. **2022**, 12, 3011 ○
- 242 Multi-Disease Validation of the RUDAS for Cognitive Screening in Alzheimer's Disease, Parkinson's Disease, and Multiple Sclerosis. **2022**, 1-13 ○
- 241 Prevalence of motoric cognitive risk syndrome among older adults: a systematic review and meta-analysis. 1-13 ○
- 240 Are neuropsychiatric symptoms a marker of small vessel disease progression in older adults? Evidence from the Lothian Birth Cohort 1936. **2023**, 38, ○
- 239 Circadian rest-activity rhythm and longitudinal brain changes underlying late-life cognitive decline. ○
- 238 Development of a Gastrointestinal-Myoelectrical-Activity-Based Nomogram Model for Predicting the Risk of Mild Cognitive Impairment. **2022**, 12, 1861 ○
- 237 New Therapeutics in Alzheimer's Disease Longitudinal Cohort study (NTAD): study protocol. **2022**, 12, e055135 ○
- 236 Coherence in event-related EEG oscillations in patients with Alzheimer's disease dementia and amnesic mild cognitive impairment. ○
- 235 New methods for the diagnosis and monitoring of cognitive function in patients with type 2 diabetes. 13, ○
- 234 Bacterial DNAemia in Alzheimer's Disease and Mild Cognitive Impairment: Association with Cognitive Decline, Plasma BDNF Levels, and Inflammatory Response. **2023**, 24, 78 ○
- 233 Differences in Subjective and Objective Cognitive Decline Outcomes Are Associated with Modifiable Protective Factors: A 4-Year Longitudinal Study. **2022**, 11, 7441 ○
- 232 Frailty and functional brain connectivity (FBC) in older adults with mild cognitive impairment (MCI): baseline results from the SYNERGIC Trial. ○
- 231 The recency ratio assessed by story recall is associated with cerebrospinal fluid levels of neurodegeneration biomarkers. **2022**, ○
- 230 Rationale and Design of the PARTNER Trial: Partnered Rhythmic Rehabilitation for Enhanced Motor-Cognition in Prodromal Alzheimer's Disease. **2022**, 1-15 ○
- 229 Development of a simple screening tool for determining cognitive status in Alzheimer's disease. **2023**, 18, e0280178 ○
- 228 Deep segmentation of OCTA for evaluation and association of changes of retinal microvasculature with Alzheimer's disease and mild cognitive impairment. *bjophthalmol-2022-321399* ○
- 227 Translational potential of synaptic alterations in Alzheimer's disease patients and App knock-in mice. ○
- 226 Exercise and the brain in cardiovascular disease: A narrative review. **2022**, 0 ○

225	Application of machine learning techniques for dementia severity prediction from psychometric tests in the elderly population. 1-9	0
224	Validation of the cross-cultural dementia screening test in Alzheimer's disease and Parkinson's disease. 13,	0
223	Retinal Vascular Changes in Alzheimer's Dementia and Mild Cognitive Impairment: A Pilot Study Using Ultra-Widefield Imaging. 2023 , 12, 13	0
222	Forgetting Rates of Prose Memory in Mild Cognitive Impairment. 2023 , 1-10	0
221	Photobiomodulation improves frontal lobe cognitive functions and mental health of older adults with non-amnesic mild cognitive impairment: Case studies. 13,	1
220	EEG Entropy in REM Sleep as a Physiologic Biomarker in Early Clinical Stages of Alzheimer's Disease. 2023 , 1-16	0
219	Whole-brain DTI parameters associated with tau protein and hippocampal volume in Alzheimer's disease.	0
218	The ambivalence toward neuropsychology in dementia research, diagnosis, and drug development: Myths and misconceptions.	0
217	Impact of atrial fibrillation on the cognitive decline in Alzheimer's disease. 2023 , 15,	0
216	Neuropsychiatric Symptom Burden across Neurodegenerative Disorders and its Association with Function. 070674372211474	0
215	Visuoconstructional Abilities of Patients With Subjective Cognitive Decline, Mild Cognitive Impairment and Alzheimer's Disease. 089198872211355	0
214	Application of Marine Natural Products against Alzheimer's Disease: Past, Present and Future. 2023 , 21, 43	0
213	Initial non-amnesic symptoms relate to faster rate of functional and cognitive decline compared to amnesic symptoms in neuropathologically confirmed dementias.	0
212	Applying joint graph embedding to study Alzheimer's neurodegeneration patterns in volumetric data.	0
211	Neuropsychological test performance of former American football players. 2023 , 15,	0
210	Characterising the prodromal phase in dementia with Lewy bodies. 2023 , 107, 105279	0
209	Effects of methionine intake on cognitive function in mild cognitive impairment patients and APP/PS1 Alzheimer's Disease model mice: Role of the cystathionine-β-synthase/H2S pathway. 2023 , 59, 102595	2
208	Effects of two Ayurvedic formulations, Dhanwantaram Kashaya and Saraswatarishta on life history parameters and toxic aggregates in Drosophila models of Huntington's and Alzheimer's disease. 2023 , 305, 116080	0

- 207 Towards better interpretable and generalizable AD detection using collective artificial intelligence. **2023**, 104, 102171 ○
- 206 A conceptual history of Mild Cognitive Impairment (MCI) and its assessment [Part 1: Historical background. **2021**, 1, 6-10 ○
- 205 Use of the Laboratory in the Diagnostic Workup of Older Adults. **2022**, ○
- 204 Fecal Microbiota Transplantation Reduces Pathology and Improves Cognition in a Mouse Model of Alzheimer's Disease. **2023**, 12, 119 ○
- 203 Exploring cognitive and biological correlates of sleep quality and their potential links with Alzheimer's disease (ALFASleep project): protocol for an observational study. **2022**, 12, e067159 ○
- 202 Accelerated Cognitive Decline Associated With Hearing Loss and Bilateral Vestibulopathy: Insights From a Prospective Cross-Sectional Study Using the Repeatable Battery for the Assessment of Neuropsychological Status Adjusted for the Hearing Impaired in the DFNA9 Population. Publish Ahead of Print. ○
- 201 White matter alterations in amnesic mild cognitive impairment: a tract-based spatial statistics study. ○
- 200 Lost in space(s): multimodal neuroimaging of disorientation along the Alzheimer's disease continuum. ○
- 199 Diastolic Blood Pressure and Intensive Blood Pressure Control on Cognitive Outcomes: Insights From the SPRINT MIND Trial. 1
- 198 Apathy as a Predictor of Conversion from Mild Cognitive Impairment to Alzheimer's Disease: A Texas Alzheimer's Research and Care Consortium (TARCC) Cohort-Based Analysis. **2023**, 1-11 ○
- 197 Could Temperamental Features Modulate Participation in Clinical Trials?. **2023**, 12, 1121 ○
- 196 Lower semantic fluency scores and a phonemic-over-semantic advantage predict abnormal CSF P-tau181 levels in Aβ+ patients within the Alzheimer's disease clinical spectrum. ○
- 195 Urinary protein biomarkers based on LCMS/MS analysis to discriminate vascular dementia from Alzheimer's disease in Han Chinese population. 15, ○
- 194 Effect of Cognitive Reserve on Physiological Measures of Cognitive Workload in Older Adults with Cognitive Impairments. **2023**, 1-11 ○
- 193 Classifying Alzheimer's disease and frontotemporal dementia using machine learning with cross-sectional and longitudinal magnetic resonance imaging data. ○
- 192 Using Explainable Artificial Intelligence in the Clock Drawing Test to reveal the cognitive impairment pattern. ○
- 191 Effects of candesartan on cerebral microvascular function in mild cognitive impairment: Results of two clinical trials. 174749302311533 ○
- 190 Transcranial Magnetic Stimulation Improves Executive Functioning through Modulation of Social Cognitive Networks in Patients with Mild Cognitive Impairment: Preliminary Results. **2023**, 13, 415 ○

- 189 Cognitive impairment with Type 2 Diabetes Mellitus among community-dwelling older adults in Chile: Prevalence, risk factors and cognitive characteristics. 16, ○
- 188 Intrasection Repeatability of Optical Coherence Tomography Angiography Parameters in Neurodegenerative Disease. **2023**, 100275 ○
- 187 Interplay between the catecholaminergic enzymatic axis and neurodegeneration/neuroinflammation processes in Alzheimer's disease continuum. ○
- 186 Diffusion Kurtosis Imaging in Evaluating the Mild Cognitive Impairment of Occupational Aluminum Workers. **2023**, ○
- 185 CELLULAR STRESS RESPONSE (HORMESIS) IN RESPONSE TO BIOACTIVE NUTRACEUTICALS WITH RELEVANCE TO ALZHEIMER DISEASE. ○
- 184 Regional White Matter Hyperintensities and Alzheimer's Disease Biomarkers Among Older Adults with Normal Cognition and Mild Cognitive Impairment. **2023**, 1-17 ○
- 183 In vivo synaptic density loss correlates with impaired functional and related structural connectivity in Alzheimer's disease. 0271678X2311537 1
- 182 Hippocampal subfield viscoelasticity in amnesic mild cognitive impairment evaluated with MR elastography. **2023**, 37, 103327 ○
- 181 Predictors of early postoperative cognitive dysfunction in middle-aged patients undergoing cardiac surgery: retrospective observational study. ○
- 180 Combining Neuropsychological Assessment with Neuroimaging to Distinguish Early-Stage Alzheimer's Disease from Frontotemporal Lobar Degeneration in Non-Western Tonal Native Language-Speaking Individuals Living in Taiwan: A Case Series. **2023**, 12, 1322 ○
- 179 Plasma Extracellular Vesicle MicroRNA Analysis of Alzheimer's Disease Reveals Dysfunction of a Neural Correlation Network. **2023**, 6, ○
- 178 Alzheimer's and vascular disease classification using regional texture biomarkers in FLAIR MRI. **2023**, 38, 103385 ○
- 177 Gray Matter Volume as Evidence for Cognitive Reserve in Bilinguals With Mild Cognitive Impairment. **2023**, 37, 7-12 ○
- 176 The value of maintaining cognition in patients with mild cognitive impairment: The innovation headroom and potential cost-effectiveness of roflumilast. ○
- 175 Dynamic functional connectivity MEG features of Alzheimer's disease. ○
- 174 Mindfulness-based stress reduction for community-dwelling older adults with subjective cognitive decline (SCD) and mild cognitive impairment (MCI) in primary care: a mixed-methods feasibility randomized control trial. **2023**, 24, ○
- 173 Cognitive Function and Depressive Symptoms among Chinese Adults Aged 40 Years and Above: The Mediating Roles of IADL Disability and Life Satisfaction. **2023**, 20, 4445 ○
- 172 Remnant cholesterol and mild cognitive impairment: A cross-sectional study. 15, ○

- 171 Free water imaging of the cholinergic system in dementia with Lewy bodies and Alzheimer's disease. ○
- 170 DementiaBank: Theoretical Rationale, Protocol, and Illustrative Analyses. **2023**, 32, 426-438 ○
- 169 Comprehensive genetic screening of early-onset dementia patients in an Austrian Cohort-Suggesting new disease-contributing genes. ○
- 168 Redefinition of dementia care in Italy in the era of amyloid-lowering agents for the treatment of Alzheimer's disease: an expert opinion and practical guideline. ○
- 167 Causal Relationship Between Basal Metabolic Rate and Alzheimer's Disease: A Bidirectional Two-sample Mendelian Randomization Study. ○
- 166 Mortality Risks and Causes of Death by Dementia Types in a Japanese Cohort with Dementia: NCGG-STORIES. **2023**, 92, 487-498 ○
- 165 Steeper memory decline after COVID-19 lockdown measures. **2023**, 15, ○
- 164 Gut-brain axis through the lens of gut microbiota and their relationships with Alzheimer's disease pathology: Review and recommendations. **2023**, 211, 111787 ○
- 163 Influence of mild cognitive impairment and body mass index on white matter integrity assessed by diffusion tensor imaging. ○
- 162 Differentiation of Alzheimer's Disease from Frontotemporal Dementia and Mild Cognitive Impairment Based on Arterial Spin Labeling Magnetic Resonance Imaging: A Pilot Cross-Sectional Study from PUMCH Dementia Cohort. **2023**, 1-11 ○
- 161 Auditory Event-Related Potentials in Older Adults with Subjective Memory Complaints. **2023**, 92, 1093-1109 ○
- 160 Do Individuals Aged 50 or Older View Cognitive Conditions Differently than Physical Conditions?: Evidence from a Pooled Analysis of Illness Perceptions in Type 2 Diabetes and Mild Cognitive Impairment. ○
- 159 Cognitive Impairment in Older Adults and Oral Health Considerations. **2023**, 39, 295-310 ○
- 158 Retinal photoreceptor layer thickness has disease specificity and distinguishes predicted FTLD-Tau from biomarker-determined Alzheimer's disease. **2023**, 125, 74-82 ○
- 157 Alzheimer's disease: Insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs. **2023**, 211, 115522 ○
- 156 Precise profiling of exosomal biomarkers via programmable curved plasmonic nanoarchitecture-based biosensor for clinical diagnosis of Alzheimer's disease. **2023**, 230, 115269 ○
- 155 A mobile application using automatic speech analysis for classifying Alzheimer's disease and mild cognitive impairment. **2023**, 81, 101514 ○
- 154 Influence of mild cognitive impairment on patient and care partner decision-making for acute ischemic stroke. **2023**, 32, 107068 ○

- 153 Clinical diagnostic utility of transcranial magnetic stimulation in neurological disorders. Updated report of an IFCN committee. **2023**, 150, 131-175 o
- 152 Episodic and Semantic Autobiographical Memory in Mild Cognitive Impairment (MCI): A Systematic Review. **2023**, 12, 2856 o
- 151 Cortical hyperexcitability and plasticity in Alzheimer's disease: developments in understanding and management. **2022**, 22, 981-993 o
- 150 Patients with Alzheimer's disease dementia show partially preserved parietal hubs modeled from resting-state alpha electroencephalographic rhythms. 15, o
- 149 Emotion recognition and baseline cortisol levels relationship in early Alzheimer disease. **2023**, 177, 108511 1
- 148 Re: Aducanumab-Related ARIA. Publish Ahead of Print, o
- 147 A New Smart 2-Min Mobile Alerting Method for Mild Cognitive Impairment Due to Alzheimer's Disease in the Community. **2023**, 13, 244 o
- 146 Comparison of Machine Learning-based Approaches to Predict the Conversion to Alzheimer's Disease from Mild Cognitive Impairment. **2023**, 514, 143-152 o
- 145 Hippocampus-centred grey matter covariance networks predict the development and reversion of mild cognitive impairment. **2023**, 15, o
- 144 Digital Methods for Performing Daily Tasks Among Older Adults: An Initial Report of Frequency of Use and Perceived Utility. 1-22 o
- 143 Mobility and associations with levels of cerebrospinal fluid amyloid and tau in a memory clinic cohort. 15, o
- 142 Examining the Validity and Utility of Montreal Cognitive Assessment Domain Scores for Early Neurocognitive Disorders. **2023**, 24, 314-320.e2 o
- 141 An attention-based deep learning approach for the classification of subjective cognitive decline and mild cognitive impairment using resting-state EEG. **2023**, 20, 016048 o
- 140 Comparison of Retinal Structural and Neurovascular Changes between Patients with and without Amyloid Pathology. **2023**, 12, 1310 o
- 139 Outcome measures for Alzheimer's disease: A global inter-societal Delphi consensus. o
- 138 Outcomes of a computer-based cognitive training (CoRe) in early phases of cognitive decline: a data-driven cluster analysis. **2023**, 13, 1
- 137 Long-Term Neuromodulatory Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) on Plasmatic Matrix Metalloproteinases (MMPs) Levels and Visuospatial Abilities in Mild Cognitive Impairment (MCI). **2023**, 24, 3231 o
- 136 Otolith vestibular function appears to affect human hippocampal volume. o

- 135 Sex-specific declines in cholinergic-targeting tRNA fragments in the nucleus accumbens in Alzheimer's disease. ○
- 134 A FinnGen pilot clinical recall study for Alzheimer's disease. ○
- 133 The dynamics of plasma biomarkers across the Alzheimer's continuum. **2023**, 15, ○
- 132 Association of Fruit and Vegetable Consumption With Mild Cognitive Impairment in Low- and Middle-Income Countries. ○
- 131 Biopsychosocial frailty and mild cognitive impairment subtypes: Findings from the Italian project on the epidemiology of Alzheimer's disease (IPREA). ○
- 130 Lower cognitive function attenuates the convergence between self-ratings and observer ratings of depressive symptoms in late-life cognitive impairment. **2023**, 13, ○
- 129 Neural biomarker diagnosis and prediction to mild cognitive impairment and Alzheimer's disease using EEG technology. **2023**, 15, ○
- 128 Genetic Liability, Exposure Severity, and Post-Traumatic Stress Disorder Predict Cognitive Impairment in World Trade Center Responders. **2023**, 92, 701-712 ○
- 127 Multifunctional Nanoprobes for the Surveillance of Amyloid Aggregation. **2023**, 1-24 ○
- 126 Comparison Between 18F-Florapronol and 18F-Florbetaben Imaging in Patients With Cognitive Impairment. 19, ○
- 125 Biomarkers of diagnosis, prognosis, pathogenesis, response to therapy: Convergence or divergence? Lessons from Alzheimer's disease and synucleinopathies. **2023**, 187-218 ○
- 124 Genetic analysis of VCP variants in a Turkish dementia cohort. ○
- 123 Immune cell counts in cerebrospinal fluid predict cognitive function in aging and neurodegenerative disease. ○
- 122 Challenges and opportunities of diagnostic markers of Alzheimer's disease based on structural magnetic resonance imaging. **2023**, 13, ○
- 121 Neuropathology-based APOE genetic risk score better quantifies Alzheimer's risk. ○
- 120 Evaluation of Cognitive Functioning Before and After Cochlear Implantation in Adults Aged 55 Years and Older at Risk for Mild Cognitive Impairment. **2023**, 149, 310 ○
- 119 Accurate module induced brain network construction for mild cognitive impairment identification with functional MRI. 15, ○
- 118 Cognitive Trajectories and Associated Biomarkers in Patients with Mild Cognitive Impairment. **2023**, 92, 803-814 ○

117	Background Music and Memory in Mild Cognitive Impairment: The Role of Interindividual Differences. 2023 , 92, 815-829	o
116	Applying Retinal Vascular Structures Characteristics Coupling with Cortical Visual System in Alzheimer's Disease Spectrum Patients. 2023 , 13, 339	o
115	New possibilities for the treatment of mild cognitive impairment and prevention of dementia in patients with cerebrovascular disease. Results of the PRIORITET Observation Program. 2023 , 15, 65-70	o
114	Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer's disease diagnosis in a memory clinic cohort. 2023 , 15,	o
113	Effectiveness of lifestyle medicine on cognitive functions in mild cognitive impairments and dementia: A systematic review on randomized controlled trials. 2023 , 86, 101886	o
112	Multivariate functional mixed model with MRI data: An application to Alzheimer's disease.	o
111	Vascular-water-exchange MRI (VEXI) enables the detection of subtle AXR alterations in Alzheimer's disease without MRI contrast agent, which may relate to BBB integrity. 2023 , 270, 119951	o
110	Based on Tau PET Radiomics Analysis for the Classification of Alzheimer's Disease and Mild Cognitive Impairment. 2023 , 13, 367	1
109	Levels of Soluble Interleukin 6 Receptor and Asp358Ala Are Associated With Cognitive Performance and Alzheimer Disease Biomarkers. 2023 , 10, e200095	o
108	Bilateral Hippocampal Volume Mediated the Relationship Between Plasma BACE1 Concentration and Memory Function in the Early Stage of Alzheimer's Disease: A Cross-Sectional Study. 2023 , 92, 1001-1013	o
107	Exploring Neurocognitive Deterioration in Alzheimer's Disease. 2023 , 12, 343	o
106	Rates of Undiagnosed Cognitive Impairment and Performance on the Montreal Cognitive Assessment Among Older Adults in Primary Care.	o
105	Macular vessel density in the superficial plexus is not associated to cerebrospinal fluid core biomarkers for Alzheimer's disease in individuals with mild cognitive impairment: The NORFACE cohort. 17,	o
104	The Protective Role of Cognitive Reserve in Mild Cognitive Impairment: A Systematic Review. 2023 , 12, 1759	1
103	Altered glutamate-glutamine and amide proton transfer-weighted values in the hippocampus of patients with amnesic mild cognitive impairment: A novel combined imaging diagnostic marker. 17,	o
102	The Association Between Neurocognitive Disorders and Gustatory Dysfunction: A Systematic Review and Meta-Analysis.	o
101	Role of nerve growth factor on cognitive impairment in Alzheimer's disease patients carrying apolipoprotein E 4.	o
100	Normative Scores on the Norwegian Version of the Mini-Mental State Examination. 2023 , 92, 831-842	o

- 99 Neuroplasticity, brain entrainment, cognition and intellectual functions amelioration through the complex integrative approach of biological regenerative medicine. **2020**, 6, 41-51 ○
- 98 Education reduces cognitive dysfunction in Alzheimer's disease by changing regional cerebral perfusion: An in-vivo arterial spin labeling study. ○
- 97 Using digital technology to quantify habitual physical activity in community-dwellers with cognitive impairment: A systematic review (Preprint). ○
- 96 Endosome and Lysosome Membrane Properties Functionally Link to BSecretase in Live/Intact Cells. **2023**, 23, 2651 ○
- 95 The influence of stimulus eccentricity on prosaccade outcomes in patients with Alzheimer's Disease dementia at an early stage and amnesic mild cognitive impairment. **2022**, 44, 713-729 2
- 94 Usability of an Embodied CAVE System for Spatial Navigation Training in Mild Cognitive Impairment. **2023**, 12, 1949 1
- 93 Clinical outcomes of increased focal amyloid uptake in individuals with subthreshold global amyloid levels. 15, ○
- 92 Disruption of early visual processing in amyloid-positive healthy individuals and mild cognitive impairment. **2023**, 15, ○
- 91 Plasma biomarkers for diagnosis of Alzheimer's disease and prediction of cognitive decline in individuals with mild cognitive impairment. 14, ○
- 90 Sex-specific differences in neuropsychological profiles of mild cognitive impairment in a hospital-based clinical sample. 1-10 ○
- 89 Cognitive and Neuropathophysiological Outcomes of Gamma-tACS in Dementia: A Systematic Review. ○
- 88 Mild Cognitive Impairment (MCI) [A brief overview: The history, use and a clear conceptualised approach. **2023**, 1, 6-10 ○
- 87 Do service-users find the outcome of Mild Cognitive Impairment useful? A summary of Blatchford & Cook's (2020) systematic review. **2023**, 1, 11-16 ○
- 86 Psychometric properties of the Alzheimer's Disease Cooperative Study [Activities of Daily Living for Mild Cognitive Impairment (ADCS-MCI-ADL) scale: a post hoc analysis of the ADCS ADC-008 trial. **2023**, 23, ○
- 85 Blood biomarkers in mild cognitive impairment patients: Relationship between analytes and progression to Alzheimer disease dementia. ○
- 84 Plasma amyloid beta 40/42, phosphorylated tau 181, and neurofilament light are associated with cognitive impairment and neuropathological changes among World Trade Center responders: A prospective cohort study of exposures and cognitive aging at midlife. **2023**, 15, ○
- 83 Utility of Amyloid Positron Emission Tomography Imaging in Older Adults With Epilepsy and Cognitive Decline. **2023**, 38, 153331752311600 ○
- 82 Toxic agents and health disparities in the socially marginalized. **2023**, ○

81	Subjective Complaints are Similar in Subjective Cognitive Decline and Early-Stage Alzheimer's Disease when Assessed in a Memory Clinic Setting. 089198872311643	o
80	EEG resting-state networks in Alzheimer's disease associated with clinical symptoms. 2023 , 13,	o
79	Missorting of plasma miRNAs in aging and Alzheimer's disease. 2023 , 165, 149-161	o
78	Associations between self-reported sleep quality and cerebrospinal fluid biomarkers in mild cognitive impairment and Alzheimer's disease. 2023 ,	o
77	Driving practice effects for older drivers with mild cognitive impairment: A preliminary study. 2023 , 30, 550-558	o
76	Photobiomodulation in Alzheimer's Disease: A Complementary Method to State-of-the-Art Pharmaceutical Formulations and Nanomedicine?. 2023 , 15, 916	o
75	Angiotensin II Receptor Blockers Reduce Tau/A β 2 Ratio: A Cerebrospinal Fluid Biomarkers Case-Control Study. 2023 , 15, 924	o
74	Clinical symptoms in mild cognitive impairment with Lewy bodies: Frequency, time of onset, and discriminant ability.	o
73	Predicting Conversion from Subjective Cognitive Decline to Mild Cognitive Impairment and Alzheimer's Disease Dementia Using Ensemble Machine Learning. 2023 , 1-16	o
72	Comparison of the Six Item Cognitive Impairment Test (6CIT) to Commonly-Used Short Cognitive Screening Instruments in a Memory Clinic Population. 2023 , 7, 299-306	o
71	Low Ankle-Brachial Index Relates to Alzheimer-Signature Cerebral Glucose Metabolism in Cognitively Impaired Older Adults. 2023 , 1-9	o
70	Discrepancy Between Patient and Caregiver Estimate of Apathy Predicts Dementia in Patients with Amnesic Mild Cognitive Impairment. 2023 , 1-12	o
69	Contribution of clinical information to the predictive performance of plasma β amyloid levels for amyloid positron emission tomography positivity. 15,	o
68	2023 Alzheimer's disease facts and figures. 2023 , 19, 1598-1695	1
67	Involvement of ApoE4 in dementia with Lewy bodies in the prodromal and demented stages: evaluation of the Strasbourg cohort.	o
66	The Differential Role of Executive Apathy in Alzheimer's Disease Dementia, Mild Cognitive Impairment and Healthy Cognitive Ageing. 2023 , 8, 38	o
65	Phenotyping Superagers Using Resting-State fMRI. 2023 , 44, 424-433	o
64	The relationship of insulin resistance and diabetes to tau PET SUVR in middle-aged to older adults. 2023 , 15,	o

- 63 A digital health home intervention for people within the Alzheimer's disease continuum: results from the Ability-Telerehabilitation pilot randomized controlled trial. **2023**, 55, 1080-1091 ○
- 62 Gene therapy using PLGA nanoparticles. **2023**, 393-414 ○
- 61 Comparison of the telephone-Montreal Cognitive Assessment (T-MoCA) and Telephone Interview for Cognitive Status (TICS) as screening tests for early Alzheimer's disease. ○
- 60 Exploratory Study on Chemosensory Event-Related Potentials in Long COVID-19 and Mild Cognitive Impairment: A Common Pathway?. **2023**, 10, 376 ○
- 59 The roles of apolipoprotein E ϵ 4 on neuropathology and neuroinflammation in patients with Alzheimer's disease. ○
- 58 Multi-networks connectivity at baseline predicts the clinical efficacy of left angular gyrus-navigated rTMS in the spectrum of Alzheimer's disease: A sham-controlled study. ○
- 57 Relationship between Brain-Derived Neurotrophic Factor and Cognitive Decline in Patients with Mild Cognitive Impairment and Dementia. **2023**, 13, 570 ○
- 56 Enfermedad de Alzheimer. **2023**, 13, 4360-4371 ○
- 55 Ginkgo biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review. Volume 19, 647-660 ○
- 54 Prefrontal EEG slowing, synchronization, and ERP peak latency in association with prodementia stages of Alzheimer's disease. 15, ○
- 53 The Potential Role of Gustatory Function as an Early Diagnostic Marker for the Risk of Alzheimer's Disease in Subjective Cognitive Decline. **2023**, 7, 249-262 ○
- 52 Reduced levels of N6-methyladenosine in RNA of peripheral blood mononuclear cells from patients with Alzheimer's disease. ○
- 51 Toward a new nosology of neurodegenerative diseases. ○
- 50 Natural language processing techniques for studying language in pathological ageing: A scoping review. ○
- 49 The Future of Cognitive Screening in Neurodegenerative Diseases. **2023**, 1-13 ○
- 48 Neuropsychological evaluation of preconversion risk in REM sleep behaviour disorder: A scoping review. ○
- 47 Sleep features and long-term incident neurodegeneration: a polysomnographic study. ○
- 46 A Hybrid-Layered Framework for Detection and Diagnosis of Alzheimer's Disease (AD) from Fundus Images. **2023**, ○

45	The Promotion of Health Literacy.	o
44	Alzheimer's disease genetic risk and cognitive reserve in relationship to long-term cognitive trajectories among cognitively normal individuals. 2023 , 15,	o
43	Baseline grey matter volumes and white matter hyperintensities predict decline in functional activities in older adults over a 5-year follow-up period. 2023 , 38, 103393	o
42	Interaction analysis of ancestry-enriched variants with APOE-e4 on MCI in the Study of Latinos-Investigation of Neurocognitive Aging. 2023 , 13,	o
41	Mild cognitive impairment is associated with passive suicidal ideation in older adults: A population-based study.	o
40	Predicting cognitive stage transition using p-tau181, Centiloid, and other measures.	o
39	Suitability of memory aids and strategies for people with posterior cortical atrophy: protocol for a scoping review. 2023 , 12,	o
38	Cognitive Intervention Effects Vary as a Function of Plasma Neurofilament Light Chain Levels: A PICMOR Randomized Controlled Trial.	o
37	The Use of Diffusion Kurtosis Imaging for the Differential Diagnosis of Alzheimer's Disease Spectrum. 2023 , 13, 595	o
36	White matter hyperintensities in cholinergic pathways may predict poorer responsiveness to acetylcholinesterase inhibitor treatment for Alzheimer's disease. 2023 , 18, e0283790	o
35	Fornix fractional anisotropy mediates the association between Mediterranean diet adherence and memory four years later in older adults without dementia.	o
34	Uncorrected errors and correct saccades in the antisaccade task distinguish between early-stage Alzheimer's disease dementia, amnesic mild cognitive impairment, and normal aging. 1-22	1
33	Design of the Think PHRESH longitudinal cohort study: Neighborhood disadvantage, cognitive aging, and Alzheimer's disease risk in disinvested, Black neighborhoods. 2023 , 23,	o
32	Attitudes and Viewpoints Toward Prevention Trials in Alzheimer's Disease.	o
31	Repurposing drugs against Alzheimer's disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?.	o
30	Blood Kallikrein-8 and Non-Amnesic Mild Cognitive Impairment: An Exploratory Study. 1-11	o
29	Plasma biomarkers for Alzheimer's disease: a field-test in a memory clinic. jnnp-2022-330619	o
28	NEURONORMA Cognitive Battery Associations with Cerebrospinal Fluid Amyloid- β and Tau Levels in the Continuum of Alzheimer's Disease. 2023 , 92, 1303-1321	o

- 27 Psilocybin to promote synaptogenesis in the brains of patients with mild cognitive impairment. **2023**, 111068 ○
- 26 Éducation Thérapeutique du Patient (ETP) dans la maladie d'Alzheimer et les maladies apparentées en France : État des lieux et retours d'expérience. **2022**, 14, 20204 ○
- 25 Olfactory function reflects episodic memory performance and atrophy in the medial temporal lobe in individuals at risk for Alzheimer's disease. **2023**, ○
- 24 Prognostic value of cerebrospinal fluid biomarkers in mild cognitive impairment due to Alzheimer disease. **2023**, ○
- 23 PROTOCOL: The effectiveness of sensory interventions targeted at improving occupational outcomes, quality of life, well-being and behavioural and psychological symptoms for older adults living with dementia: A systematic review and meta-analysis. **2023**, 19, ○
- 22 Depressive Symptoms Mediate Associations between Subjective Memory Complaints, Cognitive Ability, and Instrumental Activities of Daily Living. 1-20 ○
- 21 Volume changes of hippocampal and amygdala subfields in patients with mild cognitive impairment and Alzheimer's disease. ○
- 20 Properties of odor identification testing in screening for early-stage Alzheimer's disease. **2023**, 13, ○
- 19 Stimulus material selection for the Dutch famous faces test for older adults. 10, ○
- 18 Effect of visit-to-visit blood pressure variability on mild cognitive impairment and probable dementia in hypertensive patients receiving standard and intensive blood pressure treatment. 10, ○
- 17 Coupling Between Hippocampal Parenchymal Fraction and Cortical Grey Matter Atrophy at Different Stages of Cognitive Decline. **2023**, 1-11 ○
- 16 A Phenome-Wide Association Study (PheWAS) of Late Onset Alzheimer Disease Genetic Risk in Children of European Ancestry at Middle Childhood: Results from the ABCD Study. ○
- 15 Should artificial intelligence be used in conjunction with Neuroimaging in the diagnosis of Alzheimer's disease?. 15, ○
- 14 Multimodal imaging of microstructural cerebral changes and loss of synaptic density in Alzheimer's disease. ○
- 13 Validation of automated hippocampus volume assessment using deep learning convolutional neural networks in patients with Alzheimer's disease. ○
- 12 MicroRNA expression in extracellular vesicles as a novel blood-based biomarker for Alzheimer's disease. ○
- 11 Neuropsychological Comparison of Patients With Alzheimer's Disease and Dementia With Lewy Bodies. 19, ○
- 10 Utility of Blood-Based Tau Biomarkers for Mild Cognitive Impairment and Alzheimer's Disease: Systematic Review and Meta-Analysis. **2023**, 12, 1184 ○

- 9 Degradation of EEG microstates patterns in Subjective Cognitive Decline and Mild Cognitive Impairment: early biomarkers along the Alzheimer's Disease continuum?. **2023**, 103407 ○
- 8 Adaptive data-driven selection of sequences of biological and cognitive markers in pre-clinical diagnosis of dementia. **2023**, 13, ○
- 7 PRedicting the EVolution of SubjectivE Cognitive Decline to Alzheimer's Disease With machine learning: the PREVIEW study protocol. ○
- 6 Digital Endpoints for Assessing Instrumental Activities of Daily Living in Mild Cognitive Impairment: A Systematic Review (Preprint). ○
- 5 Cortical thickness is related to cognitive-motor automaticity and attention allocation in individuals with Alzheimer's disease: a regions of interest study. ○
- 4 Normative data for the verb fluency test in the adult French-Quebec population and validation study in mild cognitive impairment. 1-7 ○
- 3 Saccadic Eye Movements in Patients with Mild Cognitive Impairment: A Longitudinal Study. 1-19 ○
- 2 Impact of pharmaceutical care integrated at a psychosocial intervention to reduce caregiver's burden in Alzheimer's disease or related dementias: Negative results at 18 months and difficulties to conduct PHARMAID RCT. **2023**, 101146 ○
- 1 Differential Diagnosis of MCI with Lewy bodies and MCI due to Alzheimer's disease by Visual Assessment of Occipital Hypoperfusion on SPECT images. ○